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Abstract  
 
Retinol dehydrogenase 10 (RDH10) catalyzes the first oxidative step in the metabolism 
of vitamin A to its active form retinoic acid (RA). Insufficient or excess RA can result in 
various congenital abnormalities, such as Hirschsprung disease (HSCR). In HSCR, 
neurons are absent from variable lengths of the gastrointestinal tract due to a failure of 
neural crest cell (NCC) colonization or development, leading to megacolon and/or the 
failure to pass meconium. Enteric neurons are derived from neural crest cells (NCC); 
hence HSCR is associated with incomplete NCC development or colonization of the GI 
tract. We investigated our hypothesis that RDH10 is necessary for proper NCC 
contribution to the enteric nervous system (ENS). The mouse point mutant Rdh10
trex/trex 
exhibits decreased retinoid signaling and colonic aganglionosis. Organ explant culture 
and in utero retinal supplementation experiments define a temporal requirement for RA 
in ENS development between E7.5-E9.5. Tamoxifen-inducible temporal deletion of 
RDH10 at E6.5-E7.5 confirms this early retinal role, while later RDH10 deletion suggests 
retinal independence for continued enteric NCC colonization. Removing RDH10 from 
NCCs shows no gross or ENS-specific neuronal defects, suggesting that RDH10 is not 
intrinsically required in enteric NCCs for proper colonization of the gut, but rather is 
necessary as a paracrine signal in the vagal NCC microenvironment. We investigated 
signaling cascades that are known to play a role in gut microenvironment maintenance 
that may be altered in these RDH10 mutants using both a targeted expression analysis 
approach as well as RNA-sequencing. Candidates include GDNF and its signaling family 
members such as RET and GFRα1, as well as extracellular matrix proteins. Novel models 
of HSCR, such as Rdh10
trex/trex
 will improve our understanding of RA contribution to 
intestinal development and may lead to innovative non-surgical treatment approaches to 
reduce the morbidity and mortality of this common congenital disease. 
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I. INTRODUCTION 
This section describes the gastrointestinal tract, which is controlled by the enteric 
nervous system (ENS). The ENS is the peripheral nervous system of the gut, formed by a 
cell population termed neural crest cells (NCC). A failure of these cells to migrate, 
proliferate, differentiate, or survive may result in a devastating congenital disease, called 
Hirschsprung Disease (HSCR). This section will also introduce Vitamin A metabolism 
and deficiency, as well as the effects this deficiency may play in the development of the 
gastrointestinal tract.  
Much of the introduction of Gastrointestinal Tract Development, Hirschsprung 
Disease, Neural Crest Cells, and Vitamin A metabolism has been edited and published in 
Translational Research as an invited review (Butler Tjaden and Trainor, 2013). 
Gastrointestinal Tract  
The gastrointestinal (GI) tract is an endoderm derived organ system that begins at 
the mouth and terminates at the anus. During fetal life, the GI tract is divided into three 
segments based on vascular supply. The foregut, supplied by the celiac artery, consists of 
the esophagus, stomach, part of duodenum, and biliary apparatus. The midgut, supplied 
by the superior mesenteric artery, contains the rest of small and large bowel up to the 
splenic flexure. Lastly, the hindgut consists of the remainder of the large bowel to the 
superior part of anal canal, and is supplied by the inferior mesenteric artery.  
This organ system functions to digest and process foods and liquids taken in 
through the mouth via two types of digestion: mechanical, such as chewing and gut 
peristalsis, and chemical, such as enzymatic breakdown. The GI tract also plays a role as 
a major part of the immune system via the recognition of and response to introduced 
pathogens.  
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GASTROINTESTINAL TRACT DEVELOPMENT AND INNERVATION BY ENTERIC NERVOUS 
SYSTEM 
There are two salient features of gut development, which make it unique in 
comparison to the rest of the developing embryo. The gut tube itself grows faster than the 
abdominal cavity. As a result, in a human fetus at 6 weeks of gestation, the midgut lies 
outside the cavity together with the umbilicus. It then undergoes significant elongation 
and a 270° counterclockwise rotation before returning to the fetal abdominal cavity at 
around 10 weeks gestation, with an intestinal anatomy reminiscent of familiar adult 
structures. Additionally, this organ system is controlled by a “second brain,” the enteric 
nervous system, which functions almost independently of the central nervous system 
(Gershon, 1997).  
REGULATION OF GI TRACT FUNCTION BY THE ENTERIC NERVOUS SYSTEM 
The ability of the GI tract to respond to the state of the lumen and gut wall by 
activating peristalsis, controlling blood flow and secretions and thus maintain proper 
physiological balance depends on the enteric nervous system (ENS) (Heanue and 
Pachnis, 2007). The ENS is the largest part of the peripheral nervous system and is in 
direct control of the GI tract (Karaosmanoglu, 1996). ENS neurons and glia are organized 
into ganglia that are interconnected to form two plexi extending along the length of the 
bowel. The outer myenteric (Auerbach) plexus develops first during embryogenesis, runs 
the full length of the gut and regulates gut motility, while the inner submucosal 
(Meissner) plexus develops later, is found only in the small and large intestine and is 
responsible for regulating blood flow and the transport of ions across the intestinal 
epithelium. All of the neurons and glia of the ENS are derived from a cell population 
called the enteric neural crest cells (ENCC), whose proper development, differentiation, 
and survival is crucial for formation of a functional ENS. 
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Neural Crest Cells (NCCs) 
NCCs are a multipotent, migratory cell population that gives rise to many cell 
lineages in vertebrate development, including the craniofacial skeleton, smooth muscle, 
melanocytes, and most of the peripheral nervous system. In mammals, NCCs are formed 
during neurulation at the border between neural and non-neural ectoderm. After 
induction, they undergo an epithelial to mesenchymal transition and subsequently 
delaminate to migrate to the periphery where they differentiate into various cell types. 
The fate of NCCs varies along the anterior-posterior axis of an embryo. Depending on the 
axial level of neural crest induction, NCCs are divided into four main territories, cranial 
neural crests which contributes to most of the craniofacial bone and cartilage and cranial 
nervous system, cardiac neural crest, which regulates the septation of the cardiac outflow 
tract into aorta and pulmonary tract, vagal and sacral neural crests which gives rise to the 
ENS, and the trunk neural crest, which forms all of the peripheral nervous system of the 
trunk and also forms the chromaffin cells within the adrenal gland. 
ENTERIC NEURAL CREST CELLS (ENCCS)  
Enteric Neural Crest cells (ENCCs) is the name given to all the NCCs that 
populate the developing gut and form the ENS. This includes vagal neural crest cells, 
(originating at the vagal (somites 1-7) regions of the embryonic axis) and sacral neural 
crest cells (originating at the sacral (caudal to somite 24) regions of the embryonic axis). 
The vagal and sacral neural crest cells contribute to the ENS at different gut regions 
(Burns et al., 2000; Durbec et al., 1996; Wallace and Burns, 2005; Young and Newgreen, 
2001). Vagal NCCs migrate in a rostral to caudal direction and sequentially contribute to 
the foregut and midgut and proximal portion of the hindgut (Durbec et al., 1996; 
Gershon, 1997; Young et al., 1998). In contrast, sacral NCCs contribute to the distal 
hindgut (Burns and Le Douarin, 1998; Kapur, 2000).  
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In mice, ENCCs take about six days to colonize the gut.  Vagal NCCs enter the 
foregut around embryonic day E8.5/E9.0 and gut colonization is complete around E14.5 
(Figure II-1) (Newgreen and Young, 2002; Young and Newgreen, 2001), with typical 
mouse gestation ranging from 18-21 days. In humans, this process takes about three 
weeks (Anderson et al., 2006b), beginning around week 4 and ending by week 7 
(Druckenbrod and Epstein, 2005; Fu et al., 2003).  
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ENTERIC NEURAL CREST CELL MIGRATION 
ENCCs migrate through the gut tube as chains of interconnected cells. The cells at 
the leading edge of the migrating ENCC population are referred to as the wavefront, 
while the cells behind the wavefront are referred to as the trailing cells (Druckenbrod and 
 
Figure I-1: Enteric neuron (Tuj1) immunostaining in wild-type embryonic guts. Tuj1 
(red) immunostaining of E11.5 to E14.5 whole guts show the extent of 
colonization at the particular embryonic stage. At E11.5, the embryonic 
gut is in a hairpin formation and neurons are present to the cecum. At 
E12.5 the gut has grown, and the neurons have reached the proximal 
hindgut. At E14.5 neurons have reached the distal hindgut and grown 
significantly and the hairpin formation is no longer present.  Nuclei are 
counterstained with 4’,6-diamidino-2-phenylindole (DAPI) (blue). 
(Figure 1 from (Butler Tjaden and Trainor, 2013)). 
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Epstein, 2005, 2007; Young et al., 2004). The migratory behavior of the leading and 
trailing cells is different, suggesting a role for the micro-environment and cell-cell 
interactions during the process of ENCC migration (Druckenbrod and Epstein, 2007). For 
example, it has been shown that the leading wavefront cells display significant caudal 
expansion, while the trailing cells exhibit limited expansion. Thus, it is the wavefront 
ENCCs that are responsible for the colonization of the hindgut (Nishiyama et al., 2012).  
It had been previously proposed that migration of ENCCs through the cecum 
(circumflex ENCCs: cfENCCs) was important for hindgut colonization (Barlow et al., 
2003; Coventry et al., 1994; Kruger et al., 2003). However, recent real-time imaging 
experiments have shown that, between E10.5-11.5, ENCCs destined for the hindgut 
traverse the mesentery (trans-mesenteric ENCCs: tmENCCs) as solitary cells. At this 
stage, the gut is in a hairpin formation and the midgut and hindgut are positioned opposite 
to each other in parallel, which allows for this trans-mesenteric migration of ENCCs. 
These tmENCCs, which were previously thought to be sacral neural crest cells (Young et 
al., 2004), are the major source of the ENS in the hindgut (Figure I-2) (Nishiyama et al., 
2012).  
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Since the midgut and hindgut are juxtaposed only during E10.5-11.5, and 
tmENCCs are the primary cell population contributing to the hindgut ENS, these cells 
have only a limited period of time to reach the hindgut. Should these tmENCCs 
experience delayed migration through the mesentery, the result will be impaired 
colonization of the hindgut (Nishiyama et al., 2012). Whether there is a strict time 
window for ENCCs to colonize the hindgut is still debatable. ENCC grafting experiments  
done by Druckenbrod et al. showed that the age of the recipient, not the donor, 
determined whether the colon could be colonized, suggesting that the hindgut 
microenvironment changes at E14.5, indicated by increased laminin levels, and these 
 
Figure I-2: Trans-mesenteric enteric neural crest cells migrate through the mesentery 
of E11.75 guts. Whole-mount co-immunostain of GFP and Tuj1 staining 
of E11.75 gut from a RosaeYFP; Wnt1Cre embryo. White arrows depict 
tmENCCs in the mesentery between the midgut and hindgut. Mesentery 
is located between dotted lines. Neural crest cells are stained with GFP 
and mature neurons are stained with Tuj1 (red). Nuclei are 
counterstained with 4’,6-diamidino-2-phenylindole (DAPI) (blue). 
(Figure 2 from (Butler Tjaden and Trainor, 2013)). 
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changes are no longer permissive to ENCC migration (Druckenbrod and Epstein, 2009).  
In contrast, using another mouse model that has delayed ENCC migration, Barlow et al 
has shown that colonization can be completed after E14.5, suggesting that there may not 
be a strict permissive window for hindgut colonization (Barlow et al., 2012).  
A completely colonized gut with a functioning ENS is necessary for peristaltic 
activity of the gut wall and proper gut function. Defects in ENCC survival, migration, 
proliferation, or differentiation result in their failure to colonize the entire gut (Clavel, 
1988; Gaillard, 1982; Hoehner et al., 1996; Langer, 1994; Tosney et al., 1986; Webster, 
1973) and present as a devastating neurocristopathy, Hirschsprung disease (HSCR). 
Hirschsprung Disease (HSCR) 
Hirschsprung Disease (HSCR) is a devastating neurocristopathy that affects 
1/5000 live births and usually presents with the inability to pass meconium, together with 
abdominal distension and discomfort. Most HSCR cases are limited to the rectum and 
sigmoid colon, but cases of total intestinal aganglionosis are possible, occurring in 3-8% 
of HSCR patients (N-Fékété, 1986). Patients with HSCR typically present with sustained 
contraction of the aganglionic bowel segment, leading to intestinal obstruction and 
distension of proximal segments (megacolon) and subsequently, the inability to pass 
stool. Currently, the only treatment available is surgical removal of the aganglionic bowel 
(Parisi, 2006).  
CLINICAL PRESENTATION 
Histologically, aganglionosis is pathognomonic for HSCR. In 80-85% of HSCR 
cases, this aganglionosis is limited to the rectum and sigmoid (short-segment disease). 
Long segment disease occurs in up to 20% of cases, where the aganglionosis extends 
proximal to the sigmoid colon. Total aganglionosis is more rare, occurring in 3-8% of 
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patients with HSCR (N-Fékété, 1986). Another rare variant is ultra-short segment 
disease, affecting only the distal rectum below the pelvic floor and anus (Neilson and 
Yazbeck, 1990). Hypoganglionosis and aganglionosis of the terminal gut can be caused 
by a reduction in enteric progenitor cells (Gianino et al., 2003; Stanchina et al., 2006). 
The portion of the bowel with reduced enteric neuron density is termed the transition 
zone, and it is always cranial to the aganglionic region (Kapur, 2009). The zone of 
aganglionosis results in tonic contraction of the affected bowel, leading to obstructive 
symptoms. Most often, patients are diagnosed in the neonatal period (Singh et al., 2003), 
presenting with a distended abdomen, the delayed passage of meconium (>24 hours), and 
vomiting. When patients are diagnosed later in childhood, they often have short-segment 
aganglionosis and present with chronic constipation and distension, vomiting, and failure 
to thrive (Parc, 1984). In 10% of HSCR cases, patients can present with enterocolitis, 
fever, and even septicemia. 
HSCR occurs in 1/5000 live births and has an overall 4:1 male predominance 
(Spouge, 1985).  However, for short segment disease there is a 4.2-4.4 male: female 
predominance and for long-segment disease there is a 1.2-1.9 male: female predominance 
(J A Badner, 1990). Furthermore, the risk of an HSCR sibling recurrence is 200 times 
higher than in the general population (4% versus 0.02%) (Bodian and Carter, 1963; J A 
Badner, 1990). Up to 30% of patients with HSCR also exhibit other abnormalities 
(Passarge, 1967; Spouge, 1985), such as velocardiofacial defects (Kerstjens-Frederikse et 
al., 1999), congenital heart defects (Ryan et al., 1992), gastrointestinal tract 
malformations, CNS abnormalities, genitourinary problems, craniofacial malformations 
and spina bifida (Amiel and Lyonnet, 2001; J A Badner, 1990; Parisi and Kapur, 2000; 
Ryan et al., 1992; Sarioglu, 1997). In addition, 2-15% of HSCR cases are also associated 
with Down’s syndrome (Amiel and Lyonnet, 2001; Fu et al., 2003).  
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DIAGNOSIS 
The diagnosis of HSCR can be made by a variety of methods. However, the 
preferred first diagnostic procedure is a contrast enema. In about 70-90% of the cases, 
this contrast enema will show the transition zone between normal (dilated) bowel and the 
narrow aganglionic bowel (Rosenfield, 1984; Smith and Cass, 1991). The rectosigmoid 
ratio is used to evaluate the transition zone, with a ratio greater than 1 being considered 
‘normal.’ A stool-filled proximal bowel will decrease the rectum to sigmoid ratio. Plain 
radiographs showing dilated bowel loops, and anorectal manometry may also help with 
the diagnosis. When using anorectal manometry, clinicians note an absent rectoanal 
inhibitory reflex (Tobon et al., 1968). This absence of internal sphincter relaxation (Emir 
et al., 1999) is a reliable test after neonatal day 12, when the rectoenteric reflex is present 
(Lopez Alonso, 1992).  
The gold standard for an HSCR diagnosis is a rectal biopsy, and it is possible to 
obtain a submucosal rectal suction biopsy without anesthesia (R J Andrassy, 1981). A 
positive diagnosis for HSCR includes confirming the absence of ganglionic cells in the 
myenteric and submucosal plexi, and presence of hypertrophic nerve trunks. Clinicians 
must be careful to biopsy proximal to the pectinate (dentate) line, which is normally 
physiologically hypoganglionotic, and caudal enough to detect even very short segment 
aganglionosis (Kapur, 2006). The biopsy specimen can also be stained for increased 
acetylcholinesterase activity, which contributes to a positive diagnosis (Kurer et al., 
1986). If a suction biopsy does not provide an accurate diagnosis, a full-thickness biopsy 
is indicated.  
TREATMENT 
Currently, the only treatment for HSCR is surgery. Failure to surgically treat 
HSCR can be fatal due to malnutrition or sepsis following bowel perforation. Although 
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surgery is the routine therapy for HSCR patients, surgical outcomes can vary widely, 
with a range of long term consequences, such as constipation, fecal incontinence and 
enterocolitis (Baillie et al., 1999; Menezes et al., 2006). The surgical treatments aim to 
remove the aganglionic bowel and anastomose the normal bowel with the anus while 
preserving sphincter function. The main techniques used currently include the total 
transanal endorectal pull-through (TERPT) (Albanese et al., 1999; De la Torre-
Mondragón and Ortega-Salgado, 1998; Langer et al., 1999) and the laparoscopic assisted 
pull-through (Georgeson et al., 1995; Jona, 1998) procedures. 
Compared to traditional transabdominal open surgery, TERPT and laparoscopic 
assisted pull-through facilitate faster recoveries, shorter hospital stays, improved 
cosmetic appearance, and fewer perioperative complications (Fujiwara et al., 2007; 
Georgeson, 1999). The TERPT is useful for aganglionosis confined to the rectosigmoid 
area (De la Torre and Ortega, 2000), as it minimizes intraabdominal contamination, 
adhesion formation, and the risk of damage to pelvic structures. The laparoscopic assisted 
pull-through has the added benefit of collecting seromuscular biopsies for the 
identification of normal colon, better mobilization and dissection of the aganglionic 
colon, and minimized dilation of the anal canal (Georgeson, 1999; Georgeson et al., 
1995).  
Although the TERPT and laparoscopic assisted pull-through procedures have 
better outcomes than traditional open surgery, there are risks and complications. 
Common post-surgical problems include long-term obstructive symptoms and soiling. 
Milder obstructive symptoms can be treated by dietary changes, laxatives, enemas or 
botulinum toxin injections every 3-4 months (Minkes and Langer, 2000; Patrus et al., 
2011). Patients who are responsive to botulinum toxin injections but are unable to 
undergo repeated injections can have a myectomy procedure (Wildhaber et al., 2004). 
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Although a repeat pull-through procedure can be done if there is residual or acquired 
aganglionosis, strictures or dysfunctional, dilated proximal bowel, it is very difficult due 
to the scarring from the previous procedure (Langer, 1999; Teitelbaum and Coran, 2003).  
PATHOGENESIS 
Proper neural crest cell migration, proliferation, differentiation, survival and 
apoptosis all contribute to a functional ENS. Perturbation in any of these processes can 
lead to a Hirschsprung disease phenotype.  Many genes which play a critical functional 
role in neural crest cell development have been implicated in HSCR, including the proto-
oncogene RET, endothelin signaling genes, and transcription factors (Parisi and Kapur, 
2000). Although over a dozen genes have been identified that contribute to the etiology 
of HSCR, these pathways only account for about half of the known cases (Table I-1).  
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Table I-1: Hirschsprung disease genes and contribution to neural crest cell migration, 
proliferation, differentiation and survival. (Adapted from Table 1 from 
(Butler Tjaden and Trainor, 2013)). 
Gene Migration Proliferation Differentiation Survival/Cell 
Death 
RET Attracted to 
GDNF 
Promote 
proliferation 
Promote neuronal 
differentiation 
Promote ENCC 
and enteric neuron 
survival, Inhibit 
non-apoptotic cell 
death 
GDNF Gradient to attract 
RET+ and 
GFRα1+  ENCCs 
Promote 
proliferation 
Promote neuronal 
differentiation 
Promote survival 
GFRa-1 Attracted to 
GDNF, necessary 
to cross mesentery 
  Promote enteric 
neuron survival 
EDNRB Necessary for 
normal migration 
Maintain 
proliferative state 
  
EDN3/ET3 Necessary for 
normal migration, 
may maintain 
permissive 
environment 
 Inhibit neuronal 
differentiation 
 
ZFHX1B Neural 
specification, 
Epithelial-to-
mesenchymal 
transition 
   
PHOX2B Expressed in 
migrating ENCCs 
   
BMPs Regulation of 
ENCC migration 
 Required for 
normal ganglion 
formation 
 
PAX3   Required for 
normal ganglion 
formation 
 
SHH Oppose GDNF, 
reduce migration 
Promote 
proliferation 
Inhibit neuronal 
differentiation by 
affecting 
responsiveness to 
GDNF 
 
CXCR4 Indirect support of 
trans-mesenteric 
migration by 
regulating 
vascular 
development 
   
SOX10  Maintain ENS 
progenitor state 
  
NRTN/NTN  Promote 
proliferation 
Promote neuronal 
differentiation 
Promote survival 
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For the sake of simplification, I have classified the HSCR phenotype causing gene 
mutations into two categories: (1) affecting ENCC migration and (2) affecting ENCC 
survival, proliferation and differentiation. 
ENCC MIGRATION 
Many genes contribute to normal enteric neural crest cell migration to form a 
functional enteric nervous system, and mutations in any of these genes may cause an 
HSCR phenotype (Table I-1). 
GDNF and RET regulate neural crest cell migration 
Mutations in receptor tyrosine kinase (Ret) and glial cell line-derived neurotrophic 
factor (Gdnf) family members are the major contributors for HSCR cases caused due to 
failed ENCC migration. Mutations in the Ret receptor tyrosine kinase pathway account 
for 15-35% of patients with sporadic HSCR (HSCR in a single family member) and 50% 
of familial cases (Brooks et al., 2005). Patients with heterozygous mutations in Gdnf have 
also been diagnosed with HSCR. GDNF is a secreted ligand protein that binds 
glycosylphosphatidylinositol-linked receptor (GFRα1), expressed on ENCCs. Together, 
the GDNF- GFRα1 complex then binds and activates RET, a transmembrane protein also 
expressed on ENCCs. RET then auto-phosphorylates and activates downstream pathways 
(Tansey et al., 2000) that influence ENCC survival and apoptosis, proliferation, migration 
and differentiation. (Figure I-3) (Eng, 1999; Mulligan, 2014).  
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GDNF expression in the gut mesoderm is the primary chemoattractant for the 
ENCC wavefront (Figure I-4). Prior to the entry of ENCCs into the foregut, GDNF is 
expressed in the gut mesoderm (Natarajan et al., 2002). During ENCC entry into the gut, 
RET and GFRα1 are expressed on the ENCCs (Tomac et al., 1999). When the ENCC 
wave front reaches the esophagus, GDNF is expressed in the stomach, and as the ENCCs 
approach the distal small intestine GDNF expression is again elevated in the cecum, 
suggesting GDNF acts to attract RET and GFRα1 expressing ENCCs to the proper 
 
Figure I-3: GDNF and RET are expressed on enteric neural crest cells. GNDF is 
expressed in the gut mesoderm. GNDF forms a complex with GFRα1, 
which bind and activate RET to influence ENCC survival, proliferation, 
migration and differentiation. Figure 1B from (Mulligan, 2014). 
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location (Natarajan et al., 2002; Young et al., 2001). This GDNF- GFRα1-RET pathway 
is also important for the tmENCC migration through the mesentery between the midgut 
and hindgut (Figure I-4). Without GFRα1, tmENCCs are unable to leave the midgut 
(Nishiyama et al., 2012).  Defects in the formation of the GDNF-RET-GFRα1 complex 
result in an aganglionosis phenotype, irrespective of whether the mutation is in RET, 
GDNF or GFRα1 (Cacalano et al., 1998; Eketjäll and Ibáñez, 2002; Moore et al., 1996; 
Nishiyama et al., 2012; Pichel et al., 1996; Sanchez et al., 1996; Schuchardt et al., 1994; 
Shepherd et al., 2004).  
 
 
Figure I-4: Enteric neural crest cell colonization of mouse GI tract. GDNF (red) 
expression acts to attract RET+ /GFRα1+ ENCCs (black dots) 
throughout gut development. Yellow shows where Edn3 expression is 
present, and blue shows where retinoic acid signaling is present. Neural 
crest cells must differentiate into neurons (green) and glia (purple) during 
their migratory phase. Adapted from Figure 1 from (Lake and 
Heuckeroth, 2013), modified by Joaquin Navajas Acedo. 
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Patients with long and short segment disease have been identified with mutations 
in RET (Edery et al., 1994; Romeo et al., 1994). However, penetrance is estimated 
between 50-70% (Bolk et al., 2000). The “gene dosage” necessary for normal ENS 
development differs between mice and humans. For example, a heterozygous mutation of 
RET in humans can lead to HSCR, but RET
+/-
 only exhibit hypoganglionosis in mice 
(Carniti et al., 2006). In contrast, RET
-/-
 mice have complete intestinal aganglionosis 
(Schuchardt et al., 1994). To mimic the aganglionic phenotype, mice need to lose at least 
60-70% of RET expression (Uesaka et al., 2008). RET has two isoforms: RET9 and 
RET51, both of which are conserved between humans and mice (Carter, 2001). Deletion 
of Ret51 (Ret
9/9
), does not affect colonization of distal colon in mice. In contrast, point 
mutations and complete deletion of Ret9 result in failure of distal colon colonization 
suggesting that unlike RET51, RET9 is necessary and sufficient for normal ENS 
development (Asai et al., 2006; Carniti et al., 2006; de Graaff et al., 2001; Nishiyama et 
al., 2012). 
Interestingly, Ret+ intestinal ENS progenitor cell transplantation from wild-type 
E11.5 embryos to the E8.5 vagal region of recipient control and Ret
-/- 
embryos resulted in 
colonize of the entire length of the control intestine by transplanted cells, but only the 
proximal foregut in the Ret
-/- 
embryos, suggesting a non-cell autonomous Ret effect on 
early gut colonization and ENS development (Bogni et al., 2008). Combined with 
previous transplantation experiments (Natarajan et al., 1999), which transplanted Ret+ 
cells directly into the gut wall of Ret
-/- 
embryos, and resulted in full colonization of the 
gut, this vagal transplantation study emphasizes the capacity of Ret+ cells to colonize the 
gut, but the extent of colonization relies on the transplantation location and timing, and 
number of transplanted progenitors.  
 18 
Endothelin Pathway regulation of neural crest cell migration 
Endothelin signaling is another pathway necessary for normal ENCC migration 
and helps maintain a permissive NCC environment. Endothelin 3 (EDN3 or ET3) is a 
peptide secreted by gut mesenchyme (Figure I-4) (Nataf et al., 1998), that binds to the G-
protein coupled receptor ENDRB, which is expressed on migrating ENCCs. Endothelin 
converting enzyme 1 (ECE1) post-translationally modifies the immature form of EDN3 
into its active form (Baynash et al., 1994; Xu et al., 1994).  The EDN3-EDNRB signaling 
pathway is involved in regulating the normal migration of ENCCs, and maintains enteric 
progenitors in a proliferative state (Barlow et al., 2003; Bondurand et al., 2006). Thus, 
END3 inhibits ENCC differentiation (Bondurand et al., 2006; Hearn et al., 1998; Nagy 
and Goldstein, 2006; Wu et al., 1999).  
Patients with heterozygous mutations in the EDN3-EDNRB pathway account for 
5% of HSCR cases (Amiel and Lyonnet, 2001), including one case caused by a mutation 
in ECE1 (Hofstra et al., 1999). EDN3 and EDNRB mutations are associated with both 
syndromic (Waardenburg Shah) and non-syndromic forms of Hirschsprung disease 
(Amiel and Lyonnet, 2001; Brooks et al., 2005). Patients with Waardenburg Shah 
Syndrome have colonic aganglionosis, pigmentation defects and sensorineural deafness. 
The inheritance of this syndrome can be either recessive (which is the case for patients 
with mutations in EDNRB and EDN3 cases) or dominant (Amiel and Lyonnet, 2001; 
Brooks et al., 2005). Patients with EDNRB Hirschsprung disease are associated with a 
large Mennonite population (Mulligan et al., 1993). Carriers of the EDNRB Tryp276Cys 
mutation display incomplete penetrance, with heterozygous mutations leading to HSCR 
in 21% of the affected patients, and 74% in patients with homozygous mutations 
(Puffenberger et al., 1994). As with RET mutations, the human ENS is more sensitive to 
reduced ENDRB signaling than in mice (Wallace and Anderson, 2011). 
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Mouse models with mutations in Edn3, Ednrb or Ece1 display various 
aganglionosis and pigmentation defects (Baynash et al., 1994; Hosoda et al., 1994; 
Yanagisawa et al., 1998). Lethal spotted mice have a mutation in the EDN3 ligand 
(Edn3
ls/ls
), and piebald lethal have an EDNRB mutation (Ednrb
sl/sl
). Both these mutants 
exhibit ENCC migration defects (delayed number of ENCCs in small intestine), and lack 
enteric neurons in the distal bowel, and display piebaldism (Barlow et al., 2003; Baynash 
et al., 1994; Hosoda et al., 1994; Lee et al., 2003; Ro et al., 2006). Conditional deletion 
studies suggest that the critical time window where EDN3-EDNRB signaling is necessary 
is between E10.5-12.5 (Shin et al., 1999). Interestingly, beginning at E10.0, Edn3 mRNA 
is detected ahead of migrating ENCCs (Barlow et al., 2003). It has been suggested that 
because aganglionosis in Ednrb- and Edn3-deficient mice is restricted to the distal colon, 
the EDN3-EDNRB signaling pathway is required for hindgut colonization (Leibl et al., 
1999).  
Homozygous deletion of Ednrb results in a 24 hour delay in ENCC advancement. 
By E14.5, wild-type guts are fully occupied by ENCCs, but in mutant guts, ENCCs have 
altered trajectories and reduced speed. Grafting experiments suggest that donor invasion 
is restricted by the age of the recipient tissue, not genotype. It has been previously 
hypothesized that at E14.5 the gut microenvironment changes to become non-permissive 
to ENCC migration and that if ENCCs have not finished migration by E14.5, the embryos 
will present a HSCR phenotype (Druckenbrod and Epstein, 2009). However, recent 
experiments in Tcof1 haploinsufficient mice, a mouse model for reduced NCC formation, 
challenge this hypothesis. In spite of delayed ENCC migration between E10.5-E14.5, 
Tcof haplosufficient embryos display continued colonization from E14.5-E18.5 and form 
a complete ENS, suggesting that the balance between NCC proliferation in concert with 
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differentiation and extrinsic gut microenvironmental influences can overcome pathogenic 
migration and decreased cell numbers (Barlow et al., 2012). 
Additional genes regulating neural crest cell migration 
The zinc finger homeobox 1b, SMAL interacting protein, or 
ZFHX1B/SIP1/SMADIP1, is expressed in premigratory and migratory vagal neural crest 
cells. This transcription factor is involved in neural specification and the epithelial to 
mesenchymal transition that occurs during early NCC development. A human mutation in 
ZFHX1B is associated with Mowat-Wilson syndrome, of which HSCR is a component 
(Yamada et al., 2001). Zfxh1b
-/- 
embryos exhibit a complete absence of vagal NCC 
precursors, and die around E9.5 due to cardiovascular and neural defects (Van de Putte et 
al., 2003). Analysis of neural crest cell-specific Zfx1b mutants suggests that ZFHX1B 
may be required for anterior vagal NCCs differentiation for the colonization of the GI 
tract (Van de Putte et al., 2007). 
Paired-like homeobox2b (PHOX2b) is a transcription factor expressed in 
migrating ENCCs, enteric neurons and glial cells (Corpening et al., 2008). This 
transcription factor is required for RET expression in ENCCs. Mouse and zebrafish 
models lacking Phox2b have total intestinal aganglionosis due to a failure of ENCCs to 
colonize the gut properly (Elworthy et al., 2005; Pattyn et al., 1999). Phox2b mutant mice 
lack a PNS, and die at birth (Pattyn et al., 1999). Human mutations in PHOX2b have 
recently been described in association with HSCR, particularly with congenital central 
hypoventilation syndrome (CCHS) and neuroblastoma (NB), referred to as CCHS-
HSCR-NB. (Amiel et al., 2003; Nagashimada et al., 2012; Trochet et al., 2005).  
Bone morphogenetic proteins (BMPs) also play a role in the regulation of NCC 
migration and ENS enteric ganglion formation (Faure et al., 2007; Goldstein et al., 2005). 
Targeted inhibition of intestinal BMP activity using noggin leads to delayed ENCC 
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migration by interfering with the migratory effects of GDNF signals. Therefore, 
appropriate BMP and GDNF interactions are necessary for the proper formation of a 
complete ENS (Goldstein et al., 2005). 
Sonic Hedgehog (SHH) is another key regulator of ENCCs migration (Fu et al., 
2004) and ENS plexus formation (Ramalho-Santos et al., 2000). SHH and GDNF have 
opposing effects on ENCC migration. ENCCs migrate in the presence of GDNF, but 
addition of SHH reduces this migration by affecting the responsiveness of ENCCs 
towards GDNF signaling or by regulating proliferation and differentiation of ENCCs in 
the gut (Fu et al., 2004). Thus, a balance between GDNF and SHH may be important for 
the proper positioning of the ENS plexus. 
CXCR4 is a cell surface receptor for the CXC chemokine PBSF/SDF-1 (pre-B-
cell growth-stimulating factor/stromal-cell derived factor). This factor is expressed in 
developing vascular endothelial cells. Cxcr4 null mice display a failure to properly form 
the large vessels that supply the GI tract (Tachibana et al., 1998). These mice also exhibit 
fewer tmENCCs at E11.5 and impaired hindgut colonization of ENCCs by E14.5 
compared to wild-type littermates (Nishiyama et al., 2012). This implies that tmENCC 
migration is partially dependent on vascular-derived signals, as CXCR4 indirectly 
supports trans-mesenteric migration by regulating vascular development. 
ENCC PROLIFERATION, SURVIVAL AND DIFFERENTIATION 
Proliferation rates in the developing GI system are equivalent throughout the 
ENS. Active ENCC proliferation at the wavefront is necessary to colonize the gut, while 
that behind the wavefront is necessary to fully populate the expanding intestine (Young et 
al., 2005). Millions of enteric neurons and glia are present in the adult intestine (Gianino 
et al., 2003), and a balance between proliferation and differentiation ensures maintenance 
of a sufficient progenitor pool of cells necessary for complete ENS colonization (Heanue 
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and Pachnis, 2007; Laranjeira and Pachnis, 2009; Stanchina et al., 2006). Many of the 
genes discussed above, such as RET, GDNF, GFRα1 and another GDNF family member, 
NRTN, also function to maintain ENCCs and post-mitotic enteric neuron survival in the 
gastrointestinal tract. 
Ret, Gdnf, and Gfrα1 are necessary for early ENCC survival (Taraviras and 
Pachnis, 1999). Gfrα1 and Ret are essential for survival of colonic enteric neurons. 
GDNF and RET promote proliferation of ENS progenitors and their differentiation into 
neurons and glia (Heuckeroth et al., 1998; Taraviras et al., 1999), whereas GDNF 
determines the rate of ENS progenitor proliferation (Gianino et al., 2003). Additionally, 
enteric neuron survival is sensitive to Ret dosage (Uesaka et al., 2007; Uesaka et al., 
2008).  Low Ret dosage leads to delayed migration and increased non-apoptotic cell death 
in ENCCs (Uesaka et al., 2008). Inhibiting cell death in Ret hypomorphic embryos results 
in formation of a normal ENS, suggesting that cell death, not a migratory delay of 
ENCCs, is a principle cause of isolated HSCR (Uesaka and Enomoto, 2010).  
The EDN3-EDNRB signaling pathway is not only involved with regulating 
ENCC migration, but also plays a role in maintaining enteric progenitors in a 
proliferative state (Barlow et al., 2003; Bondurand et al., 2006). By keeping progenitors 
in a self-renewing state, the presence of Edn3 inhibits ENCC differentiation (Bondurand 
et al., 2006; Hearn et al., 1998; Nagy and Goldstein, 2006; Wu et al., 1999).   
Neurturin (NRTN or NTN) is a ligand in the GDNF family, which binds to 
GFR2 to activate RET and promote the projection and branching of some enteric 
neuron axons. This trophic factor is important for the maintenance of neuronal 
projections, as neuturin-deficient mice have reduced nerve fiber density in the ENS, 
smaller enteric neuron cell bodies and abnormal GI motility, as well as abnormal gut 
neurotransmitter release and motility (Gianino et al., 2003; Heuckeroth et al., 1999). 
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NRTN promotes the proliferation of ENS precursors and neuronal differentiation to 
increase the number of neurons and glia (Heuckeroth et al., 1998). Homozygous mice 
with null mutations in Nrtn and Gfr2 have reduced excitatory fibers present in the ENS 
and decreased gut motility along the entire GI tract (Gianino et al., 2003; Heuckeroth et 
al., 1999; Rossi et al., 2003). Myenteric ganglion cells were also smaller in Nrtn
-/-
 adult 
mice compared to wild-type mice, suggesting that NRTN plays a supportive role for 
neurons and cell size maintenance (Heuckeroth et al., 1999), and promotes survival of 
enteric NCCs as well as the maintenance of enteric neurons and glia. In addition, Ret+ 
cells from embryonic rat guts were cultured and failed to survive in the absence of GDNF 
or NRTN (Taraviras et al., 1999). Thus, it has been shown both in vivo and in vitro that 
NRTN promotes survival of enteric NCCs as well as the maintenance of enteric neurons 
and glia.  
SOX10 (SRY-related high mobility group-box transcription factor) is expressed 
in NCCs as they emigrate from the neural tube. Sox10+ cells are used as a marker of ENS 
progenitors as it is expressed during NCC migration, and maintains the ENS progenitor 
state (Bondurand et al., 2006; Bondurand et al., 2003). This transcription factor regulates 
key genes required for ENS, melanocyte and glial development (Kelsh, 2006), such as 
Ednrb and Ret in ENCCs (Lang et al., 2000; Lang and Epstein, 2003; Zhu et al., 2004). In 
humans, SOX10 mutations account for less than 5% of both syndromic and nonsyndromic 
forms of HSCR. In patients, SOX10 mutations are associated with the dominant 
inheritance of HSCR in Waardenburg Syndrome (Pingault et al., 1998), and some 
patients have additional neurologic phenotypes (Inoue et al., 1999; Southard-Smith et al., 
1999; Touraine et al., 2000), which is attributed to dysmyelination of their central and 
peripheral nervous systems (Touraine et al., 2000). Homozygous Sox10
lacZ
 mice display 
total intestinal aganglionosis and die perinatally (Britsch et al., 2001). Zebrafish sox10 
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homozygous mutants display abnormal ENS and melanocyte phenotypes. Sox10
Dom 
mice 
have a single base pair insertion leading to a spontaneous dominant negative mutation.  
This truncates Sox10 downstream of its DNA binding domain (Southard-Smith et al., 
1998). These mice display a smaller pool of ENS progenitors, compared to wild-type 
mice (Britsch et al., 2001; Paratore et al., 2002), and lack enteric neurons through the 
entire GI tract (Kapur, 1999; Southard-Smith et al., 1998). Sox10 homozygous mutant 
mice die at birth, and exhibit total intestinal aganglionosis, as the vagal NCC die prior to 
their entry into the gut (Britsch et al., 2001; Kapur, 1999).  Up to 20% of the 
heterozygous mice have colonic aganglionosis, but the incidence is background-
dependent (Cantrell et al., 2004; Maka et al., 2005; Southard-Smith et al., 1998; 
Stanchina et al., 2006).  
GENETIC INTERACTIONS BETWEEN INVOLVED IN ENCC DEVELOPMENT AND HSCR 
PHENOTYPE 
Noncoding mutations in RET have been shown to increase susceptibility to other 
HSCR mutations (Brooks et al., 2005; Emison et al., 2005; Griseri et al., 2007). These 
noncoding mutations may be involved with regulatory elements and cellular mechanisms, 
such as transcription, translation, location or level of gene expression, or may be 
associated with linked susceptible loci. For example, the 9q31 locus segregates with the 
HSCR phenotype in families with noncoding RET mutations, suggesting that a 
combination of these specific loci may cause a HSCR phenotype (Brooks et al., 2005). 
Additionally, a genome-wide association study on a Mennonite population (with a ten-
fold increase in HSCR compared to the general population), identified a HSCR-
associated, non-coding RET mutation in the transcriptional enhancer of intron 1, which 
associates with EDNRB mutations (Carrasquillo et al., 2002). It was later found that this 
same RET Mennonite haplotype makes a 20-fold greater contribution to HSCR risk than 
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the rarer protein-coding HSCR mutations (Emison et al., 2005). However, not all RET 
variants increase susceptibility to HSCR. A common variant in the 3’UTR of the RET 
gene has been shown to slow mRNA transcript decay (Griseri et al., 2007). The 
increasing number of identified non-coding susceptibility RET mutations is a reminder 
that although noncoding mutations may have low penetrance (Emison et al., 2005), they 
are capable of acting synergistically with other mutations to affect a disease phenotype.  
As noted above, mutations may act synergistically resulting in a more severe 
phenotype. Numerous models which typically cause distal colonic aganglionosis when 
crossed to an endothelin pathway mutant, resulting in total colonic aganglionosis, which 
is indicative of genetic interactions. For example, RET
51/51
; Edn3
ls/ls
 double mutants 
(Barlow et al., 2003), Sox10
Dom/+
; Edn3
ls/ls
 double mutants (Stanchina et al., 2006) and 
Sox10
Dom/+
; Ednrb
sl/sl
 double mutants (Cantrell et al., 2004) all exhibit total intestinal 
aganglionosis, suggesting genetic interactions that increase the penetrance and severity of 
the HSCR phenotype.  
Gdnf also has a synergistic effect with Edn3 to enhance this proliferative effect, 
but inhibits neuronal differentiation to maintain the precursor cell population (Hearn et 
al., 1998; Nagy and Goldstein, 2006).  
PAX3 (Paired box 3) is also required for normal enteric ganglion formation, and 
does so by acting through RET. Pax3 and Sox10 bind to the RET enhancer, and thus 
activate RET transcription and expression (Lang et al., 2000). Furthermore, neither 
Pax3
+/-
 nor Tcof1
+/-
 mice exhibit colonic aganglionosis, but the compound Tcof1
+/-
; 
Pax3
+/-
 animals have distal colonic aganglionosis at E18.5, suggesting that Pax3 acts a 
modifier of the Tcof1
+/-
 phenotype by increasing the apoptosis of ENCCs, reducing the 
number of NCCs that can migrate into the foregut (Barlow et al., 2013). 
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A reciprocal interaction between Sox10 and Phox2b is illustrated using a model 
for CCHS-HSCR-NB, created by a introducing a nonpolyalanine repeat expansion 
mutation in PHOX2B in the Phox2b mouse locus. These mouse mutants have persistent 
Sox10 expression, leading to reduced proliferation and biased glial differentiation 
(Nagashimada et al., 2012). Therefore, the interaction between Sox10 and Phox2b is 
necessary to maintain appropriate differentiation of neurons and glia in the ENS. 
Rare human cases have been documented with NTN mutations, and of those 
cases, a mutation was found in RET or another HSCR gene, suggesting a modifier effect 
(Angrist et al., 1996; Doray, 1998; Eketjäll and Ibáñez, 2002; Hofstra et al., 1996; 
Ivanchuk et al., 1996; Parisi and Kapur, 2000; Salomon et al., 1996).  
DISCUSSION: PROMISING MOUSE TRANSPLANTATION RESCUE EXPERIMENTS 
Currently the only treatment available for patients with HSCR is surgical removal 
of the aganglionic bowel. However, recently it has been suggested that stem cell therapy 
may be a viable option to treat patients with aganglionosis. Studies have been conducted 
in both embryonic and postnatal intestines to further elucidate the role and 
microenvironmental requirements of ENS progenitors, as well as to investigate a 
potential rescue during postnatal development of the HSCR phenotype. 
There have been numerous studies  showing the potential of progenitor and stem 
cells to give rise to neurons of the embryonic ENS (Bondurand et al., 2003; Lindley et al., 
2008; Mosher et al., 2007; Natarajan et al., 1999), but until recently it was unclear 
whether this could be a viable treatment option for humans born and diagnosed with 
HSCR. Recently, in a very promising  study, transplanted fetal and postnatal intestinal 
NCC-derived neurospheres into the colons of postnatal mice revealed that the cells 
derived from the neurosphere transplantations were able to migrate, proliferate and 
generate neurons and glia in the recipient colons (Hotta et al., 2013). This study 
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emphasizes the importance to treat disease such as HSCR in the postnatal period, as the 
diagnosis is definitively made after birth.  
DISCUSSION: NEED TO CONTINUE TO ELUCIDATE GENES THAT CONTRIBUTE TO HSCR 
Many genes that contribute to the pathogenesis of HSCR have been identified, 
however, mutations in these genes only account for about half of the known human cases. 
Other genes may contribute to the etiology of HSCR by acting as modifiers or 
contributing to critical ENCC developmental processes, such as migration, proliferation, 
differentiation and survival (Butler Tjaden and Trainor, 2013). There needs to be a 
continued effort in finding genes that are responsible for or associated with HSCR, not 
only through mouse models but also by identifying mutations in affected individuals. 
Whole exome and whole genome sequencing of patient samples would be an ideal way to 
identify these genes and mutations. 
With new genetic models of HSCR and new tools to examine them, new modes of 
pathogenesis may be proposed. For example, recent time lapse imaging using a 
photoconvertible mouse mutant showed that ENCCs reach the hindgut by migrating 
through the mesentery between the midgut and hindgut, as opposed to a sequential 
migration from midgut to cecum to hindgut (Nishiyama et al., 2012). Even this single 
deviation from the previous model of ENCC migration necessitates that mutants with 
migratory dysfunction be revisited to examine the possible changes in tmENCC and 
cfENCC behaviors (Nishiyama et al., 2012), and the effects those changes may have on 
the progression of colonic aganglionosis.  
Hirschsprung disease is a highly complex and non-Mendelian disease, with wide 
phenotypic variability and incomplete penetrance. Additionally, the same phenotype 
(HSCR) is associated with mutations of multiple distinct genes (multigenic disease). 
These characteristics suggest the involvement of modifier genes or environmental 
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influences (Angrist et al., 1996; Bolk et al., 2000; Parisi and Kapur, 2000; Salomon et al., 
1996). For example, rare human cases have been documented with NTN mutations, and 
many of these cases had a concomitant mutation in RET or another known HSCR gene, 
suggesting a modifier effect (Doray, 1998).  
Thus, great strides are being made to better understand HSCR, but much is still 
unknown. Although the most promising transplantation rescue experiments have 
emphasized treating patients postnatally, after a definitive HSCR diagnosis (Hotta et al., 
2013), the continuation to find new animal models and more associated human genes 
along with new techniques to study these genetic disruptions are necessary, in the hopes 
that patients can be routinely screened, and newer potential treatments can be 
administered before clinical symptoms arise. 
Recently, mouse and chick studies have revealed important roles for the Vitamin 
A-derived molecule, retinoic acid, during ENS development (Fu et al., 2010; 
Niederreither et al., 2003; Sato and Heuckeroth, 2008; Simkin et al., 2013). These models 
will be discussed in the following section, and a new genetic model for RA-deficiency-
induced-HSCR is presented as the bulk of this thesis work. 
Vitamin A  
Vitamin A is an essential nutrient that plays major roles in embryonic 
development, gene transcription, bone growth and metabolism, skin and mucous 
membrane health, vision, hematopoiesis, and immune system maintenance (NAP, 2001). 
In food, vitamin A is found in two major forms: Retinol and carotenoids, of which beta-
carotene is the most important. Retinol is the highly bio-available form, found in animal 
liver, eggs, and milk products. Because this form of vitamin A is fat-soluble, it can build 
up in the body and become toxic. Beta-carotene, a “pro-vitamin A,” is a vitamin A 
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precursor that must be converted in the body to become a usable retinoid. This anti-
oxidant is found in deeply colored fruits and vegetables, and is most well-known for 
giving orange color to carrots. Although a diet high in fruits and vegetables may provide 
vitamin A and other necessary nutrients, relying totally on this source of vitamin A 
through beta-carotene can lead to deficiencies, as the conversion of carotenoids to retinol 
is low (12:1) (NAP, 2001). Furthermore, this conversion takes place mainly in the small 
intestine during absorption (Bendich and Langseth, 1989), and is tightly regulated to 
avoid excessive vitamin A absorption (Underwood, 1985).  
The recommended daily allowance of retinol varies from 400-600µg/day in 
infants to 600-1700µg/day in adults, and 750-2800µg/day in lactating or pregnant 
women. Too little vitamin A can result in infectious disease and vision problems, and too 
much vitamin A in the form of retinol can be toxic. Too much beta-carotene can make 
skin turn yellow or orange. Hypervitaminosis A (vitamin A excess) is a minor 
epidemiological problem compared with vitamin A deficiency, but typically happens 
acutely by ingesting high doses over a short period of time (by eating the liver of a 
carnivore or by overuse of supplements), or chronically by continually ingesting high 
doses. Some symptoms may include headache, nausea, vomiting, fever, vertigo and 
visual disruptions (Bendich and Langseth, 1989). Serious teratogenic defects can result 
from excess retinoids during pregnancy, targeting all major organ systems (Zile, 1998). 
VITAMIN A DEFICIENCY (VAD) 
Vitamin A also plays a role in embryonic development. In both adults and 
embryos, vitamin A functions through its active form, retinoic acid (RA). RA is an 
important signaling molecule in embryonic development, crucial for patterning, 
morphogenesis and organogenesis. Congenital abnormalities and fetal death can result 
from excess or insufficient RA. Major organ systems affected by vitamin A (and retinoid) 
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deficiency include the craniofacial, cardiovascular and ocular tissues, circulatory, 
respiratory (Antipatis et al., 1998) and urogenital (Moreau et al., 1998) systems (Zile, 
1998). 
Vitamin A deficiency (VAD) is a major preventable cause of nyctalopia (night 
blindness), a large contributor to morbidity and mortality due to infections leading to 
diarrhea and respiratory diseases, particularly in children and pregnant and lactating 
women, especially in lower income countries (WHO, 2009). VAD is predominantly a 
nutritional concern, brought on by a consistent diet insufficient in vitamin A. This 
vitamin deficiency is one of the most serious and common nutritional disorders 
worldwide (Barber et al., 2014). A chronic poor diet can lead to decreased vitamin A 
stores in the body, which then results in VAD-associated pathology such as 
xerophthalmia (dry eyes), anemia, hyperkeratosis, and decreased immunity (WHO, 2009, 
2015). Xerophthalmia is the leading cause of preventable childhood blindness.  A chronic 
poor diet often coexists in countries with frequent infections (including those that cause 
diarrhea), leading to further reduced vitamin A intake due to appetite suppression, 
increased metabolism and increased excretion of retinol (Alvarez et al., 1995). This 
results in a cycle of depleted retinol stores in the body, and leads to further susceptibility 
to severe infection (especially measles and diarrheal diseases) (WHO, 2009, 2015).  
Numerous studies of various organ systems have implicated Vitamin A 
Deficiency Diseases (VADD) with alterations of ECM expression, such as increased 
collagen levels, decreased MMP activity and decreased laminins (Esteban-Pretel et al., 
2013; Marin et al., 2005), which often leads to organ fibrosis and dysfunction (Barber et 
al., 2014). NCCs use proteases ADAM10, and matrix metalloproteases 2 and 9 (MMP2 
and MMP9) to break down portions of the ECM as they migrate through it (Taneyhill and 
Padmanabhan, 2014). 
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In 1995, WHO estimated that 60 countries are afflicted with severe endemic VAD 
based on the level of xerophthalmia and low serum retinol concentration (<0.35μM/L). In 
2005 it was estimated that 122 countries have VAD based on night blindness and serum 
retinol concentrations of <0.70μM/L in pre-school children (WHO, 2009). In 2015, the 
WHO declared VAD a public health problem in more than half of all countries (WHO, 
2015). 
Various studies have shown a reduction in maternal and infant death associated 
with severe VAD by supplementing pregnant mothers and infants with vitamin A 
(reviewed in (WHO, 2009)). The three major ways to improve vitamin A status in 
communities that are highly affected with VAD is to encourage dietary diversification, 
fortification of staple foods, and to deliver high-potency supplements (WHO, 2009). 
Specifically, children at risk can be given high dose vitamin A capsules, which provide 
supplementation for 4-6 months, and lactating mothers can be given high dose 
supplementation tablets while being encouraged to breast feed their infant, as breast milk 
is a natural source of vitamin A (WHO, 2009, 2015). 
VITAMIN A METABOLISM TO RETINOIC ACID 
Vitamin A functions through its active form, retinoic acid (RA). RA acts 
predominantly in a paracrine fashion (Duester, 2008), as a ligand for nuclear RA 
receptors (RARs) and retinoid X receptors (RXRs) to regulate transcriptional activity of 
target genes (Niederreither and Dolle, 2008). Vitamin A (retinol) is stored primarily in 
the hepatic stellate cells and is transported by retinol binding protein 4 (RBP4) to the cell 
surface RBP receptor Stra6 (stimulated by retinoic acid gene 6). Once inside the cell, 
retinol is bound by cellular retinol binding proteins (CRBP) and undergoes two 
consecutive oxidation reactions to become retinoic acid. In the first reaction, retinol is 
oxidized to all-trans-retinal (also called retinaldehyde) by microsomal retinol 
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dehydrogenase 10 (RDH10) or cytosolic alcohol dehydrogenases (ADH). Although 
studies initially indicated that members of the ADH family catalyzed this reaction 
ubiquitously throughout the embryo (Molotkov et al., 2002), more recent loss of function 
studies have revealed primarily postnatal importance for ADH oxidation (Kumar et al., 
2011), whereas a homozygous mouse mutation in RDH10 (Sandell et al., 2007) indicated 
that RDH10 is the critical enzyme necessary for the regulation of this first oxidation step 
during embryonic development (Cammas et al., 2007).  
All-trans retinal is then oxidized by retinaldehyde dehydrogenases RALDH1, 
RALDH2 and RALDH3 to retinoic acid. RA can also be produced by an alternative route 
through beta carotene. Beta-carotene is cleaved by beta, beta-carotene 15/15’-
monooxygenase 1 (BCMO1/BCOX) to retinaldehyde. RALDH expression patterns are 
highly correlated with RA signaling, as shown using RA response element (RARE) 
reporter mice (Methods: Mouse lines, pg 37) (Haskell and LaMantia, 2005; Rossant et 
al., 1991). RALDH2, the first retinaldehyde dehydrogenase to be expressed, is induced in 
the primitive streak and mesoderm during gastrulation, and is later restricted to the 
posterior embryonic region. This enzyme is responsible for almost all retinaldehyde to 
RA conversion during early embryogenesis. A deficiency in RALDH2 affects the 
forebrain, hindbrain, heart, forelimbs and somites (Mic et al., 2002; Mic et al., 2004; 
Niederreither et al., 2001; Niederreither et al., 2000; Niederreither et al., 2002; Ribes et 
al., 2006; Sirbu and Duester, 2006; Vermot and Pourquie, 2005). Newly formed RA is 
bound by cellular retinoic acid binding proteins (CRABPs). All-trans RA will then bind 
to the in vivo RAR ligand, and the 9-cis RA to the RXR ligand (in vitro) (reviewed in 
(Niederreither and Dolle, 2008), Figure I-5).   
In addition to controlling the level of RA via production through vitamin A 
metabolism, and the distribution of the retinoid receptors, the levels and spatiotemporal 
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distribution of this biologically active morphogen is also regulated by catabolism and RA 
feedback mechanisms.  
Cytochrome P450 26B1 is also expressed in embryonic tissues at the sites of RA 
production and it catalyzes the conversion of retinol to retinaldehyde and RA (Chambers 
et al., 2007). When necessary, RA can be transformed to 4-hydoxy-RA for metabolism 
and elimination by cytochrome P450 26A1, B1, and C1 (Cyp26) enzymes. Just as the 
oxidation enzymes that convert vitamin A to RA are important, so are the enzymes that 
prevent excess RA by reducing RA back to retinol. Dehydrogenase/reductase superfamily 
member 3 (DHRS3) catalyzes the reduction of retinal to retinol, and when this reductase 
is absent in mice, Dhrs3
-/- 
embryos exhibit excess retinal activity, leading to several 
developmental abnormalities, and late embryonic and perinatal lethality (Billings et al., 
2013), indicating that reduction of retinal by DHRS3 is critical for maintaining the 
delicate balance of RA production.  Collectively, the balance between retinoic acid 
synthesis and catabolism is critical to regulate the precise spatiotemporal domains of 
retinoid signaling during embryogenesis. 
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RETINOID DEFICIENT HSCR MOUSE MODELS 
Currently, more than 50% of HSCR cases have an identified gene and mechanism 
of pathogenesis, but many affected individuals’ mutations remain unaccounted for, 
leaving an important task to identify novel genes and pathways that may cause or 
potentiate HSCR. Recently, a role for retinoid signaling in ENS development and the 
pathogenesis of colonic aganglionosis has been suggested (Fu et al., 2010; Niederreither 
et al., 2003). 
As evidenced by numerous mouse knock-out studies, RA is necessary in the 
development of various organ systems, such as the eye, brain, liver, kidneys, lungs, 
 
 
Figure I-5: Retinoid signaling and metabolism from retinol and beta-carotene, as well 
as catabolism via CYP26A1-C1 (Modified from Figure 1 from 
(Niederreither and Dolle, 2008)). 
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spleen, heart, face, and limbs (reviewed in (Cunningham and Duester, 2015; Zile, 1998)), 
and now, the enteric nervous system of the gastrointestinal tract (Fu et al., 2010; 
Niederreither et al., 2003). Currently, there are two mouse models of depleted retinoid 
signaling that display evidence of colonic aganglionosis, Rbp4
 -/-
 and Raldh2
-/-
 (Fu et al., 
2010; Niederreither et al., 2003). However, these mouse models of depleted retinoid 
signaling rely on dietary modifications (vitamin A restriction or RA supplementation) to 
visualize and evaluate their ENS phenotypes.  
The first study depicting the role for Vitamin A deficiency as a non-genetic risk 
factor for HSCR penetrance and severity was done in Rbp4
-/-
 mice (Fu et al., 2010).   
Rbp4
-/- 
mice are unable to store retinol in their livers. When subjected to a vitamin A 
deficient diet during embryogenesis (starting at E7.5), these mice become fully depleted 
of Vitamin A and its active form, RA, and exhibit distal bowel aganglionosis due to 
increased phosphatase and tensin homolog (Pten) accumulation-mediated slowed ENCC 
migration. The migrating ENCCs in Rbp4
-/-
mice display a defect in maintaining 
lamellipodia formation, suggesting a requirement of RA in maintaining signals for ENCC 
migration.  
The studies done in Raldh2
-/-
 mouse model, also deficient in RA signaling, further 
suggest a role for RA in ENCC colonization of the gut. Although these mice typically die 
by E9.5, prior to ENS development, maternal RA supplementation between E7.5-E8.5 
rescues the animals long enough to observe deficiency in vagal NCC and agenesis of the 
enteric ganglia (Niederreither et al., 2003). Compound Raldh1
-/-
; Raldh2
+/-
; Raldh3
+/-
 
mutant mice also demonstrate reduced myenteric and submucosal neuron density in adult 
mouse colons, suggesting that all three enzymes, RALDH 1, 2 and 3, contribute to ENS 
development (Wright-Jin et al., 2013).   
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Although these studies suggest a role for retinoid signaling in the pathogenesis of 
colonic aganglionosis, they require a dietary intervention to elucidate this, creating a 
somewhat artificial situation (Butler Tjaden and Trainor, 2013). The phenotype in Rbp4
-/- 
mutants is only observed in response to a vitamin A deficient diet. Similarly, without 
providing RA rescue, Raldh2
-/-
 mutants die before a colonic aganglionosis phenotype can 
be examined. These partially-rescued mice develop with a range of physical anomalies, 
so the precise role of RA remains to be completely characterized.  Thus, additional 
experiments are necessary to reveal the true contribution of retinoic acid on 
gastrointestinal tract development. Furthermore, the effects of RA on NCC formation, 
migration proliferation and differentiation are not completely understood. A mouse 
model without the need for dietary control or partial RA rescue would be ideal to further 
investigate the role of RA in ENS development, as exogenous RA is known to cause 
developmental malformations (Quemelo et al., 2007). Human studies are also needed to 
complement these animal models. Collectively, this could validate the importance of 
retinoid signaling in the etiology and pathogenesis of HSCR.  
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II. METHODS 
This chapter will describe mouse lines, experimental laboratory methodology, 
imaging techniques, as well as RNA sequencing and qPCR protocols.  
Mouse Lines 
Mice were housed in the Laboratory Animal Services Facility at the Stowers 
Institute for Medical Research according to IACUC animal welfare guidelines. Control 
mice described in experiments using Rdh10
trex
 were either wild-type or heterozygous 
littermates. Control mice described in experiments using Rdh10
flox/flox
 x Cre lines were 
either Rdh10
fx/+ 
or Rdh10
flox/flox
 littermates. 
RDH10
 
MOUSE LINES 
The hypomorphic Rdh10
trex/trex 
mice were derived from an ENU screen and have 
previously been described in detail (Cunningham et al., 2011; Farjo et al., 2011; Sandell 
et al., 2011; Sandell et al., 2012; Sandell et al., 2007), and the allelic deletions of RDH10 
(Rdh10
βgeo
, Rdh10
flox/flox
 and Rdh10
Δ/Δ
) were created using Rdh10_D08 embryonic stem 
cells from the Knockout Mouse Project (KOMP) consortium. The resulting KOMP 
mouse line (C57BL/6N-Rdh10
tm1a(KOMP)Wtsi
) and derivative lines have been previously 
described (Sandell et al., 2012), but are also summarized here for convenience to the 
reader. 
ENU Screen 
Our lab conducted an unbiased three-generation forward genetic screen using N-
ethyl-N-nitrosurea (ENU) in an effort to phenotypically identify early craniofacial 
mutants (Sandell et al., 2011). 8-12 week old male C57BL/6 mice were intraperitoneally 
injected once a week for three weeks with 100mg/kg of ENU (Sandell et al., 2011). ENU 
is a known alkylating agent that induces approximately 1 mutation every 800 base pairs 
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when given in this fractionated dose regimen (Justice et al., 2000). This mutagen 
specifically targets spermatogonial stem cells, where it induces point mutations. After 90 
days, the injected male mice (G0) were bred to wild-type FVB/NJ female mice. The 
resultant heterozygous males generated from this cross are termed founder males (F1).  
These founder males (F1) were then outcrossed to FVB/NJ females to create Generation 
2 (G2) animals. G2 females were then backcrossed to their fathers (F1) and embryos 
were examined at E9.5-10 for reproducible craniofacial defects. From the 50 founder 
males, 10 new recessive mouse mutant lines were generated.  
Mapping the mutation to Rdh10 
These lines were maintained by crossing to FVB/NJ, which allowed for 
chromosomal positional mapping of regions of the C57BL/6 genome that co-segregated 
with the mutant phenotype. Using a panel of 140 polymorphic microsatellite markers 
between C57BL/6 and FVB/NJ strains, ear biopsies of both parents as well as the yolk 
sac for each mutant (and control) were screened to determine the region of the C57BL/6 
genome that was linked to the mutant phenotype. Once the phenotype was mapped to the 
single chromosomal location, the region was narrowed via single nucleotide 
polymorphisms (SNP), and candidate genes were sequenced to find the causative 
mutation (Sandell et al., 2011). 
Of the 10 new mouse mutants created, one mutant displayed a small forelimb 
phenotype, and was named “trex,” after the dinosaur T. rex (Sandell et al., 2011). This 
mutation mapped to the proximal portion of chromosome 1 using microsatellite markers. 
This region was narrowed using single nucleotide polymorphisms and subsequent 
candidate gene sequencing. SNP analysis and sequencing revealed a T to C pyrimidine 
transition at position 251 of the retinol dehydrogenase 10 (Rdh10) gene, causing a 
cysteine to arginine substitution in the RDH10 protein (Figure II-1), leading to 
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destabilization of the protein (Figure II-2 A)(Sandell et al., 2007). The first four 
generations following the ENU mutagenesis screen are shown in Figure II-2 D.  
 
 
 
 
Figure II-1: Sequence electropherograms for wild-type, heterozygous and 
homozygous mutant Rdh10
trex/trex 
animals. This sequencing revealed a T 
to C pyrimidine transition at position 251 of the retinol dehydrogenase 
10 (Rdh10) gene, causing a cysteine to arginine substitution in the 
RDH10 protein. (D) Pedigree for first four generations following ENU 
mutagenesis. Squares represent adult males, circles are adult females, 
blue embryo icons are mutant embryos, and red/blue split indicates 
heterozygous animals. Wild-type (A), heterozygous (B) and 
homozygous mutant Rdh10
trex/trex 
animals (C). Figure 2 from (Sandell et 
al., 2007). 
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The RDH10 protein model revealed that the substituted amino acid in 
Rdh10
trex/trex 
mutant is located in the core of the RDH10 protein, which would cause steric 
clashes and destabilize the protein structure (Figure II-2 A). Western blot analysis using 
wild-type and mutant RDH10 protein expressed in tissue culture suggest that mutant 
RDH10 is less stable than the wild-type version (Figure II-2 B). Furthermore, RDH10 
enzymatic assays using wild-type and mutant RDH10 protein revealed that the mutated 
RDH10 has significantly less enzymatic activity than wild-type RDH10 (Figure II-2 C).  
 
Phenotypic Description 
Along with the obvious forelimb defect, which gives this mouse mutant its name, 
the Rdh10
trex/trex 
mutant has other developmental malformations, which have previously 
been described (Figure II-3, Figure II-4) (Cunningham et al., 2011; Farjo et al., 2011; 
Sandell et al., 2011; Sandell et al., 2012; Sandell et al., 2007). In the craniofacial region, 
the Rdh10
trex/trex 
mutant has an obvious orofacial cleft (Figure II-4: L), absent pharyngeal 
 
Figure II-2: Mutation in Rdh10
trex/trex
 disrupts protein stability and function of RDH10 
enzyme. (A) RDH10 protein model. The substituted amino acid in the 
Rdh10
trex/trex
 mutant is located in the core of the RDH10 protein, which 
would cause steric clashes and destabilize the protein structure. (B) Western 
blot with wild-type and mutant RDH10 protein expressed in tissue culture. 
Results suggest that mutant RDH10 is less stable than the wild-type version 
(C) RDH10 enzymatic assays using wild-type and mutant RDH10 protein. 
Mutated RDH10 has significantly less enzymatic activity than wild-type 
RDH10. Figure 4A-C from (Sandell et al., 2007). 
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arches 3-6 (Figure II-3 D), deformed eye (Figure II-4: J), and duplicated otic vesicles 
(Figure II-3 B). There is deficient arterial remodeling in the pharyngeal arches, as well as 
vasculogenesis anomalies (Sandell et al., 2011). Along with a reduced forelimb, this 
mutant also has a reduction in the cartilage condensations of the limb (Figure II-4: B; H; 
R). In addition, there are organ defects, such as hypoplastic lungs (Figure II-4: N) and 
liver (Figure II-4: P), as well as severe cardiac defects. The mutant Rdh10
trex/trex 
heart fails 
to septate, and maintains a single outflow tract (Figure II-5). These mutants also exhibit 
peripheral nervous system defects, such as total colonic aganglionosis, which is described 
extensively in this manuscript. These embryos die during mid-gestation, around 
embryonic day E13.5 (Figure II-4: E, F), possibly due to severe cardiac hemorrhaging. 
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Figure II-3: E9.5 and E10.5 wild-type and mutant embryos. Wild-type (A,C) and 
mutant (B,D) embryos were stained with DAPI and confocal imaged as 
a Z-stack and processed into a maximum intensity projection. 
Rdh10
trex/trex 
mutants display duplicated otic vesicles (B), and absent 
posterior pharyngeal arches 3-6 (D). Adapted from (Sandell et al., 
2012). 
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Figure II-4:  E10.5 to E13.5 RDH10
trex/trex
 embryos have numerous developmental 
defects.Mutant embryos display various physical deformities, including 
smaller forelimbs (A,B; G,H); reduced cranial ganglia (C,D); 
hemorrhaging just prior to mid-gestational lethality (E,F); eye 
malformations (I,J); orofacial clefting (K,L); reduced liver and lung 
sizes (M,N; O,P) and reduction of limb cartilage condensations (Q,R). 
Figure 1 from (Sandell et al., 2007).  
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Rdh10
 βgeo
 
A splice acceptor lacZ gene trap cassette (flanked by FRT sites) was knocked into 
the Rdh10 gene between the first and second exons, creating the null allele Rdh10
βgeo
 
mice (Figure II-6 B). Additionally, Rdh10
βgeo
 mice have loxP sites flanking the second 
exon. The gene trap insertion creates a lacZ fusion transcript that disrupts endogenous 
Rdh10 transcript production. Rdh10
βgeo
 heterozygous animals appear similar to wild-type 
animals. When these heterozygous animals are stained for -galactosidase activity, 
staining revealed the gene trap transcript in the same pattern as Rdh10 RNA expression 
(Sandell et al., 2012). Homozygous Rdh10
βgeo/βgeo
 animals are functionally null. When 
 
Figure II-5: Cardiac models of wild-type and mutant Rdh10
trex/trex
 embryos. H & E 
section at the level of the outflow tract reveals an unseptated, single 
outflow tract in the Rdh10
trex/trex
 heart. Image courtesy of Lisa Sandell, 
PhD. 
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Rdh10
βgeo
 mice are crossed to an FLP-recombinase line, the “ geo” gene trap is excised, 
leaving a phenotypically wild-type animal with a conditional allele (with the second exon 
of Rdh10 flanked by loxP sites), termed Rdh10
flox 
(Figure II-6 C). 
 
Rdh10
flox
 (Rdh10
fx
) 
Rdh10
flox
 mice are a result of Rdh10
βgeo
 mice crossed to an FLP-recombinase line 
(in this case, FLPeR in the Rosa26 locus, official name: B6.129S4-
Gt(ROSA)26Sor
tm1(FLP1)Dym
/RainJ; Jax stock #009086), leaving the second exon of Rdh10 
flanked by loxP sites (“floxed”). This floxed exon is  the conditional line (Figure II-6 C) 
(Sandell et al., 2012).  This can then be crossed to various Cre recombinase lines to 
excise the second exon in specific tissues (Figure II-6 D), such as the oocyte specific 
 
Figure II-6: Schematic map of Rdh10 allelic deletion animals. (A) Wild-type Rdh10 
(B) Rdh10
βgeo
 has a splice acceptor lacZ gene trap cassette (flanked by 
FRT sites) knocked into the Rdh10 gene between the first and second 
exons. When crossed to a FLP recombinase, the “ geo” gene trap is 
excised, leaving a phenotypically wild-type animal with a conditional 
allele, termed Rdh10
flox
 (C). When Rdh10
flox
 is crossed to a Cre 
recombinase, the second exon is excised, creating Rdh10
delta
 mice, 
which have a premature stop codon, resulting in a null mutation. 
Adaption of Figure 2 from (Sandell et al., 2012). 
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ZP3Cre (official name: C57BL/6-TgN(Zp3-Cre)93Knw; Jax stock #003651), neural crest 
cell specific Wnt1Cre, or the ubiquitous tamoxifen inducible ER
T2
Cre lines. 
Heterozygous and homozygous Rdh10
flox
 mice are functionally wild-type. 
Rdh10
delta 
(Rdh10
Δ
)  
Rdh10
delta 
mice are produced by crossing Rdh10
flox/flox
 mice to the oocyte specific 
ZP3Cre, which caused excision of exon 2, flanked by loxP sites (Figure II-6 D) (Sandell 
et al., 2012), resulting in a null stop codon mutation.  Heterozygous Rdh10
delta/+ 
mice 
display a wild-type phenotype and homozygous Rdh10
delta/delta 
mice are embryonic lethal 
at E10.5 and have a defects consistent with other severe retinoid deficiency models.  
Quantitative RT-PCR was used to determine the transcript levels of Rdh10
delta 
mice. 
Mutant Rdh10
delta/delta 
mice had only ~50% transcript level as compared to their wild-type 
littermates, suggesting nonsense mediated decay (Figure II-7) (Sandell et al., 2012). 
 
 
Figure II-7: Histogram showing relative levels of Rdh10 mRNA by qPCR analysis.  
Rdh10delta animals have significantly reduced mRNA levels. Figure 
4F from (Sandell et al., 2012). 
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CRE RECOMBINASE LINES 
Two Cre recombinase lines were used extensively to conditionally remove the 
second exon of Rdh10. Wnt1Cre is used in a tissue specific manner, by excising Rdh10 
from dorsal neural tube cells. ER
T2
Cre is a tamoxifen-inducible Cre line used in a 
temporal manner removing RDH10 ubiquitously when tamoxifen is administered to 
pregnant dam.  
Wnt1Cre 
Wnt1Cre mice were obtained from the Jackson Laboratories (official name: 
Tg(Wnt1-cre)11Rth Tg(Wnt1-GAL4)11Rth/J; stock #003829). This transgene was 
created by inserting a Cre recombinase cDNA sequence in a polylinker site between the 
mouse Wnt1 promotor and enhancer elements. When Wnt1Cre mice are crossed to floxed 
animals (ie Rdh10
flox
), cre-mediated recombination results in the deletion of the floxed 
DNA sequence in a Wnt1 pattern of expression, in the midbrain and neural tube, 
beginning at E8.5. Rdh10
flox/flox
; Wnt1Cre embryos will have the second exon of Rdh10 
excised from dorsal neural tube cells which encompass neural crest cell progenitors.  
ER
T2
Cre 
ER
T2
Cre mice were obtained from the Jackson Laboratories (official name: 
B6.129-Gt(ROSA)26Sor
tm1(cre/ERT2)Tyj
/J; Jax stock #008463). This mouse line has a 
conditional Cre recombinase fused to the estrogen receptor T2 cassette inserted into the 
Rosa 26 locus (Ventura et al., 2007). Without tamoxifen available, the Cre-ER
T2
 fusion 
protein is retained in the cytoplasm bound to the heatshock protein 90 (HSP90). When 
tamoxifen is administered (in our case, by maternal oral gavage), the tamoxifen binds to 
the ER
T2 
domain, releasing the inhibition by HSP90, allowing the translocation of the 
Cre-ER
T2
 into the nucleus where it mediates recombination using loxP flanked DNA sites 
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(Figure II-8), such as in Rdh10
flox 
(Figure II-6 C), leading to excision of the floxed exon 
(Figure II-6 D).  
 
 
Previous studies using a similar tamoxifen-inducible cre-recombinase line 
(EsrCre, Official Name:  B6.Cg-Tg(cre/Esr1)5Amc/J, Stock # 004682) have shown 
~50% recombination after 24 hours and ~90% recombination after 48 hours, with similar 
levels of recombination when using between 2mg and 6mg of tamoxifen (Hayashi and 
McMahon, 2002). This study used intraperitoneal injection (IP) as a method of tamoxifen 
and progesterone delivery. 
Using EsrCre as a guide, we have empirically determined an appropriate 
tamoxifen dosage of 5mg of tamoxifen and 1mg progesterone, and demonstrated efficient 
tamoxifen-induced Cre-recombination by crossing to a cre-responsive -galactosidase 
reporter strain, Rosa R26R (Figure II-9). Unlike in the EsrCre model, IP injection of 
 
Figure II-8: Schematic of tamoxifen-inducible cre recombinase. In the absence of 
Tamoxifen, the Cre-ER
T2
 fusion protein is retained in the cytoplasm 
bound to the heatshock protein 90 (HSP90). When tamoxifen is 
administered, (1) the drug binds to the ER
T2 
domain, (2) releasing the 
inhibition by HSP90, (3) allowing the translocation of the Cre-ER
T2
 into 
the nucleus where it (4) mediates recombination using loxP flanked DNA 
sites. Figure 1 B from (Leone et al., 2003). 
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tamoxifen did not result in reliable recombination in the ER
T2
Cre line. Instead, we used 
maternal gavage with doses of tamoxifen dissolved in corn oil. In an effort to minimize 
fetal abortions in female mice, progesterone was co-administered.  
ER
T2
Cre mice were crossed to the Rosa R26R reporter line and pregnant mothers 
were treated with either 2.5mg Tamoxifen and 1mg Progesterone (Figure II-9 A,C) or 
5mg Tamoxifen and 1mg Progesterone (Figure II-9 B,D). Mothers were gavaged at E8.5 
and embryos were harvested at E11.5 to determine the appropriate dosage needed for full 
cre excision. This three day post-gavage period allows for sufficient recombination. 
R26R; ER
T2
Cre
+ 
embryos stain blue with β-galactosidase (Figure II-9 C,D). It is evident 
that 2.5mg of Tamoxifen gavage is not sufficient for total cre excision (Figure II-9 C), 
whereas 5mg of Tamoxifen is sufficient for total cre excision (Figure II-9 D).  
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REPORTER LINES 
Various reporter lines have been used for visualizing retinoid signaling 
(RARElacZ), cell lineage tracing (RosaEYFP and Rosa R26R), tamoxifen-inducible 
efficiency (Rosa R26R) and neural crest cell lineage tracing (F10N). These lines are 
detailed in this section. 
 
Figure II-9: ER
T2
Cre mice were crossed to the Rosa R26R reporter line Pregnant 
mothers were treated with either 2.5mg Tamoxifen and 1mg 
Progesterone (A,C) or 5mg Tamoxifen and 1mg Progesterone (B,D) at 
E8.5 to determine the appropriate dosage needed for full cre excision. 
R26R; ER
T2
Cre
+ 
embryos stain blue with β galactosidase (C,D). It is 
evident that 2.5mg of Tamoxifen gavage is not sufficient for total cre 
excision (C), whereas 5mg of Tamoxifen is sufficient for total cre 
excision (D). Images A and C courtesy of Shachi Bhatt, PhD. 
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RARElacZ 
RARElacZ mice were a generous gift from J Rossant (Rossant et al., 1991) and are 
available through the Jackson Laboratory (Official name: Tg(Rare-Hspa1b/lacZ)12Jrt/J, 
Stock # 008477). In these mice, 3 copies of the RARE sequence lie upstream of the heat 
shock protein 1B (Hspa1b) promotor and the β galactosidase gene (Figure 1B in (Rossant 
et al., 1991)).  This mouse line is used as a retinoid acid signaling reporter strain, and can 
be crossed to mutant mouse lines, such as Rdh10
trex
, and stained with β galactosidase to 
visualize where retinoid signaling is present in these mutants.  
RosaEYFP 
RosaEYFP animals are used extensively in cell lineage tracing (Official name: 
B6.129X1-Gt(ROSA)26Sor
tm1(EYFP)Cos
/J; Stock # 006148). These animals have a loxP-
flanked STOP sequence followed by the Enhanced Yellow Fluorescent Protein gene 
(EYFP) inserted into the Gt(ROSA)26Sor locus. When these mice are crossed to mice 
expressing a Cre recombinase, the STOP sequence is removed and EYFP expression is 
observed in the cre-expressing tissues of interest. This reporter line was particularly 
useful in the studies in this thesis for neural crest cell lineage tracing experiments when 
crossed to Wnt1Cre animals. 
Rosa R26R 
Rosa R26R animals (Official name: FVB.129S4(B6)-Gt(ROSA)26Sor
tm1Sor
/J; Jax 
stock #009427) are useful as a cre-reporter strain when stained with β-galactosidase. It 
can be used both for testing tissue expression patterns as well as for testing the efficiency 
of the drug inducible cre lines, such as ER
T2
Cre.  Similar to RosaEFYP animals, when 
Rosa R26R mice are crossed to a cre recombinase line, the STOP sequence is deleted and 
lacZ is expressed in the cre-expressing tissues of interest and their derivatives (Friedrich 
and Soriano, 1991; Soriano, 1999).  
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Mef2c-F10N, referred to as “F10N” 
Our lab has created a new transgenic mouse line in which the F10N enhancer of 
the Mef2c gene was fused to lacZ. A full description of the F10N (Mef2c-F10N-lacZ) has 
been described (Aoto et al., 2015). The F10N line expresses β galactosidase in all 
migrating NCC that have delaminated from the neural tube, and maintains expression in 
subsequent NCC derivatives. Early in development, this line has a very similar 
expression pattern to Wnt1Cre;R26R mice (Figure II-10).   
 
 
Analyses of Mef2c cis regulatory elements in transient transgenic animals by the 
Black laboratory have revealed the F10N enhancer element transiently marked migrating 
NCC in E9.5 embryos (De Val et al., 2008). The Mef2c-F10N plasmid provided by Brian 
Black, PhD was cloned into the Hsp68-LacZ reporter plasmid to create the Mef2c-F10N-
lacZ plasmid (Figure II-11 A), which was then injected into the pronucleus of CBA: B10 
F1 hybrid embryos to create stable transgenic lines. Expression of this plasmid is 
 
Figure II-10: Comparison of F10N and Wnt1Cre;R26R expression from E8.5 to E9.0. 
Figure 5 of (Aoto et al., 2015).
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examined via lacZ staining of whole and sectioned embryos at various stages (Figure 
II-11 B-M). 
 
 
Figure II-11: Mef2c-F10N-lacZ plasmid construct and expression from E7 to E13.5. 
This construct was injected into the pronucleus of CBA: B10 F1 hybrid 
embryos to create a stable transgenic line. (B-M) lacZ expression from E7 
to E13.5. (K-M) Embryos from E11.5-E13.5 have been cleared using 
ScaleA2. Adapted from Figure 1 of (Aoto et al., 2015). 
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Of particular interest for this project, F10N mice express β-galactosidase in gut 
neurons and glia (Figure II-12). This can been seen with triple stained 
immunohistochemistry for β-galactosidase which co-localizes in the enteric nervous 
system with differentiated neuronal marker Tuj1, and autonomic neuronal marker 
Phox2B, which mark the enteric nervous system neurons (Figure II-12 A, B). 
Additionally, β galactosidase co-localizes in the enteric nervous system glial markers 
SOX10 and neurofilament (NF) (Figure II-12 C, D).  
 
The plasmid used to create this new F10N line has also been adapted into a 
Mef2c-F10N-Cre line for cre-mediated excision of neural crest cells (Aoto et al., 2015). 
Gut Organ Culture 
E11.5 embryos were dissected from the uterus and placed on ice cold PBS. The 
gut (esophagus, stomach, small and large intestines with accompanying mesentery) were 
dissected in clean PBS and placed in L15 Leibowitz medium (Sigma). The gut was then 
transferred to a Millicell 0.4μm cell culture insert (Millipore) in a 6-well tissue culture 
dish (Millipore). The L15 medium was replaced with 400μL OptiMEM (Invitrogen) with 
1mM L-Glutamine (Life Technologies Glutamax) and Penicillin/Streptomycin 
 
Figure II-12: F10N mice express β galactosidase in gut neurons and glia. (A, B) β 
galactosidase co-localizes in the enteric nervous system with differentiated 
neuronal marker Tuj1, autonomic neuronal marker Phox2B, as well as 
(C,D) the glial marker SOX10 and neurofilament (NF).  Figure Adapted 
from Figure 10 I-L of (Aoto et al., 2015). 
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(Invitrogen). The explants were cultured in a 37°C incubator with 5% CO2 and media 
was changed every 2 days. This protocol was adapted from (Natarajan et al., 1999). For 
retinoid-supplemented cultures, guts were prepared as described above, and 1μM all-
trans-retinoic acid (Sigma R2625) or 1μM all-trans-retinal (Sigma R2500) was added to 
the culture media (a 10
-6
 M concentration of RA produces morphological changes in 50% 
of cultured guts (Pitera et al., 2001)).  
Whole gut immunohistochemistry  
Embryos (E11.5, 15.5, 18.5) were dissected from the uterus and placed in ice cold 
PBS. Whole embryonic guts (E11.5 cultured, E11.5, E15.5 and E18.5) were fixed in 4% 
paraformaldehyde in PBS (PFA) overnight at 4
°
C. Guts were washed 3 x 5 minutes in 
PBS with 0.1% TritonX100 (PBT) at room temperature. Blocking and antibody 
hybridization was performed in 10% heat-inactivated lamb serum in PBT. Non-specific 
antibody binding was blocked by 20 minute incubation with blocking solution, and 
primary antibody was applied overnight at 4
°
C in the same solution. Guts were then 
washed 5 x 1 hour in PBT at room temperature. Secondary antibody hybridization was 
performed in blocking solution overnight at 4
°
C. Secondary antibody was removed by 3 x 
20 minute washes in PBT at room temperature. TUNEL staining was performed as 
follows: guts were incubated at a slant with nutation for 2 hours at 37
°
C in 100μL 
TUNEL reaction (in situ Cell Death Detection Kit) (Roche), and then washed 2 x 30 
minutes in PBT at room temperature. Guts were then stained with DAPI dilactate, 10 
µg/ml in PBT, 10 minutes or longer at room temperature.  Specimens were then placed 
into Vectashield with DAPI (Vector Laboratories) for storage and imaging. 
In situ hybridization 
Embryos (E8.5, 9.5, 10.5, 11.5) were dissected from the uterus and placed in ice 
cold DEPC-PBS. They were then fixed in 4% paraformaldehyde (PFA) in phosphate 
buffered solution (PBS) overnight at 4ºC. Embryos were washed 3 x 5 minutes in DEPC-
PBS-1% Tween (PBS-Tw), and then treated with 10μg/mL Proteinase K in PBS-Tw 
without shaking. Proteinase K treatment time varied based on the age of the embryos. 
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Embryos were washed 5 minutes in 2mg/mL glycine in PBS-Tw, and then washed 2 x 5 
minutes in PBS-Tw. Embryos were re-fixed in 4% paraformaldehyde/0.2% 
glutaraldehyde solution in PBS for 20 minutes. Embryos were washed 3 x 5 minutes in 
PBS-Tw and rinsed in 65°C pre-warmed hybridization solution (for hybridization 
solution, MABT and NTMT recipes, see (Nagy A, 2003)), then placed in fresh pre-
warmed hybridization solution for 2 hours at 65°C. Probe was added to fresh 
hybridization solution and placed on the embryos at 65°C overnight. Embryos were 
washed in pre-warmed hybridization solution 2 x 30 minutes, then 3 x 30 minutes at 
65°C with Formamide Wash Solution (50% formamide, 1xSSC, pH4.5, 0.1% Tween). 
Next, embryos were washed 30 minutes in a 1:1 formamide wash solution: MABT, then 
3 x 5 minutes MABT. Embryos were blocked in MABT + 2% Boehringer Blocking 
Reagent (BBR) for 1 hour at room temperature, then an additional 1-2 hours in MABT + 
2% BBR +20% heat-treated goat serum. Embryos were incubated overnight at 4°C in 
1:1000 anti-DIG in MABT + 2% BBR + 20% heat-treated goat serum. Embryos were 
rinsed, and then washed 2 x 15 minutes in MABT, then 5-7 x 1.5 hour in MABT, 
followed by an overnight RT MABT wash. For antibody detection, embryos were washed 
3 x 10 minutes in NTMT, then incubated in the dark in NBT/BCIP reaction mix (3.375 
µl/mL of 100mg/mL NBT and 3.5µL/mL of 50mg/mL BCIP per 1mL reaction mix) until 
the reaction was deemed complete. Finally, embryos were washed with PBS-Tw and 
fixed with 4% PFA/0.1% glutaraldehyde. 
Whole mount immunohistochemistry 
E11.5 embryos were dissected from the uterus and placed in ice cold PBS. 
Embryos were fixed in 4% PFA overnight at 4
º
C, then washed in PBS and transferred 
through a graded series into 100% methanol.  Tissues and embryos to be immunostained 
were permeabilized in Dent’s bleach (MeOH:DMSO:30%H2O2, 4:1:1) for 2 hours at 
room temperature, then washed with 100% methanol and transferred (through a graded 
series) into PBS.  Blocking and antibody hybridization was performed in 0.1M Tris 
pH7.5/0.15M NaCl buffer.   Non-specific antibody binding was blocked by two hour 
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incubation in Tris/NaCl buffer with 3% Bovine Serum Albumen with gentle rocking.  
Primary antibody hybridization was performed in same blocking buffer overnight at 4
o
C.  
Following primary antibody hybridization specimens were washed 5 x 1 hour in PBS at 
room temperature.  Secondary antibody hybridization was performed in blocking buffer 
overnight at 4
o
C.  Secondary antibody was removed by 3 X 20 minutes washes in PBS at 
room temperature.  Specimens were stained with DAPI dilactate, 10 µg/ml in PBS, 10 
minutes or longer at room temperature or overnight at 4
o
C. Prior to imaging, 
immunostained specimens were cleared with ScaleA2 for at least 5 days (Hama et al., 
2011), or Clear
T2 
for at least 2 days (Kuwajima et al., 2013). Glass imaging wells were 
prepared by coating a Teflon O-ring with vacuum grease and affixing the ring to a glass 
depression slide.  ScaleA2 or Clear
T2 
cleared specimens were placed into the well and the 
well filled with ScaleA2 or Clear
T2
. A coverslip was then adhered to the vacuum grease 
coated O-ring. 
PRIMARY ANTIBODIES 
βIII neuronal tubulin antibody (TUJ1), 1/1000, (MMS-435P or MRB-435P, 
Covance); GFP antibody, 1/500, (A6455 Invitrogen/Molecular Probes); p75 antibody, 
1/300, (G323a Promega).  
SECONDARY ANTIBODIES  
Alexa Fluor 488, 1/500, (A21206 Invitrogen/Molecular Probes); Alexa Fluor 546, 
1/500, (A11030 Invitrogen/Molecular Probes). 
β-galactosidase staining 
Rdh10
trex
 mice were mated to F10N or RARElacZ (Rossant et al., 1991) mice and 
embryos/embryonic tissues were collected at E9.5, 10.5, 11.5 and 12.5. Embryos were 
fixed with 2% Paraformaldehyde + 0.25% Glutaraldehyde, and then stained using the β-
galactosidase staining solution kit (Chemicon/Millipore) according to manufacturer’s 
instructions. 
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Mouse Gavage Administration 
RETINAL GAVAGE 
For retinal supplementation experiments, pregnant mothers were gavaged with 
312.5μg of all-trans-retinal (Sigma R2500) in 100µL corn oil (3.125mg/mL) on mornings 
and/or nights of E6.5, E7.5, 8.5, 9.5, 10.5 and/or 11.5 (Farjo et al., 2011).  
TAMOXIFEN AND PROGESTERONE GAVAGE 
5 mg of tamoxifen (Sigma T5648) was administered via maternal gavage at 
varying embryonic days (E) in 100µL corn oil (50mg/mL). To prevent pregnancy loss, 
1mg of progesterone (Sigma P3972) was also co-administered via 100µL corn oil gavage 
(10mg/mL). To dissolve tamoxifen, 500mg of tamoxifen was initially dissolved in 1mL 
of ethanol, and 9mL of corn oil was added and warmed to 37
o
C until all tamoxifen went 
into solution (approximately 8 hours).  
Imaging 
CONFOCAL IMAGING 
Confocal images were captured on an upright Zeiss LSM510 or LSM700 Pascal 
equipped with a 405 nm laser.  For each specimen, a z-stack of images was collected and 
processed as a maximum intensity projection.  
BRIGHT FIELD IMAGING 
Stacks of light microscope images were taken on a Leica MZ9.5 stereomicroscope 
and assembled in Helicon Focus.  
ZEISS SLIDE SCANNER IMAGING 
6µm sections of Rdh10
trex/trex 
and control embryos were stained with Hematoxylin 
and Eosin (H&E) and 10µm sections of Rdh10
trex/trex
; F10N and control embryos were 
stained with LacZ and Eosin. These sections of control and mutant embryos were placed 
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on glass slides and were scanned at 20x in a Zeiss Axio Scan.Z1 slide scanner. Images 
were detected using the “tissue detection wizard” and optimized for each batch of slides.  
qPCR 
500 ng of mouse RNA harvested from the otic vesicle to the seventh somite 
region of E9.5 embryos was used as a template in 40µl total volume reaction of 
Superscript III (Life Technologies) reverse transcription kit utilizing random hexamer 
primers. The 40ul reaction was diluted 10 times and 2µl of cDNA was used in 10ul total 
qPCR reactions prepared with PerfeCTa SYBR Green FastMix, ROX (Quanta 
Biosciences) and cycled on an ABI 7900HT according to Quanta Biosciences standard 
protocol.  Analysis of the fluorescence curves was done using Life Technologies SDS2.4 
software. All curves that showed errors as determined by the SDS2.4 software or that 
were above 35 Ct were thrown out. The remaining Ct values were exported and analyzed 
using the Biogazelle qBase plus version 2.4. Three appropriate endogenous controls (M-
value < .5) for each sample set were selected from a panel of five primer sets using 
geNorm in qBase plus. All primer sets (Table II-1) used were experimentally determined 
to be within 10% of ideal efficiency. Individual gene results are graphed with standard 
error bars, and relative expression (of all genes) results are graphed with 95% confidence 
intervals. 
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Table II-1: qPCR primers 
Target Primer Sequence Product Size (bp) 
Gapdh F – TGGCCAAGGTCATCCATGA 
R – CAGTCTTCTGGGTGGCAGTGA 
84 
Canx F – CCAGACCCTGATGCAGAGAAG 
R – CCTCCCATTCTCCGTCCATA 
61 
Atp5b F – TTGACAACATCTTCCGCTTTACC 
R – AAGGGATTCTGCCCAATAAGG 
66 
Gdnf F – CTAAAGGAAAGGGTCAGGAG 
R – TTGCTGCTCAGATGGATAG 
106 
Ret F – GCACAATTACAAGCTGATTCT 
R – GAAATGGAGGACGAGGATAC 
130 
Gfrα1 F – GACTCCTGCAAGACAAATTAC 
R – ACTGTGCCAATCAGTCC 
146 
Col1a1 F – CTAGACATGTTCAGCTTTGTG 
R – GACTTCAGGGATGTCTTCTT 
93 
Col1a2 F – CTGGACCAATGGGTTTAATG 
R – AGCAGGTCCTTGGAAAC 
83 
Lamc3 F – TCCTACCTCACAGACTTCC 
R – ATCTCATAGGCCTTCCCTAA 
125 
Gata3 F – CGATCCAGCACAGAAGG 
R – GGCATTGCAAAGGTAGTG 
96 
TnC F – CAGGGTTGCCACCTATTT 
R – CTAGAGGATCCCACTCTACTT 
89 
Fn1 F – TGTACCTCCAGAAACAGATG 
R – TTTCCTCGGTTGTCCTTC 
89 
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RNA Sequencing 
Two rounds of RNA Sequencing were performed on Rdh10
trex
 embryos at E9.5. 
In RNA Seq1, we used a portion of the embryo from below the otic vesicle to the base of 
the tail (Figure II-13 A). In the RNA Seq2, we used a portion of the embryo from just 
posterior to the otic vesicle to the seventh somite, and removed the heart (Figure II-13 B). 
 
 
Total RNA was extracted using a Qiagen RNEasy kit according to the 
manufacturer’s protocol. Samples were run on the Agilent 2100 BioAnalyzer and 
subsequently used to create polyA strand-specific libraries. Samples were sequenced on 
 
Figure II-13: Portion of E9.5 embryo used for RNA Sequencing experiments. Tissue 
portion used for RNA Seq is outlined in red on this black and white Tuj1 
pseudo-SEM embryo. (A) RNA Seq1 included posterior to the otic vesicle 
to the base of the tail. (B) RNA Seq2 included posterior to the otic vesicle 
to the 7
th
 somite, just anterior to the forelimb bud. 
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the Illumina HiSeq 2500 platform. Sequences for each RNA sample were aligned using 
TopHat (v2.0.10). The reference genome and annotation files used for the alignment were 
from the UCSC mm10 genome and the ensembl build 73 for RNA Seq1 and ensembl 77 
for RNA Seq2. Gene expression levels for genes were calculated using R and 
Bioconductor. TopHat aligned reads were tabulated using the GenomicFeatures library, 
and differential expression was assessed using edgeR (Robinson et al., 2010).  RNA 
sequencing analysis was performed by Chris Seidel, PhD. 
RNA Seq1 analysis was performed on a single time point of tissue taken from the 
torso of mouse embryos at developmental time E9.5. The experiment was performed in 
triplicate on 3 mutants and 3 wild-type littermates. Data was collected by counting read 
mappings to 39017 genes. However after filtering for genes with a sum total of at least 1 
count per million (cpm) across all six samples, the final analyzed data set contains 19205 
genes. 
RNA Seq2 analysis was performed on a single time point of tissue taken from the 
area of the first seven somites of mouse embryos at developmental time E9.5. The 
experiment was performed in triplicate on 4 mutant and 4 wild-type littermates. Data was 
collected by counting read mappings to 39017 genes. However after filtering for genes 
with a sum total of at least 1 count per million (cpm) across all eight samples, the final 
analyzed data set contains 22674 genes. 
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III. HYPOTHESIS AND SPECIFIC AIMS 
The overall project hypothesis and specific aims have previously been proposed 
in the National Institutes of Health (NIH) Ruth L. Kirschstein National Research Service 
Award (NRSA) Individual Predoctoral MD/PhD fellowship (Parent F30). The revised 
application F30DK096842-01A1 was successfully funded. The proposed studies 
investigate the role of vitamin A metabolism in NCC and GI tract development using new 
animal models of retinoid deficiency. 
HYPOTHESIS 
RDH10 has a significant impact on RA synthesis and is necessary for 
organogenesis, specifically via a role in NCC proliferation, differentiation or migration 
during formation of the enteric nervous system (ENS). 
SPECIFIC AIMS 
The proposed study investigates the role of vitamin A metabolism on neural crest 
cells (NCC) and gastrointestinal (GI) tract development using new mouse models of 
retinoid deficiency. Understanding the mechanisms that govern NCC formation, 
migration and differentiation is important for understanding the etiology and 
pathogenesis of neurocristopathies such as Hirschsprung disease (HSCR), which arise as 
a consequence of defects in NCC development.  We identify RDH10 as a novel regulator 
of vitamin A metabolism and embryonic RA synthesis, and note digestive system defects 
in our RA deficient mouse line, Rdh10
trex/trex
, similar to those seen in human cases of total 
intestinal aganglionosis. RA is an important signaling molecule, crucial for patterning, 
morphogenesis and organogenesis during embryonic development. Our newly generated 
tamoxifen inducible RDH10 conditional knock out allele, Rdh10
flox/flox
;ER
T2
Cre, allows 
for selective temporal disruption of RA signaling.  
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As evidenced with previous retinoid deficient mouse models, the effects of RA, 
and specifically RDH10, on NCC formation, migration proliferation and differentiation 
have not been well understood, and until now, we have not had the necessary mouse 
models to investigate spatially and temporally the precise cellular and molecular 
mechanisms of RDH10 and RA during ENS development without any dietary 
modification. Because vitamin A deficiency is so widespread throughout the world, and 
metabolism of this nutrient results in an important developmental morphogen, it is 
important to continue to understand when RA is spatiotemporally required, and how it 
may contribute to the etiology and pathogenesis of disease such as HSCR. 
The following studies address the effects of retinoid deficiency on gut and ENS 
development, as well as investigate the cause and potential rescue of the HSCR 
phenotype in mutant Rdh10 embryos. To further understand mechanisms by which RA 
directs ENS development, we have examined the following specific aims. 
Aim 1: Retinoic acid signaling is spatiotemporally required for proper ENS 
formation and gut development 
Although there have been a few studies examining the role of retinoids on ENS 
development, there has not yet been an in-depth spatiotemporal examination of the role of 
vitamin A metabolism (specifically the contribution of RDH10) in the formation and 
development of the enteric nervous system (ENS) and GI tract.  
The phenotypes observed in Rdh10
trex/trex
 mice together with mid-gestational 
lethality of these mutants, reiterate the importance of RA signaling during embryonic 
development. It is therefore critical to understand the temporal and spatial dynamics of 
this small signaling molecule. The goal of this aim is to elucidate the spatiotemporal 
requirements of retinoic acid signaling for appropriate NCC colonization of the ENS to 
occur. This is relevant as nutritional anomalies can occur prior to and during pregnancy, 
 65 
hence it is extremely beneficial to understand when and in what cells RA signaling is 
required, for formation of ENS during embryogenesis.  
Using the RARElacZ reporter line, gut cultures supplemented with retinoids, in 
utero retinal gavage supplementation experiments in pregnant Rdh10
trex/+
 females, and a 
tamoxifen inducible Rdh10
flox/flox
;ER
T2
Cre mouse line, we have defined the precise 
temporal requirements for retinoid signaling for proper NCC colonization of the gut and 
complete ENS formation. Supplementing pregnant mothers with retinal during specific 
gestational time points allows us to determine the range of development in which retinoic 
acid is crucial to forming a complete ENS. The tamoxifen inducible RDH10 conditional 
knock out confirmed both the RA temporal requirement range, as well as provided a 
clean genetic model for retinoic activity disruption.  
Using an RDH10 NCC-specific knockout line, Rdh10
flox/flox
;Wnt1Cre, we were 
able to determine if RDH10 is intrinsically required in ENCCs or if RDH10 plays a more 
important role in maintaining a permissive microenvironment. Additional experiments 
examining cell death in the RDH10 expressing mesenchyme surrounding the foregut 
have provided further support for this spatial requirement of RDH10.  
These results clarify the spatiotemporal importance of RA signaling throughout 
embryonic development as well as in the pathogenesis of HSCR, and have acted as a 
springboard for research into understanding the cellular and molecular mechanisms 
responsible for the HSCR phenotype in the Rdh10
trex/trex
 mutant embryos. 
Aim 2: RDH10 is required for migration and entry of vagal neural crest cells into 
the foregut during enteric nervous system and gastrointestinal development.  
Previous experiments have shown that normal gut colonization relies on a 
combination of survival, proliferation, migration and differentiation of the NCC 
population (Amiel et al., 2008; Anderson et al., 2006a; Bogni et al., 2008; Heanue and 
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Pachnis, 2007). To understand the pathogenesis of HSCR and design novel treatment 
options for such neurocristopathies, it is necessary to first understand the cellular and 
molecular mechanisms that govern normal NCC formation, migration and differentiation 
during ENS formation in the gut. 
We have investigated the cellular and molecular mechanisms underlying defective 
ENS development in Rdh10
trex/trex 
mutants, including interactions with known genes that 
contribute to overall ENCC development, by investigating genes known to play important 
roles in NCC migration, proliferation, differentiation and survival during ENS 
development. Specifically, we examined the genes that when mutated, cause a 
devastating total intestinal aganglionosis phenotype, similar to Rdh10
trex/trex 
mutants, such 
as Ret (Eng, 1999; Natarajan et al., 2002; Uesaka et al., 2008), Gdnf (Gianino et al., 2003; 
Young et al., 2001), Gfrα1 (Nishiyama et al., 2012; Tansey et al., 2000), Ednrb (Barlow 
et al., 2003), Edn3 (Bondurand et al., 2006; Nagy and Goldstein, 2006; Wu et al., 1999), 
Phox2b (Corpening et al., 2008; Pattyn et al., 1999), Pax3 (Lang et al., 2000), and Sox10 
(Bondurand et al., 2006; Kelsh, 2006). Analysis of expression of these markers will allow 
us to further investigate potential RA signaling pathway interactions that are critical for 
NCC migration and colonization of the gut. 
 Additionally, in an effort to identify novel genes and potential pathways that may 
be regulated by RDH10, we have employed RNA-sequencing to determine transcriptome 
differences between Rdh10
trex/trex 
mutants and control littermates at E9.5. Consequently, 
we have identified numerous genes that are up- and downregulated in Rdh10
trex/trex
 
embryos that may mediate the effects of deficient RA signaling.  
CONCLUDING STATEMENTS 
In summary, these studies offer a new model for investigating the role of vitamin 
A and its active form, retinoic acid, in the ENS development. This work provides 
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information regarding the spatiotemporal requirements for RA during embryonic 
intestinal development, pathogenic cellular mechanisms of RDH10 deficient animals, as 
well as the interactions of RA with pathways that regulate normal NCC colonization and 
ENS formation. Our hope is that these data may lead to novel non-surgical therapeutic 
options in human HSCR cases. These studies will have a significant impact on our 
understanding of the pathogenesis of RA-deficient intestinal aganglionosis and may lead 
to improved treatments and preventive measures to reduce the morbidity and mortality 
associated with Hirschsprung disease. 
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IV. RESULTS 
This section will discuss results from pertinent experiments that contribute to 
understanding whether RDH10 has a significant impact on the RA synthesis necessary 
for organogenesis, specifically on NCC proliferation, differentiation or migration during 
formation of the enteric nervous system (ENS).  
Establishing vitamin A metabolism defects as a cause of Hirschsprung 
Disease 
This initial portion of this study provides a temporal analysis of the importance of 
retinoic acid signaling to emphasize that this small molecule is dynamically active 
throughout gut development.  Additionally, we show that Rdh10
trex/trex
; RARElacZ 
mutants have a significant retinoid signaling deficiency as compared to wild-type 
embryos, both in the context of the whole animal at E9.5 and more specifically in the 
gastrointestinal tract at E12.5.  
These retinoid deficient animals have peripheral and enteric nervous system 
defects, as evidenced by Tuj1 immunohistochemical staining. This mimics the early 
pathogenesis of Hirschsprung disease and suggests retinoid signaling is essential for 
proper formation of a complete enteric nervous system. 
RETINOIC ACID IS EXPRESSED DYNAMICALLY THROUGHOUT DEVELOPMENT 
RARElacZ reporter mice were used to visualize the spatiotemporal domains of 
active retinoid signaling using beta-galactosidase (X-gal) staining during gastrointestinal 
tract development (Figure IV-1) (Rossant et al., 1991). At E10.5, the small intestines and 
distal colon have active RA signaling, whereas the hindgut does not have active RA 
signaling at this time. In the next 24 hours (E11.5), the GI tract has grown almost twice as 
long and the expression domain of retinoid signaling remains in the anterior foregut and 
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continues distally ¾ of the way down towards the cecum.  The most distal colonic 
retinoid activity becomes diminished from E11.5 to E12.5. At E12.5, the entire foregut 
and midgut are active with retinoid signaling, whereas the cecum and beginning of the 
hindgut are devoid of RA. It is at this stage that the lower esophagus and anterior 
stomach become active with retinoid signaling. E14.5 is the stage at which the entire 
small and large intestines display active retinoid signaling, although the esophagus is now 
devoid of retinoid signaling, and the stomach continues to have a more restricted retinoid 
signaling domain. Although the cecum displays less active retinoid cells than the more 
distal colonic structures, it now is weakly active with retinoids.  
 
RDH10
TREX/TREX 
MICE DISPLAY RETINOIC ACID SIGNALING DEFECTS 
Rdh10
trex/trex 
point mutant embryos are deficient in the enzyme RDH10, which 
contributes to the oxidation of Vitamin A to retinoic acid. These Rdh10
trex/trex 
point 
mutants have several embryonic defects, many of which have been previously described 
both in Chapter II: Methods and in previous publications (Sandell et al., 2011; Sandell et 
al., 2012; Sandell et al., 2007). Rdh10
trex
 mice were crossed to RARElacZ to visualize the 
 
Figure IV-1: Timeline of RARElacZ expression in E10.5 to E14.5 dissected guts. This 
expression timeline highlights the dynamic changes of retinoid signaling 
during gut development. Scale bars are 500µm. 
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localization of active retinoid signaling using beta-galactosidase (X-gal) staining 
(Rossant et al., 1991).  
Rdh10
trex/trex
 mice display severely reduced RA synthesis (Kumar et al., 2011; 
Sandell et al., 2007), evident in both whole embryo staining (Figure IV-2 A, C), as well 
as specifically in the gut (Figure IV-2 B, D). At E12.5, Rdh10
trex/trex
; RARElacZ guts have 
less active retinoid signaling (Figure IV-2 D), and the active retinoid signaling domain is 
located only half-way to the cecum (Figure IV-2 C).  
 
The dynamic expression of retinoic acid, shown in Figure IV-1, is important to 
development of a fully colonized gut, as the gut microenvironment changes with the 
growing gut (Druckenbrod and Epstein, 2009). Importantly, it has previously been shown 
that retinoid receptors are present in the developing gut as the ENCCs are migrating and 
 
Figure IV-2: Rdh10
trex/trex
; RARElacZ embryos and intestines were stained for β-
galactosidase to visualize the extent of RA deficiency. This cross shows 
the RA signaling present in wild-type versus Rdh10
trex/trex 
mutant 
embryos. The RARElacZ transgenic reporter is used to visualize where 
RA is active. An overall deficit in retinoic acid signaling (in blue) is 
observed in the whole mutant mouse at E9.5 (A, B), as well as specific 
lack of signaling in E12.5 intestines (C, D). In particular, a scarce amount 
of RA signaling is detected distal to the stomach. Images C and D 
courtesy of Lisa Sandell, PhD. 
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colonizing the distal gut (Sato and Heuckeroth, 2008), indicating the responsiveness of 
the gut mesenchyme to RA. In the case of Rdh10
trex/trex
 mice, the severe deficiency of 
active retinoid signaling in the gut is indicative of an absence of this morphogen and its 
ability to participate in GI tract developmental processes. 
RDH10
TREX/TREX 
MICE DISPLAY TOTAL INTESTINAL AGANGLIONOSIS  
In addition to craniofacial, cardiac and limb deformities, Rdh10
trex/trex
 embryos 
have a complete absence of enteric neurons in the developing GI tract. Mature enteric 
neuronal differentiation was assessed in Rdh10
trex/trex 
embryos by immunohistochemical 
staining of β-tubulin III (Tuj1). The colonic aganglionosis phenotype is first evident in 
E9.5 whole embryo preparations (Figure IV-3 E). As the embryos grow, both the size 
difference and gut aganglionosis phenotype in Rdh10
trex/trex 
embryos becomes even more 
pronounced (Figure IV-3). This total intestinal aganglionosis phenotype is reminiscent of 
severe Hirschsprung Disease (HSCR) in humans, leading us to propose that Rdh10
trex/trex 
as a new genetic model for this devastating disease. 
 72 
 
The colonic aganglionosis phenotype caused by RDH10 deficiency is most 
evident in E10.5 embryos and E11.5 dissected gut preparations. In E10.5 Rdh10
trex/+
 
(control) embryos (Figure IV-4), enteric neural crest cells (ENCC) have begun 
differentiating (Tuj1+) into mature neurons throughout the GI tract (Figure IV-4 A), 
whereas Rdh10
trex/trex 
(mutant) mice exhibit total intestinal aganglionosis (Figure IV-4 C). 
When embryonic guts are dissected from E11.5 embryos, just prior to embryonic 
lethality, and immunostained for Tuj1, it is evident that wild-type guts have mature 
neurons to the level of the cecum (Figure IV-4 B), whereas Rdh10
trex/trex
 embryonic guts 
have no evidence of healthy, mature neuronal development, much less in the same 
reticular network as that seen in the wild-type littermates (Figure IV-4 D).  
 
Figure IV-3: Timeline of βtubulin and DAPI immunostaining in Rdh10
trex/trex
embryo 
and wild-type littermates from E9.5 to E12.5. The lack of mature 
neurons developing to colonize the enteric nervous system is evident 
from E9.5 onwards. Scale bars are 500µm. Images B and F courtesy of 
Liang Liang, Ph.D. 
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RA is spatiotemporally required for proper ENS development 
This portion of the study focuses on investigating the hypothesis that retinoic acid 
signaling is spatiotemporally required for the developing gastrointestinal system. To 
study the spatial and temporal contributions of RA, we utilize Rdh10
trex/trex
 mice in a gut 
explant culture system, along with maternal retinal gavage rescue experiments. 
RDH10
TREX/TREX 
TOTAL INTESTINAL AGANGLIONOSIS CANNOT BE RESCUED IN GUT ORGAN 
CULTURE 
Previous studies of HSCR in mouse models have implicated that a delay in ENCC 
migration may be the cause for an HSCR phenotype (Barlow et al., 2012; Wallace et al., 
2011). In avian models, RA was implicated as a requirement for the initial and continued 
 
Figure IV-4: βtubulin and DAPI immunostaining in E10.5 whole embryos and E11.5 
whole guts. Neurons in the body and in the digestive system (white 
arrows) in the Rdh10
trex/trex 
embryo and wild-type littermates are stained 
with Tuj1, which is specific to βtubulin (labels differentiated neuronal 
populations).  White arrows in the mutant embryo (C) indicate the absence 
of ENS neurons. Mature neurons in the E11.5 gut have reached the cecum 
in the wild-type (B) but have not colonized the gut in mutants (D). Scale 
bars are 500µm. Images A and C courtesy of Liang Liang, PhD. 
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migration of ENCCs into the developing gut (Simkin et al., 2013). Additionally, it was 
previously thought that the migration of ENCCs through the cecum (circumflex ENCCs) 
was important for hindgut colonization (Barlow et al., 2003; Coventry et al., 1994; 
Kruger et al., 2003), but recent photo-conversion real-time imaging experiments have 
shown that ENCCs destined for the hindgut traverse the mesentery (trans-mesenteric 
ENCSS: tmENCCs) as solitary cells when the midgut and hindgut are opposed in parallel 
(between E10.5-11.5), and these ENCCs are the major source of the ENS in the hindgut 
(Nishiyama et al., 2012). Because the midgut and hindgut are juxtaposed only during 
E10.5-11.5, and tmENCCs are the primary cell population contributing to the hindgut 
ENS, these cells have only a limited period of time to reach the hindgut. Should these 
tmENCCs experience delayed migration through the mesentery, the result should be 
impaired colonization of the hindgut by ENCCs (Nishiyama et al., 2012).  
With that in mind, we investigated the hypothesis that providing more time or 
additional exogenous retinoids for these Rdh10
trex/trex
 gut explants to complete 
colonization would rescue the total intestinal aganglionosis phenotype observed at the 
time of embryonic lethality. Using ENS formation as a surrogate for successful ENCC 
migration, we have assayed for Tuj1 in the subsequent experiments. We cultured E11.5 
Rdh10
trex/trex
 gut explants in RA-deficient media for up to ten days, or supplemented 
E11.5 Rdh10
trex/trex
 gut explants with retinal or retinoic acid for up to four days to 
determine if retinoids were necessary for ENS development after E11.5. 
Total intestinal aganglionosis phenotype in Rdh10
trex/trex
 embryos is not simply due to 
delayed ENCC migration or differentiation in enteric neurons 
Rdh10
trex/trex 
embryos typically die around E12.5 due to cardiovascular failure and 
hemorrhaging, prior to complete NCC colonization of the gut. However, by culturing the 
intestines in vitro, we can bypass this embryonic lethality. To investigate the possibility 
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that delayed ENCC migration is a potential cause of colonic aganglionosis in retinoid 
signaling deficient mutants, the intestines of E11.5 Rdh10
trex/trex
 embryos and their 
phenotypically wild-type littermates were removed and cultured in retinoid deficient 
media for 2, 4 or 10 days. At E11.5, wild-type intestines have mature neurons throughout 
the proximal gut up to the cecum between the midgut and hindgut. Rdh10
trex/trex
 intestines 
do not have mature neurons at this time point (Figure IV-4 B, D).  
After 2 days of culture, neurons in control intestines have reached the hindgut. At 
this time, these hindgut neurons have not yet formed the same pattern or density of neural 
network as is seen in the midgut. However, after 4 or 10 days of culture, the neurons in 
the hindgut have formed a thick, reticulated neural network. In contrast, after 2, 4, or 10 
days of culture, Rdh10
trex/trex
 intestines have little to no neuronal staining throughout 
(Figure IV-5). This gut culture experiment revealed that the gut phenotype observed in 
Rdh10
trex/trex
 embryos is not simply due to a delay in ENCC migration and/or 
differentiation. However, it is still important to determine if the phenotype is due to a 
lack of ENCCs entering into the foregut at the time of gut harvest (E11.5). Additionally, 
we must determine whether retinoid requirements in the mouse gut echo that of the avian 
gut for initial and continued ENCC migration.  
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Addition of retinoids after E11.5 does not improve the total intestinal aganglionosis 
phenotype in Rdh10
trex/trex
 intestines. 
To investigate if retinoid supplementation would improve the migration and 
differentiation of ENCCs, and hence enteric neuron formation in Rdh10
trex/trex 
gut 
explants, E11.5 intestines from control and Rdh10
trex/trex 
embryos were cultured with 
retinoids (all-trans-retinoic acid or retinal) for 4 days (Figure IV-5). All-trans-RA is an 
active small molecule, and in an unregulated manner, supplemented RA has the potential 
to elicit teratogenic defects (Quemelo et al., 2007). Hence, we also supplemented our 
control and mutant gut explants with retinal. Supplemental retinal should only be 
 
Figure IV-5: βtubulin and DAPI immunostaining at E11.5 0-day and 10-day 
cultured guts. E11.5 mutant guts were carefully dissected from the 
embryo in L15+glutamine media, and cultured in an RA-free 
environment. Cultured guts were then IHC stained with Tuj1 and 
DAPI to compare the ability to differentiate into ENS neurons (Tuj1). 
A severe deficit of ENS neurons is shown in the mutants (bottom 
row). Wild-type gut neurons continued to differentiate and colonize 
the remainder of the gut tube, while Rdh10
trex/trex 
gut is colonized 
sporadically. Scale bars are 200m. s, stomach; m, midgut; c, cecum; 
h, hindgut. 
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converted to RA in the presence of Raldh2, and thus was expected to elicit a 
spatiotemporally appropriate physiological response. Interestingly, even 0.3nM of retinal 
supplementation (Newton et al., 1980) results in changes of neuronal characteristics in 
the control gut. Instead of thick neural networks observed in Figure IV-5, and control 
untreated gut cultures in Figure IV-6, the neural network in retinal-treated gut cultures 
has fewer projections and is more disorganized (Figure IV-6).  When control guts are 
cultured with 25nM of all-trans-RA, a sub-physiological, non-teratogenic dose 
(Cunningham et al., 2011), the neuronal cell population has an even more punctate 
appearance, with few, short axonal projections (Figure IV-6). Culturing Rdh10
trex/trex
 
intestines for 4 days with either retinal or RA display no neuronal improvement (Figure 
IV-6).  
If retinoids were important only for continued ENCC migration and their 
differentiation into enteric neurons, we would have observed a restoration of neuronal 
staining within the retinoid-treated Rdh10
trex/trex
 gut cultures. Lack of neuronal staining in 
retinoid-treated and RA-deficient gut cultures led us to hypothesize that Rdh10
trex/trex
 guts 
might not have enough ENCCs, the ENS precursor cells, at the time of dissection, i.e. 
E11.5. Nevertheless, these experiments indicate to us that retinoids are specifically 
required prior to E11.5 for proper ENS development in mice embryos.  
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RDH10
TREX/TREX 
TOTAL INTESTINAL AGANGLIONOSIS CAN BE RESCUED WITH MATERNAL 
RETINAL GAVAGE BEGINNING AT E7.5 
Our gut explant culture data suggests that RA may be necessary earlier than E11.5 
for proper ENS formation. Recent photo-conversion real-time imaging experiments 
 
Figure IV-6: Four day gut explant culture with retinoid treatment. Gut preparations 
were cultured in L15+glutamine media, in an RA-free environment, or 
with the addition of 0.3nM of retinal or 25nM of all-trans-retinoic acid 
for the duration of the gut explant culture experiment. After four days of 
culture, guts were stained with Tuj1 and DAPI. Addition of retinoids 
after E11.5 development does not improve the ENCC colonization of 
Rdh10
trex/trex
 mutant guts. Scale bars are 200m. 
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(Nishiyama et al., 2012) and avian transplantation models (Simkin et al., 2013), 
combined with our gut explant culture data suggests that RA may be necessary to instruct 
ENCCs to initially colonize the foregut and/or cross the mesentery separating the midgut 
and hindgut at E10.5, and failure to do so during these time points may lead to the HSCR 
phenotype observed in Rdh10
trex/trex
 embryos. Gut explants from younger embryos are not 
viable in vitro. Thus, to further narrow down the time window of retinoid requirement we 
shifted to in vivo supplementation of pregnant Rdh10
trex/+
 mothers, carrying control and 
Rdh10
trex/trex
 embryos, using all-trans-retinal (retinal).  
Once per day retinal supplementation 
Ex vivo gut organ culture experiments indicate that Rdh10
trex/trex
 gut neural 
progenitors must require retinoid signaling prior to E11.5 for appropriate ENS 
development. To investigate this further, pregnant Rdh10
trex/+
 mothers were 
supplemented with retinal prior to E11.5 to determine when retinoid signaling is 
necessary and if it can rescue the Rdh10
trex/trex
 intestinal aganglionosis phenotype. The 
effective retinal gavage rescue dosage for Rdh10
trex/trex 
embryos has previously been 
defined (Cunningham et al., 2011). Gavage supplementation overcomes the lethal 
cardiovascular defect in these mice, and allows us to empirically determine a temporal 
requirement for RA signaling during gut colonization and ENS formation. Retinal was 
used, as this bypasses the oxidation step requiring RDH10 and helps to ensure that retinal 
will only be converted to retinoic acid where RALDH enzymes are present. Thus, RA is 
synthesized in a relatively “normal” tissue distribution, limiting the teratogenicity 
associated with exogenous retinoic acid.  
Various in utero oral gavage retinal supplementation time windows were 
assessed. Rdh10
trex/+
 mothers were gavaged with retinal (12.5mg all-trans-retinal/kg 
maternal body weight) once per day for up to six consecutive days, starting at various 
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time points between E6.5 to E11.5, and guts were subsequently harvested at E11.5 
(Figure IV-7, red arrows).  
 
In supplementation trials, once per day retinal gavage from E7.5-11.5 revealed 
normal enteric neuron development in control littermates and a partial rescue of enteric 
neuronal differentiation in Rdh10
trex/trex
 guts (Figure IV-8).  Compared to other time 
points (with different starting and ending days, and length of gavage treatment), this 
treatment regime from E7.5-11.5 gave the best phenotypic rescue for single morning 
retinal gavage treatments. Unlike a typically aganglionic gut in Rdh10
trex/trex
 embryos 
with no treatment, the treated Rdh10
trex/trex
 guts had mature neurons present in the foregut, 
half-way to the cecum (Figure IV-8).   
 
Figure IV-7: Gavage administration schedule. Pregnant Rdh10
trex
 mothers were 
gavaged with retinal on consecutive days ranging from E6.5-E11.5 
(black lines represent individual pregnancies and the duration of retinal 
treatment). Red arrows indicate when retinal gavage was administered 
for once daily morning retinal treatment. Red and purple arrows indicate 
when retinal gavage was administered for twice daily morning and 
evening retinal treatments.  
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Twice per day retinal supplementation 
To increase retinal availability and potentially further improve the rescue, we 
tested twice-a-day supplementation of retinal, for consecutive days beginning at E6.5 
(Figure IV-7 red + purple arrows). Embryos were subsequently harvested at E11.5, E15.5 
and E18.5 (only E11.5 rescued guts are shown). Compared with once daily retinal gavage 
supplementation experiments (Figure IV-8), a shorter period of morning and evening 
supplementation, between E7.5-9.5, provided a significant phenotypic rescue of enteric 
 
Figure IV-8: Retinal in utero gavage rescue beginning at E7.5. Pregnant mothers 
were gavaged once a day between E7.5-11.5, which partially rescues 
the Rdh10
trex/trex
 gut (white arrow). Pregnant mothers gavaged twice a 
day between E7.5-9.5 rescues the Rdh10
trex
 gut wavefront to a 
comparable wild-type location. 
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neuron formation in Rdh10
trex/trex
 embryos. With this supplementation regimen, neuronal 
differentiation in Rdh10
trex/trex
 guts appears comparable to treated and untreated wild-type 
guts, with mature neurons present to the cecum (Figure IV-8). When pregnant Rdh10
trex/+
 
mothers were gavaged twice a day between E6.5-E9.5, a similarly significant rescue was 
observed (data not shown). Rescues beginning at E6.5 or E7.5 and lasting at least 3 days 
resulted in complete ENS formation up to the distal gut by E15.5 (data not shown). 
Although earlier and longer gavage supplementation treatments may result in a rescue of 
the colonic aganglionosis phenotype, the minimal treatment for a full rescue is observed 
to be between E7.5 to E9.5, a time window that precedes vagal NCC invasion into the 
gut. These maternal gavage experiments suggest that active RA signaling is required 
prior to and during the vagal NCC invasion into the foregut during early embryonic 
development, and is not required for the maintenance of NCC migration or differentiation 
after the initial invasion into the foregut, or necessary to convey the ability to ENCCs to 
cross the mesentery separating the midgut and hindgut at E10.5. Perhaps the reason 
multiple days of retinal treatment (E7.5-9.5) is necessary, is to keep the tissues 
surrounding the foregut opening appropriately patterned until a sufficient number of 
NCCs have entered into the foregut. 
TEMPORAL DELETION OF RDH10 IN RDH10
FLOX/FLOX
; ER
T2
CRE MICE CONFIRMS EARLY 
REQUIREMENT OF RETINOIDS DURING ENS DEVELOPMENT  
As mentioned previously, there two major retinoid deficient mouse models that 
suggest RA as an important morphogen for ENS development. The first study 
demonstrating that RA deficiency may lead to a HSCR phenotype used Raldh2
-/-
 mice 
partially rescued with RA (maternal RA supplementation from E7.5-E9.5 or E7.5-E11.5). 
These mice have deficient Ret signaling in the vagal domain, and the VNCC are unable 
to appropriately colonize the gastrointestinal tract (Niederreither et al., 2003). The second 
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major study, which first proposed Vitamin A deficiency as a non-genetic risk factor that 
increases HSCR penetrance and severity used Rbp4
-/- 
mice, which are unable to store 
retinol in their livers. When these mice were subjected to a vitamin A deficient diet 
during embryogenesis via maternal restriction starting at E7.5, these mice became fully 
depleted of Vitamin A and RA, and had a distal bowel aganglionosis phenotype (Fu et al., 
2010).  
Although these studies provided initial evidence suggesting that RA is important 
for ENS development, these models, along with Rdh10
trex/trex
, are all reliant on dietary 
modifications suggesting a retinoic acid effect on ENS precursor development (Fu et al., 
2010; Niederreither et al., 2003; Sato and Heuckeroth, 2008). To investigate the true 
spatiotemporal requirement for RA signaling in ENS formation, we crossed Rdh10
flox/flox 
to the tamoxifen inducible ubiquitous Cre line, ER
T2
Cre (Ventura et al., 2007). The 
Rdh10
flox/flox
; ER
T2
Cre strain allowed us to selectively and temporally block RDH10, 
while simultaneously overcoming limitations of Rdh10
trex/trex
 lethality and the need for 
retinoid supplementation in other models of retinoid deficiency. 
A combination gavage of tamoxifen and progesterone (5mg tamoxifen + 1mg 
progesterone) was administered to pregnant mothers at E6.5, 7.5, 8.5, 9.5, 10.5, or 11.5. 
Progesterone is necessary to ensure pregnancy is not terminated. Using the R26R; 
ER
T2
Cre reporter line, when gavaged with 5mg tamoxifen + 1mg progesterone dosage, 
cre recombination is complete within 24 hours of oral gavage administration. 
Rdh10
flox/flox
; ERT2Cre
 
embryos were harvested at E11.5, E15.5 and E18.5 to analyze the 
extent of NCC migration and ENS differentiation via immunohistochemistry (IHC).  We 
hypothesized that conditionally deleting RDH10 at each of these times points would 
genetically define the precise temporal requirement for RA during ENS formation. 
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Temporal deletion of RDH10 at E6.5 in Rdh10
flox/flox
; ER
T2
Cre mice results in an 
intestinal hypoganglionosis phenotype, evident throughout the duodenum, cecum and 
distal colon (Figure IV-9). Very few neurons are present in various portions of the bowel 
(Figure IV-9 D, E, F). Tamoxifen-induced deletion of RDH10 at E7.5 results in normal 
enteric neuron differentiation in the duodenum and cecum, but displays distal colonic 
aganglionosis, reminiscent of a short-segment Hirschsprung disease phenotype (Figure 
IV-9 I, white arrow). Removal of RDH10 at later time points (E8.5, 9.5, 10.5, 11.5) does 
not induce a HSCR-like phenotype (Figure IV-9 J, K, L and data not shown). Normal 
ENS formation was observed in all treatment Rdh10
flox/+ 
littermates irrespective of the 
age of treatment (E10.5 gavage shown in Figure IV-9 A, B, C). These deletion studies 
confirm an early temporal requirement for retinoid signaling for proper ENS formation. 
Combined with the results from retinal-supplemented gut culture analyses and in vivo 
retinal supplementation of Rdh10
trex/trex
 embryos, it seems that RA is required during the 
time window before and right when ENCCs are invading the foregut, but might not be 
necessary for the maintenance of NCC migration or differentiation after the initial 
invasion. 
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Figure IV-9: Temporal RDH10 excision in Rdh10
flox/flox
; ER
T2
Cre. Rdh10
flox/flox
; 
ER
T2
Cre mice were administered tamoxifen and progesterone gavage in 
utero at E6.5 (D, E, F), E7.5 (G, H, I) and E10.5 (J, K, L). Control 
littermates at each of these time points is represented by the Rdh10
flox/+ 
littermates given tamoxifen and progesterone gavage at E10.5 (A,B,C). 
Guts from embryos treated after E8.5 appears indistinguishable from 
controls A, B and C, with full colonization and neural reticulation. 
Temporal deletion of RDH10 at E6.5 in Rdh10
flox/flox
; ER
T2
Cre mice 
results in an total intestinal hypoganglionosis phenotype, whereas 
deletion one day later at E7.5 results in only distal colon aganglionosis  
(I, white arrow).  
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RDH10 is required in the gut microenvironment for proper ENS 
development 
The early temporal requirement for RDH10 to form a complete enteric nervous 
system could indicate a role for RDH10 either intrinsically in ENCCs, or within the 
environment that interacts with ENCCs and through which the ENCCs traverse.  
DORSAL NEURAL TUBE DELETION OF RDH10 IN RDH10
FLOX/FLOX
; WNT1CRE MICE 
REVEALS NON-INTRINSIC ROLE OF RDH10 IN NCCS 
To determine the tissue-specific requirement for RDH10, we used the Wnt1Cre 
line to conditionally delete RDH10 from the dorsal neural tube, the territory from which 
NCCs are derived. This helped test whether RDH10 and retinoid signaling are 
intrinsically required within the NCCs during ENS development. Rdh10
flox/flox
; Wnt1Cre 
and Rdh10
flox/flox
 whole embryos stained with Tuj1 and DAPI at E9.5 showed normal 
peripheral nervous system development (Figure IV-10). At this stage, the vagal nerve is 
clearly extending towards the future enteric nervous system. 
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Whole guts from E15.5 and E18.5 embryos had mature neurons present in the 
same pattern and density in the entire length of the gut in Rdh10
flox/flox 
as well as 
Rdh10
flox/flox;
 Wnt1Cre embryos (E18.5 guts shown in Figure IV-11), indicating that the 
vagal nerve development was not only normal at E9.5 (Figure IV-10), but the nerve was 
also able to extend into the enteric nervous system by E15.5. This experiment shows that 
removing RDH10 specifically from neural crest cells does not affect the ENS formation, 
indicating that RDH10 is not intrinsically required for NCCs to enter the gut and 
differentiate into the ENS.   
 
Figure IV-10: Rdh
flox/flox
;Wnt1Cre embryos and wild-type littermates at E9.5 stained 
with Tuj1 and DAPI. When RDH10 is conditionally removed from the 
dorsal neural tube, the territory from which NCCs are derived, (as seen in 
Rdh
flox/flox
;Wnt1Cre), the peripheral nervous system develops normally 
(as seen in Rdh
flox/flox
). 
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Although RDH10 is not intrinsically required for neural crest cells to 
appropriately develop the peripheral and enteric nervous systems, it may instead be 
important in the microenvironment surrounding the developing foregut. Interestingly, by 
culturing ENS precursors ex vivo, Sato and Heuckeroth demonstrated that RA directly 
influences ENS precursor development, which can be independent of retinoid-induced 
changes in the gut mesenchyme or early neural crest development (Sato and Heuckeroth, 
2008). However, these ENS precursors were collected from E12.5 mouse stomachs, small 
bowels and colons, which we have previously found is after the most important period of 
retinoid environment patterning. We think it is important to continue investigating the 
possibility that the early environment surrounding the ENCCs during their migration is 
reliant on appropriate retinoid signaling.  
 
 
 
Figure IV-11: E18.5 guts of Rdh10
flox/flox;
 Wnt1Cre and wild-type littermates stained 
with Tuj1 and DAPI. Rdh10
flox/flox;
 Wnt1Cre guts have the same density 
and pattern of enteric neuron colonization as the control Rdh10
flox/flox
 
guts. 
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RDH10
TREX/TREX 
NCCS MIGRATE OUT OF THE NEURAL TUBE BUT DO NOT ENTER THE 
FOREGUT 
Using the newly created Mef2c-F10N-lacZ mouse line to label neural crest cells 
and derivatives (Aoto et al., 2015), we were able to investigate any potential differences 
in NCC migration and differentiation between Rdh10
trex/trex 
mice and their wild-type 
littermates via LacZ staining. Using this reporter line, it is clear that neural crest cells are 
specified but do not migrate to the appropriate location within the gastrointestinal tract 
(Figure IV-12, Figure IV-13). In E9.5 control embryos, both in wholemount and in 
section, it is clear that NCCs have already undergone appropriate ventrolateral migration 
towards the foregut (Figure IV-12). However, in mutant embryos, neural crest cells fail to 
migrate ventrally towards the foregut opening.  
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By E10.5, the differences in neural crest cell colonization are much more evident, 
with wild-type embryos exhibiting classic sympathetic ganglion colonization patterns as 
well as a clear vagal neural crest cell stream contributing to the ENS (Figure IV-13, 
Figure IV-12). However, in the mutant embryos, very few F10N+ neural crest cells 
migrate towards the entrance of the foregut.  This abnormal pattern of neural crest cell 
migration is clearer in sections.  
 
Figure IV-12: E9.5 Rdh10
trex
; F10N mice stained and sectioned. LacZ labels neural 
crest cells and derivatives. Section at the dotted line emphasizes altered 
neural crest cell migratory pattern in mutants. 
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RDH10
TREX/TREX 
MICE HAVE INCREASED CELL DEATH BUT DEATH IS NOT RESTRICTED TO 
ENTERIC NEURAL CREST CELLS 
The deficiency of neural crest cells in the gut at E10.5 of Rdh10
trex/trex 
embryos 
could be due to failed NCC survival. E9.5 cryosections were examined for the potential 
for NCC death. Sections of mutant embryos caudal to the otic vesicle near the opening of 
the foregut reveal fewer Ap2α+ neural crest cells near the entrance of the foregut, as well 
as an increase in caspase-3 mediated cell death (Figure IV-15). However, this cell death 
is not specific to neural crest cells, but rather is found in the cells immediately 
surrounding NCCs (Figure IV-14).  
 
Figure IV-13: E10.5 Rdh10
trex
; F10N mice stained and sectioned. LacZ labels neural 
crest cells and derivatives. In zoomed in vagal area of mutant embryos, it 
is obvious the vagal neural crest stream is missing. Section at the dotted 
line emphasizes altered neural crest cell migratory pattern in mutants. 
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Figure IV-14: Cryosections taken at E9.5 in mutant and wild-type embryos. Less 
Ap2α+ neural crest cells are visualized near the entrance of the foregut, 
along with increased cell death in Rdh10
trex/trex
. Images courtesy of 
Kazushi Aoto, Ph.D. 
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Rdh10 is expressed in the surrounding mesenchyme around the developing foregut 
To investigate the significance of increased cell death in the mesenchyme 
surrounding the NCCs, we used in situ hybridization to visualize the Rdh10 expression in 
the same areas. Rdh10 is expressed in the mesenchyme surrounding the foregut at E9.0. 
(Figure IV-16). Interestingly, this is the area NCCs must traverse to enter into the foregut 
to colonize the ENS and where we observe increased cell death. These data, combined 
with a lack of aganglionosis phenotype in Rdh10
flox/flox
; Wnt1-Cre, lead us to hypothesize 
a potential extrinsic, environmental role for RDH10 and RA signaling in facilitating NCC 
entry and migration into the foregut.  
 
Figure IV-15: Zoom-in at the area of significantly increased cell death in Rdh10
trex/trex
 
mutants. Cell death does not co-localize with Ap2α+ neural crest cells. 
Images courtesy of Kazushi Aoto, Ph.D. 
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Genes that play a role in total intestinal aganglionosis phenotypes are 
altered in RDH10
trex/trex
 embryos 
Although many genes influencing vagal neural crest migration are known, the 
mechanisms controlling ENS migration into the developing gastrointestinal tract are not 
completely understood. We have shown that RDH10 is not intrinsically required in NCCs 
for their entry and colonization of the gut, so there must be another extrinsic explanation 
for why Rdh10
trex/trex 
mutant embryos display this total colonic aganglionosis phenotype. 
Previous studies have shown that both ENCCs and the microenvironment surrounding 
 
Figure IV-16: Whole embryo staining of Rdh10 in E9.5 embryo shows high 
expression in foregut area. Dotted line shows level of section. Section in 
situ reveals high expression in mesenchyme surrounding the foregut. 
Section image courtesy of Lisa Sandell, Ph.D. 
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them can actively modify one another as ENCCs traverse through the environment 
(Akbareian et al., 2013; Simkin et al., 2013). Here we propose that RA is necessary for 
ENCC migration into the GI tract by either altering the expression of ENCC development 
genes, or by modifying the environment through which the ENCCs must traverse. 
Specifically, we are interested in the ENCC development genes that cause a similar total 
intestinal aganglionosis phenotype in a null mouse line, as the Rdh10
trex/trex 
mutants, such 
as the GDNF, RET, GFRa1, Sox10, Phox2b and Pax3. If these genes are changed in 
Rdh10
trex/trex
 mutants, the phenotypic changes may be attributed to genetic interactions 
between RA and these known ENCC development genes, or RA may act upstream or 
downstream of these genes. Additionally, we wanted to test whether RDH10 and RA 
signaling play a role in proper ENCC microenvironment factors, such as in maintaining a 
permissive extracellular matrix (ECM). 
Using in situ hybridization, we investigated spatiotemporal changes in expression 
of key genes associated with aganglionosis phenotype between Rdh10
trex/trex
 mutants and 
their wild-type littermates. In cases where in situ expression data were unavailable, we 
used qPCR or RNA Seq fold change values (For this section we used the data from 
“RNASeq2”). Tissue encompassing the first seven somites of E9.5 embryos was used for 
RNA Seq and qPCR experiments (Figure II-13).  
GDNF, RET, AND GFRΑ1 ARE ALTERED IN RDH10
TREX/TREX
 EMBRYOS 
Gdnf, Ret, and Gfrα1 homozygous mutants display a similar total intestinal 
aganglionosis phenotype as Rdh10
trex/trex
 embryos. Ret in situ hybridization reveals no 
expression in developing Rdh10
trex/trex
 guts (Figure IV-17). However, this lack of Ret does 
not prove causality. It is not certain whether there is no Ret signaling because RA is 
necessary for acquiring RET+ ENCCs (as in avian models), or if there is no Ret 
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expression simply because there are no ENCCs. Without further evidence, a conclusive 
statement cannot be made on the exact reason Ret is absent.  
 
It is therefore expected that Gfrα1 expression would also be absent in mutant 
animals. Other researchers have reported that when GDNF is absent, ENCCs are unable 
to locate and enter into the foregut. We hypothesized that because GDNF is such an 
 
Figure IV-17: RET in situ hybridization of mutant and wild-type littermates at E9.5 
reveals RET expression in developing gut, and no RET expression in 
mutant developing gut.  
 
 97 
important ENCC chemoattractant, it is important for us to analyze the expression of Gdnf 
in Rdh10
trex/trex
 embryos. 
qPCR data for Gdnf, Ret and Gfrα1 showed significantly reduced levels of mRNA 
for each of these genes in Rdh10
trex/trex
 embryos compared to their wild-type littermates 
(Figure IV-18). Compared to wild-type littermates, Gdnf, Ret and Gfrα1 had only 70%, 
54% and 49% relative expression levels, respectively. Each of these three gene 
expression level differences showed significant p-values (p<0.05). 
 
Currently we do not know whether RA signaling is directly required for Ret or 
Gdnf expression. Interestingly, it has been proposed in avian models that vagal NCCs 
 
Figure IV-18: qPCR results comparing Rdh10
trex/trex
 and wildtype littermates. There is 
a significantly reduced level of GDNF, RET and GFRα1 in Rdh10
trex/trex
 
embryos. Relative quantities (of each gene) are graphed with 95% 
confidence intervals. Each of these three gene expression level 
differences showed significant p-values (p<0.05). 
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experience RA secreted from the somites, and as they migrate through this field of RA, 
the vagal NCCs upregulate Ret expression, which then allows them to respond to the 
GDNF signal present in the gut mesenchyme (Simkin et al., 2013). We can speculate that 
the RA signaling deficient ENCCs in Rdh10
trex/trex
 embryos are unable to regulate Ret 
expression, rendering them non-responsive to GDNF signal. A Gdnf in situ hybridization 
would help elucidate whether the ENCCs of Rdh10
trex/trex
 embryos are experiencing the 
same phenomenon as seen in avian embryos. Nevertheless, the down-regulation of Gdnf, 
Ret and GFRα1 transcripts in Rdh10
trex/trex
 embryos suggests that RA signaling is 
somehow required for regulation of GDNF/RET signaling during ENCC migration and 
ENS formation. 
SOX10 IS ALTERED IN RDH10
TREX/TREX
 EMBRYOS 
Homozygous Sox10
lacZ/lacZ
 mice exhibit total intestinal aganglionosis (Britsch et 
al., 2001), resembling the phenotype found in Rdh10
trex/trex
 embryos. When Rdh10
trex/trex
 
embryos are stained for Sox10, there is an obvious absence of Sox10+ cells in the foregut, 
unlike the control embryos, which have a Sox10+ labeled vagal NCC stream extending 
towards the foregut region of the embryo (Figure IV-19). The expression of Sox10 is very 
similar to that of the Rdh10
trex/trex
; F10N mice, indicative of the failure of vagal NCCs to 
migrate towards and enter the opening of the foregut. Interestingly, the mutant 
Rdh10
trex/trex
 embryos have Sox10 expression in the craniofacial region and along the 
dorsal portion of the embryo, and the major deficiency in Sox10+ NCCs is seen 
specifically in the vagal NCC population, further supporting the hypothesis that RA may 
play a role in modulating ENS developmental genes, as Sox10 will play an important role 
in maintaining the ENS in a progenitor state.  
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PHOX2B, PAX3 AND EDNRB ARE ALTERED IN RDH10
TREX/TREX
 EMBRYOS 
To conclude the investigation into genes in which mutations are associated with 
total intestinal aganglionosis, we used RNA Seq to compare relative expression levels of 
Phox2b, Pax3 and Ednrb in Rdh10
trex/trex
 mutant and wild-type embryos. PHOX2B and 
PAX3 are both required for normal ENS formation, and in mice, it has been shown that 
Phox2b and Pax3 homozygous mice have total intestinal aganglionosis (Elworthy et al., 
2005; Lang et al., 2000; Pattyn et al., 1999). The EDN3-EDNRB pathway is necessary 
 
Figure IV-19: Sox10 in situ hybridization of mutant and wild-type littermates at 
E9.5Sox10 staining reveals Sox10 expression in the developing wild-type 
gut, and no Sox10+ NCCs in the mutant developing gut. 
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for normal ENCC migration, double knockout mice models of SOX10 and EDN3 or 
EDNRB3 show a worse aganglionosis phenotype that just one gene knockout alone, 
suggesting a genetic interaction between SOX10 and EDNR signaling that increases the 
penetrance and severity of the phenotype. Both the Sox10
Dom/+
; Edn3
ls/ls
 double mutants 
(Stanchina et al., 2006) and Sox10
Dom/+
; Ednrb
sl/sl
 double mutants (Cantrell et al., 2004) 
results in total intestinal aganglionosis. By RNA Seq analysis, we detected decreased 
relative expression levels of these genes in the Rdh10
trex/trex
 embryos (Table IV-1). 
Rdh10
trex/trex
 embryos have significantly less Phox2b expression (3.877 fold), and slightly 
less Pax3 (1.255 fold) and Ednrb (1.751 fold) expression than wild-type littermates. Each 
of these three gene expression level differences showed significant p-values (p<0.05). 
Rdh10
trex/trex
 embryos have a non-statistically significant minor decrease in Edn3 
expression.  
 
GUT MICROENVIRONMENT COMPONENTS ARE ALTERED IN RDH10
TREX/TREX
 EMBRYOS 
Additionally, we have assayed for changes in gene expression of molecules that 
play a role in retinoic acid signaling within the gut microenvironment, such as L1CAM, a 
neuronal cell adhesion molecule, and CRABP1, a cellular RA-binding protein important 
for RA-mediated differentiation and proliferation processes. In the avian model which 
found that RA is necessary for continued ENCC migration (Simkin et al., 2013), it was 
noted that as ENCCs passed through the paraxial tissues surrounding the foregut, the 
Table IV-1: RNA sequencing fold changes for Phox2b, Pax3, Ednrb and Edn3.  
Gene Fold Change P Value 
Phox2b -3.877 9.87E-26 
Pax3 -1.255 3.55E-4 
Ednrb -1.751 8.99E-19 
Edn3 -1.103 0.317725 
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ENCCs became Crabp1+, rendering the cells able to respond to the RA in the 
surrounding environment (Simkin et al., 2013). Crabp1 expression was analyzed in 
Rdh10
trex/trex
 mutants and wild-type littermates at E9.5 and E10.5. Rdh10
trex/trex
 mutants 
display an overall decrease in Crabp1 expression, especially surrounding the developing 
gut, while wild-type embryos have Crabp1+ cells near the developing gut (Figure IV-20). 
Similar to the Sox10 expression in mutant Rdh10
trex/trex
 embryos (Figure IV-19), Crabp1 
expression is still present in the craniofacial region, forelimb, and dorsal neural tube, but 
specifically absent in the vagal NCC population, again supporting the hypothesis that RA 
may be specifically acting to regulate ENS developmental genes.  
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L1Cam is expressed by early migrating ENCCs, and has been proposed to 
contribute to the efficiency of ENCCs movement. Although L1Cam mutant mice have a 
functional ENS at birth, they do exhibit delayed colonization during development due to 
solitary migration instead of chain migration (Anderson et al., 2006c). The first reported 
human case in a neural cell adhesion molecule was in the L1CAM gene (Okamoto et al., 
 
Figure IV-20: Crabp1 in situ hybridization of mutant and wild-type littermates at 
E9.5 and E10.5. In situ hybridization reveals Crabp1 expression near 
developing wild-type gut, and no Crabp1 expression surrounding 
mutant developing gut. 
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1997), and it has since been suggested that mutations in this X-chromosomally located 
gene may contribute to the male predominance of HSCR (Hofstra et al., 2002).  
In the RNA sequencing experiment (RNASeq2), L1Cam was significantly 
decreased, with a 1.52 fold change difference (Table IV-2). This is an interesting finding, 
as L1Cam also acts as a modifier gene in conjunction with Sox10, Edn3, and Ednrb to 
increase the incidence of aganglionosis (Wallace et al., 2010; Wallace et al., 2011). 
Again, this supports the notion that RA may allow for ENCC initial foregut migration by 
modulating the expression of genes such as L1Cam, which would then be able to act in 
conjunction with ENS development genes such as Sox10, Edn3, and Ednrb. 
ECM COMPONENTS ARE ALTERED IN RDH10
TREX/TREX
 EMBRYOS 
In addition to our targeted gene approach to understand the pathogenesis of the 
Rdh10
trex/trex
 mutant phenotype, our RNA Seq data provided an unbiased approach to 
understand additional microenvironment changes. Using the Signaling Pathway Impact 
Analysis (SPIA) algorithm (Tarca et al., 2009) to assess Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathway perturbations, we found the top two upregulated 
pathways in the Rdh10
trex/trex
 mutants as compared to their wild-type littermates were 
altered extracellular matrix (ECM) composition and focal adhesion (FA) pathways. 
 Extracellular matrix proteins such as Fibronectin (FN), Tenascin-C (TnC), 
Laminin 1 and 8, Collagen types I, III, IV, and VI, Thrombospondin-1, ADAMs 10 and 
13 and MMPs 2 and 9 are thought to play a permissive role in successful NCC migration 
(Anderson, 2010; Breau et al., 2009; Kerosuo and Bronner-Fraser, 2012; McCarthy and 
Hay, 1991; Monsonego-Ornan et al., 2012; Perris and Perissinotto, 2000; Theveneau and 
Mayor, 2014) (Akbareian et al., 2013). Non-permissive ECM components include 
Collagen type II, Perlecan, and Fibulin-1. Lastly, ECM components that inhibit NCC 
migration include Aggrecan, Versican, and Collagen IX (Perris and Perissinotto, 2000; 
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Sotoodehnejadnematalahi and Burke, 2013; Tsang et al., 2010). We hypothesized that in 
comparison to their wild-type littermates, Rdh10
trex/trex
 mutants would exhibit an up-
regulation of “non-permissive” and “inhibitory” ECM components and down-regulation 
of “permissive” components. We investigated this hypothesis using the RNA Seq RPKM 
values and fold changes for these genes (Table IV-2) and verified some of the findings 
using qPCR (Figure IV-21).  
Using RNA Seq, Collagen 1A1 and Collagen 6A3 had greater than 2 fold 
differences, with significant p-values (p<0.05). Aggrecan, Fibronectin, Tenascin-C, and 
Collagen 6A4 had greater than 1.5-fold change differences, with all having significant p-
values except Collagen 6A4.  L1Cam had a decrease in expression fold change of greater 
than 1.5-fold, with a significant p-value (p<0.05). Comparison of relative gene expression 
in Rdh10
trex/trex 
mutants and wild-type littermates by qPCR revealed that LAMC3 has a 
53% reduction of relative expression levels, and COL1A1, COL1A2, TnC and FN1 have 
172%, 136%, 122% and 120% relative expression levels, respectively (Figure IV-21). 
LAMC3, COL1A1 and COL1A2 gene expression level differences showed significant p-
values (p<0.05). There is a slightly increased level of TnC and FN1, but these changes 
are not significant. 
It is clear that the appropriate spatiotemporal distribution of ECM components has 
a profound effect on NCC migration. It has previously been postulated that abnormal 
ECM microenvironments may be responsible for, or are at least implicated in, the 
pathogenesis of enteric nervous system defects, such as Hirschsprung Disease (Alpy et 
al., 2005; Parikh et al., 1992). Our broad hypothesis that Rdh10
trex/trex
 mutants would have 
upregulated “non-permissive” and “inhibitory” ECM components and downregulated 
“permissive” components, compared to wild-type littermates seems too simplified. A 
revised hypothesis needs to take into account which ECM components are specifically 
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necessary in the microenvironment directly surrounding the foregut and directly 
interacting with the NCCs invading the foregut. Subsequently, we would be able to 
analyze how these genes are modified in Rdh10
trex/trex
 mutants.  
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Table IV-2: RNA sequencing fold changes for ECM and FA components. Permissive 
components are shown in green, non-permissive components are shown 
in orange, and inhibitory components are shown in red. FA components 
are shown in blue. Components that retinoid signaling is known to 
regulate is shown in blue.
Gene Fold Change P Value 
Collagen 2A1 1.186 0.003019 
Perlecan (HSPG2) 1.442 2.64E-08 
Fibulin-1 1.245 8.41E-05 
Aggrecan 1.829 0.032858 
Versican 1.035 0.548477 
Collagen 9A1 1.094 0.158002 
Collagen 9A2 1.188 0.181727 
Collagen 9A3 1.380 0.083503 
Fibronectin 1.545 4.59E-09 
Tenascin-C 1.99 1.05E-10 
Laminin I (α1) -1.063 0.33356 
Laminin I (β1) 1.397 9.03E-06 
Laminin I (γ1) 1.269 0.000174 
Laminin 8 (α4) 1.186 0.061167 
Collagen 1A1 2.761 8.60E-15 
Collagen 1A2 1.443 3.03E-06 
Collagen 3A1 1.430 1.92E-07 
Collagen 4A1 1.061 0.284618 
Collagen 4A2 1.154 0.009759 
Collagen 4A3 -1.046 1 
Collagen 4A4 -1.078 1 
Collagen 4A5 1.162 0.127496 
Collagen 4A6 1.442 0.000274 
Collagen 6A1 -1.051 0.679077 
Collagen 6A2 -1.037 0.773363 
Collagen 6A3 2.172 6.58E-08 
Collagen 6A4 1.595 0.109034 
Collagen 6A5 -1.262 0.495553 
Collagen 6A6 -1.119 0.342821 
Thrombospondin-1 1.242 0.007336 
ADAM 10 -1.064 0.270702 
MMP2 1.158 0.005653512 
MMP9 -1.297 0.196087539 
L1cam -1.520 0.003541816 
N Cadherin -1.005 0.934511 
Elastin 1.110 0.619503 
Entactin 1.050 0.425888 
β1 Integrin 1.109 0.097041 
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RDH10 may act as a modifier gene 
Finally, numerous studies have suggested the involvement of modifier genes or 
environmental influences in the etiology and pathogenesis of HSCR, both in mouse 
models, and in human patients (Angrist et al., 1996; Barlow et al., 2013; Bolk et al., 
2000; Cantrell et al., 2004; Doray, 1998; Parisi and Kapur, 2000; Salomon et al., 1996; 
Stanchina et al., 2006; Wallace et al., 2010; Wallace et al., 2011). The modifier genes act 
by contributing to pathways that are critical for ENCC developmental processes, such as 
 
Figure IV-21: qPCR results comparing Rdh10
trex/trex
 and wildtype littermates. There is 
a significantly reduced level of LAMC3, and significantly increased level 
of COL1A1 and COL1A2 in Rdh10
trex/trex
 embryos. Relative quantities 
(of each gene) are graphed with 95% confidence intervals. Each of these 
three gene expression level differences has a significant p-value 
(p<0.05). There is a slightly increased level of TnC and FN1, but these 
changes are not significant. 
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migration, proliferation, differentiation and survival (Butler Tjaden and Trainor, 2013). 
Of particular interest, L1cam acts as a modifier gene in conjunction with Sox10, Edn3, 
and Ednrb to increase the incidence of aganglionosis (Wallace et al., 2010; Wallace et al., 
2011) and Pax3
 
and Tcof
  
act through a p53 dependent apoptosis pathways to cause 
increased ENCC cell death, resulting in a decreased number of NCCs that can migrate 
into the foregut to complete colonization of the distal gut by E18.5. Compound Pax3
+/-
; 
Tcof1
+/- 
animals display distal colonic aganglionosis, although neither Pax3
+/-
 nor 
Tcof1
+/-
 mice exhibit colonic aganglionosis alone (Barlow et al., 2013).  
As a preliminary study, we crossed RDH10 to mouse models we have in the lab 
that have been implicated in HSCR, or have a role in NCC migration. When Rdh10
trex/+ 
was crossed with Pax3
+/-
, Gcnf
+/-
 or Tcof1
+/-
, no compound heterozygous embryos 
resulted in a distal colonic aganglionosis phenotype (Figure IV-22). Although GCNF has 
not previously been implicated in ENS development, Gcnf
-/-
 mouse mutants have a 
decreased number of NCCs, and significantly reduced Sox10 expression (data not 
shown). In each of these crosses, we see a colonized distal colon with similar density and 
pattern as the control Rdh10
+/- 
gut.  
These compound heterozygous crosses suggest that RDH10 likely does not act 
through the same ENCC developmental pathways as these genes, such as through the 
p53-dependent apoptosis (Pax3
+/-
 and Tcof1
+/-
), or by reducing the number of NCCs 
available for migration. These conclusions make sense in the broader context of this 
study, as we have already seen in our data (Figure IV-15) and others (Sato and 
Heuckeroth, 2008), that retinoid deficiency does not seem to change the level of NCC 
death. These data do not rule out the possibility that RDH10 may still be a modifier of 
other pathways that may result in colonic aganglionosis, but future investigations with 
other crosses are necessary to determine that potential role. 
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General Conclusion 
These studies have established a new model for studying the total intestinal 
aganglionosis form of HSCR, provided information regarding the spatiotemporal 
requirements for RA during embryonic intestinal development and potential pathogenic 
cellular mechanisms of RDH10 deficient animals, as well as predicted potential 
interactions of RA with pathways that govern normal NCC formation of the ENS and 
ECM maintenance of the microenvironment.  
  
 
Figure IV-22: Analysis of RDH10 as a potential modifier. Rdh10
trex/+ 
was crossed to 
Pax3
+/-
, Gcnf
+/-
 and Tcof1
+/-
, and intestines were stained with Tuj1 
(mature neurons), P75 (neural crest cells) and DAPI to analyze ENS 
formation. None of these compound heterozygous animals resulted in a 
distal aganglionosis phenotype.  
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V. DISCUSSION 
Only half of the cases of Hirschsprung disease (HSCR) have been associated with 
a specific genetic mutation. Hence, it is important to continue the search for genetic and 
environmental factors that may contribute to the etiology of HSCR as independent 
mutations or as modifiers. To that end, our lab generated mouse embryos deficient in 
RDH10, which results in decreased retinoid signaling (Sandell et al., 2011) and exhibit 
total intestinal aganglionosis (Figure IV-4). This body of work establishes Rdh10 
deficiency as a model of genetically induced Hirschsprung disease, specifically total 
intestinal aganglionosis, and vitamin A deficiency as a potential environmental modifier. 
This study investigated the spatial and temporal requirements of retinoic acid 
during gastrointestinal system development using Rdh10
trex/trex
 mice (an ENU 
mutagenesis generated point mutant) and Rdh10-conditional knockout mice. We 
discovered a critical requirement for retinoic acid during early ENCC migration and in 
establishing a receptive microenvironment for ENCC entry into the foregut tissue. In 
contrast to what has been found in avian organisms (Simkin et al., 2013), we did not 
observe a requirement for retinoic acid in maintaining continued migration of ENCCs or 
their differentiation after ENCC entry into the foregut.  
Retinoic Acid must be tightly regulated spatiotemporally, to allow for 
normal enteric nervous system development  
Insufficient or excess dietary vitamin A can result in congenital anomalies and 
even fetal death (Ross et al., 2000), largely due to the important functions of retinoic 
acid, the active form of vitamin A, during embryonic development. When vitamin A 
deficiency occurs prior to or during pregnancy, it can affect NCC development, 
potentially resulting in neurocristopathies such as HSCR. Hence it is critical to 
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understand which stage of NCC development requires retinoid signaling during ENS 
formation and gut development. Although there have been a few studies examining the 
role of retinoids on ENS development, there has not yet been an in-depth spatiotemporal 
examination of the role of vitamin A metabolism (specifically the contribution of 
RDH10) in the formation and development of the enteric nervous system (ENS) and GI 
tract in mammalian embryos. 
Currently, two mouse models implicate a role for retinoid signaling in the 
pathogenesis of colonic aganglionosis (Rbp4
-/- 
and Raldh2
-/-
) (Fu et al., 2010; 
Niederreither et al., 2003). Additionally, it has been suggested that RA is necessary for 
continued ENCC chain migration in avian models (Simkin et al., 2013).  To understand 
the RDH10 mutant intestinal aganglionosis phenotype (Figure IV-4) in a vitamin A 
metabolism deficiency context, it was important to visualize retinoic acid signaling in the 
mutant embryos to determine if the gut phenotype was correlated with a decrease in 
retinoid signaling.  Using a RARElacZ reporter mouse line that expresses lacZ under 
influence of retinoic acid signaling, we showed that Rdh10
trex/trex
 embryos have 
significantly diminished retinoid signaling in the developing gut, suggesting that RA may 
play a role in ENS formation (Figure IV-2).  
To determine whether the necessity of RA for continued ENCC migration is 
conserved between avian and murine models, we conducted gut explant culture 
experiments to determine what role RDH10 and retinoid signaling play in ENS 
development. Knowing that the etiology of previous models of HSCR in the mouse was 
due to delayed ENCC migration throughout the gut (Barlow et al., 2012), we investigated 
this as a potential cause of the aganglionosis phenotype seen in Rdh10
trex/trex 
mutant 
embryos. To that effect, we cultured Rdh10
trex/trex 
gut explants in RA-deficient media and 
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found that proper colonization of the gut by ENCCs and formation of a complete ENS 
only occurs when Rdh10 is fully functional (Figure IV-5).  
There are a few potential explanations for why the Rdh10
trex/trex
 explants do not 
have a completely colonized GI tract: there could be an insufficient number of ENCCs 
(progenitor cells), RDH10 (and hence RA) might be required for the survival of ENCCs 
within the gut, or RDH10 might be required for differentiation of ENCCs into ENS 
neurons and glia. If RDH10 or RA is required for survival or differentiation of ENCCs 
within the gut, then supplementation with RA at time of culturing should rescue the 
aganglionosis phenotype in Rdh10
trex/trex 
guts, which is not what we case observe (Figure 
IV-6). This indicates a clear requirement for RDH10-mediated conversion to RA prior to 
E11.5.  Our results support the recent results shown in avian models, where RA has been 
implicated in the initial colonization of the gut, but we find that RDH10 is not necessary 
for continued ENCC chain migration (Simkin et al., 2013). Consistent with previous data 
(Sato and Heuckeroth, 2008), we do not observe increased cell death in Rdh10
trex/trex
 guts 
(Figure IV-15), suggesting that RDH10 and RA are not required for the survival of 
ENCCs. 
RETINOIDS ARE NECESSARY PRIOR TO INITIAL ENCC INTO THE FOREGUT 
It is important to determine the critical time window during with retinoids are 
required for ENS development. Our culture experiments clearly suggest a role for 
retinoids in regulating gut colonization prior to E11.5. In vitro gut-culturing experiments 
prior to mid-gestation are technologically challenging. Instead, we approached this 
question through a maternal rescue experiment. We administered retinal to pregnant dams 
carrying control and Rdh10
trex/trex
 embryos, using oral gavage. In our initial once per day 
gavages, we found that the retinal administration for five consecutive days, between E7.5 
to E11.5, resulted in the best rescue of the neuronal colonization of the gut. When we 
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increased the gavage administrations to twice per day, we were able to narrow the critical 
time window of retinal requirement to E7.5 - E9.5 with a better rescue of gut 
colonization, where both mutant and control guts were colonized up to the cecum (Figure 
IV-8). During normal murine development, ENCCs do not enter the gut until E8.5-E9.0, 
suggesting that retinoids must be necessary in the embryo before or right as vagal neural 
crest cells begin invading into the anterior foregut. Given that retinal supplementation for 
this short time window is sufficient to allow mutant ENCC colonization of the gut 
equivalent to control guts, argues against the role for retinoids in continued migration and 
differentiation of ENS.  
Although our preliminary studies support previous work done in the field (Fu et 
al., 2010; Niederreither et al., 2003), they still rely on dietary modifications (RA or 
retinal supplementation) to elucidate the role for RDH10 in ENS colonization, and we 
were concerned that our analyses might be influenced by teratogenic effects of excess 
exogenous RA (Quemelo et al., 2007). In order to obtain a cleaner genetic model system 
to investigate the role for RA and RDH10 in ENS development, we shifted to 
Rdh10
flox/flox
; ER
T2
Cre mouse line, where we used tamoxifen administration to temporally 
excise RDH10 ubiquitously throughout the animal. The results of these in vivo 
conditional Rdh10 deletion experiments reiterate our retinal gavage rescue findings, that 
RA is necessary in early ENCC migration and their entry into the gut, but not for 
continued migration throughout the gut.  Rdh10 excision prior to vagal neural crest cell 
migration leads to either distal colonic aganglionosis (tamoxifen administration at E7.5) 
or total colonic hypoganglionosis (tamoxifen administration at E6.5), but Rdh10 excision 
later than these time-points results in normal gut colonization, emphasizing the retinoid 
independence of ENCCs for continued colonization  (Figure IV-9).  
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Thus far, we have utilized retinoid supplementation both in culture and via in 
utero gavage supplementation, along with conditional knockout mice to define the 
temporal requirement for RA signaling. Maternal gavage experiments providing retinal to 
RDH10 deficient mouse mutants revealed RA activity is critically required between E7.5-
E9.5 only. These retinoid gut culture and retinal gavage data suggest that RA is not 
necessary for the maintenance of NCC migration, differentiation or proliferation after the 
initial NCC migratory period. Rather, retinoids are important for initiating vagal ENCC 
migration and entry into the gut. In combination with data from RDH10 conditional 
knockout mice, we showed that there is a critical requirement for retinoids prior to early 
ENCC migration, but are not necessary to maintain continued ENS migration or 
differentiation, indicating that retinoic acid signaling may be necessary to establish a 
receptive NCC environment near the anterior foregut.  
Pathogenesis of RDH10
trex/trex 
is attributed to ENCC extrinsic factors 
Since the ENS is entirely derived from NCCs, we analyzed the status of NCCs in 
Rdh10
trex/trex 
embryos using the newly developed Mef2c-F10N-lacZ reporter line (Aoto et 
al., 2015). In Rdh10
trex/trex
 embryos, NCCs have failed to enter into the foregut region 
between E9.5 and E10.5 (Figure IV-12, Figure IV-13). Section analysis suggests that at 
both E9.5 and E10.5, only a few NCCs have migrated ventrally to the proximity of the 
foregut and with the majority still remaining near the neural tube. The failure of these 
Rdh10
trex/trex
 ENCCs to migrate ventrally to the same extent as control embryos and to 
enter the GI tract could be due to an intrinsic requirement for RDH10 in ENCCs or an 
extrinsic requirement for RDH10 and RA in maintaining an appropriate ENCC 
microenvironment. 
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RDH10 IS NOT INTRINSICALLY REQUIRED FOR ENCC GUT COLONIZATION  
To determine the tissue specific requirement for RDH10, we excised Rdh10 
specifically from neural crest cells using Rdh10
flox/flox
; Wnt1Cre mice. As can be observed 
in E9.5 whole embryos (Figure IV-10) and E15.5 and E18.5 guts (Figure IV-11), 
Rdh10
flox/flox
; Wnt1Cre embryos display normal neuronal differentiation and are 
indistinguishable from their wild-type littermates in the pattern and density of stained 
mature neurons, indicating that RDH10 is not intrinsically required within NCCs. 
Consistent with previous results, section immunohistochemistry reveals neural 
crest cell migration abnormalities and that loss of Rdh10 results in non-neural crest cell 
death in regions around the foregut (Figure IV-14), indicating that dying cells are not 
neural crest cells, but may be supporting cells in the microenvironment (Figure IV-15). 
Interestingly, this zone of cell death corresponds with the region of Rdh10 expression 
(Figure IV-16).  
In avian models, as ENCCs passed through the paraxial tissues surrounding the 
foregut, they became Crabp1+, rendering the cells  able to respond to the RA in the 
surrounding environment (Simkin et al., 2013). Rdh10
trex/trex
 mutants and wild-type 
littermates at E9.5 and E10.5 were stained for Crabp1 expression, which revealed 
predominantly reduced signal around the developing mutant gut region (Figure IV-20). 
The lack of Crapb1 expression can be interpreted as requiring either RDH10 or RA 
signaling to acquire CRABP1 on ENCCs, so the absence of RA resulted in an inability to 
migrate into the gut, or that the lack of Crabp1 expression in Rdh10
trex/trex
 embryos was 
simply a consequence of lacking ENCCs. Without further experimentation, we are unable 
to determine which interpretation is more likely, as CRABP1 is known to be responsive 
to RA, so one might infer ENCCs were unable to migrate into the foregut due to the lack 
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of Crabp1 expression is due to the lack of RDH10 and RA, but there are Crabp1+ NCCs 
throughout the rest of this animal that seem unaffected by the retinoid deficiency.  
Altogether, these data indicate a role for RDH10 and RA signaling in regulating 
ENCC entry into the foregut via extrinsic factors such as the ENCC microenvironment, 
and not in ENCCs themselves.  
EXTRINSIC ENCC FACTORS INFLUENCE ENS DEVELOPMENT IN RDH10
TREX/TREX
 
As highlighted in the introduction various pathways have been implicated in ENS 
development through genetic analysis of HSCR patient samples and mouse models with 
aganglionosis. Unfortunately, the relations between these pathways are not well defined 
including how retinoid signaling affects and is affected by components extrinsic to ENCC 
development, particularly how RA may play a role in targeting known ENS signaling 
pathways, the gut microenvironment, and as a modifier of other HSCR models.  
Retinoids play a role in the enteric nervous system signaling pathways that cause a 
similarly devastating total intestinal aganglionosis phenotype 
Although great strides have been made in the HSCR field to identify genes 
influencing ENCC migration to form the ENS, there is still much to learn. To evaluate if 
RDH10 causes total intestinal aganglionosis via genetic interactions between RA and 
known ENCC developmental genes, we utilized in situ hybridization, qPCR and RNA 
Seq to assess the effects of retinoid deficiency on their spatiotemporal activity.  
We analyzed the Ret, Gdnf and Gfrα1 expression using in situ hybridization and 
qPCR. Ret, Gdnf and Gfrα1 mutants display a similar total intestinal aganglionosis 
phenotype as Rdh10
trex/trex
 embryos. Expression analysis via qPCR of all three of these 
genes was significantly decreased in Rdh10
trex/trex 
embryos (Figure IV-18) suggesting that 
RDH10 and RA signaling may have a role in regulating GDNF-RET-GFRα1 signaling 
during ENS development. In situ hybridization reveals complete absence of Ret+ ENCCs 
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within the Rdh10
trex/trex
 mutant guts (Figure IV-17). Given that few ENCCs migrate into 
the Rdh10
trex/trex
 mutant guts (Figure IV-12, Figure IV-13), the lack of Ret expression can 
be interpreted as one of two things: either RDH10 and RA signaling are required for 
acquiring RET on ENCCs and absence of RET in Rdh10
trex/trex
 ENCCs inhibits them from 
migrating into the gut or RDH10 and RA signaling have no direct role in regulation of 
Ret expression and lack of Ret expression is just a consequence of missing ENCCs in 
Rdh10
trex/trex
 embryos. However, preliminary motif analysis suggests that Gdnf has a 
putative Retinoic acid receptor (RAR) binding site upstream of the coding region, 
implying a possibility that RA signaling may directly control Gdnf expression and 
therefore is required for the GDNF-RET-GFRα1 complex. It is important to visualize the 
expression pattern of Gdnf within the surrounding Rdh10
trex/trex
 mutant gut paraxial 
mesenchyme to determine how the lack of RA signaling affects this important 
chemoattractant. Additionally, a role for RA signaling has already been suggested in 
avian models, as vagal NCCs respond to RA signaling from the environment by 
upregulating Ret expression and thus becoming GDNF-responsive (Simkin et al., 2013). 
Additionally, Gdnf
+/-
 mutants have decreased Ret expression in the myenteric plexus 
(Shen et al., 2002), which suggests that Gdnf may be a regulator of Ret. Therefore, if RA 
has a role in directly regulating Gdnf, it may then indirectly regulate Ret. 
Sox10, Phox2b, Pax3 and Ednrb also play important roles in ENS development, 
as homozygous Sox10
lacZ
, Phox2b and Pax3, as well as Sox10
Dom/+
; Edn3
ls/ls
 and 
Sox10
Dom/+
; Ednrb
sl/sl
 double mutants exhibit total intestinal aganglionosis. At E9.5, we 
note Sox10 expression in the developing wild-type gut, and no Sox10 expression in the 
mutant developing gut (Figure IV-19). This lack of Sox10+ ENCCs in the developing gut 
was not unexpected, as the lack of ENCCs was evidenced in previous experiments 
(Figure IV-12, Figure IV-13). This suggests an indirect effect of RA deficiency, because 
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ENCCs are unable to enter into the foregut, and thus there will be no Sox10+ ENCCs in 
the gut during development. Molecular analysis of Phox2b, Pax3 and Ednrb in 
Rdh10
trex/trex
 mutant and wild-type littermates at E9.5 revealed significantly decreased 
levels of expression (Table VII-5), indicating that RA may act in the same pathways as 
many of these important ENS developmental pathways.  
Retinoids play a role in Rdh10
trex/trex
 microenvironment maintenance 
In addition to our targeted gene approach to understand the pathogenesis of the 
Rdh10
trex/trex
 mutant phenotype, our RNA Seq data provided an unbiased approach to 
understand additional changes that contribute to the total intestinal aganglionosis 
phenotype in Rdh10
trex/trex
 mutant. Here we discuss changes in ENS development genes 
that also play a role in the maintenance of the ENS microenvironment (Gdnf, Edn3, 
L1cam), as well as the numerous extracellular matrix (ECM) components identified via 
RNA Seq KEGG pathway analysis.  
Gdnf is found in the surrounding gut microenvironment and acts as an ENCC 
chemoattractant. The potential role of RA signaling on Gdnf expression has previously 
been discussed. Edn3 is another component found in the surrounding microenvironment 
that acts to maintain a permissive gut environment. Using RNA Seq data as a first pass of 
how changes in expression of pathways involved in ENS development are affected by 
RA deficiency, we observed a slight decrease in expression in Rdh10
trex/trex
 mutants 
(Table IV-1). L1Cam has been associated with modulating ENCC migratory efficiency 
and neurite outgrowth, and has been suggested as an HSCR modifier.  L1Cam RNA Seq 
expression data showed a significant (p<0.05) decrease in mRNA levels (Table IV-2), 
suggesting that RA may act in controlling the ENCC ability to enter into the foregut by 
acting through L1CAM. 
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Preliminary data from RNA Seq experiments revealed the extracellular matrix as 
the top changed KEGG pathway in the Rdh10
trex/trex
 mutants as compared to their wild-
type littermates. Unlike what we had initially hypothesized, the majority of the ECM 
differences were not seen as significant up-regulation of “non-permissive” and 
“inhibitory” ECM components or as downregulated “permissive” components in 
Rdh10
trex/trex
 embryos, compared to wild-type littermates. However, the numerous small 
changes in multiple ECM components indicate that the overall composition of the ECM 
as a cohesive unit is disrupted. This potential role of RA in modulating the ECM resulting 
in total intestinal aganglionosis is particularly enticing, as it has been previously 
postulated that an abnormal ECM microenvironment is associated with HSCR (Alpy et 
al., 2005). The following subheadings gives a brief introduction to particularly interesting 
ECM components and how they important for NCCs, ENS development, VAD or 
Rdh10
trex/trex
 RNA Seq results.  
Introduction to the extracellular matrix (ECM) 
The ECM provides a scaffold for cell attachment and provides signals to promote 
adequate cell function and behavior (Frantz et al., 2010). Characteristic components of 
the interstitial matrix include fibril-forming proteins (Barber et al., 2014), such as 
collagens, elastins, fibrillins, and fibronectins, whereas the basement membrane is a 
specialized sheet of cells containing laminin, collagen IV and heparan sulfate 
proteoglycans (Tsang et al., 2010). Cell adhesion molecules (CAM) are located on the 
surface of a cell and connect it to the extracellular matrix. There are several families of 
adhesion receptors, including integrins, immunoglobulins (such as L1CAM and N-
CAM), and cadherins (Albelda and Buck, 1990). Proteases are particularly important for 
migrating NCCs, as they cleave cell adhesion molecules, allowing for easier migration 
(Taneyhill and Padmanabhan, 2014). 
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Relationship between Extracellular Matrix Proteins, Cell Adhesion Molecules and 
Neural Crest Cells 
During development, cell movement is exquisitely orchestrated, partly through to 
the ability of cells to talk to one another and their surrounding environment. This 
intercellular movement is mediated by cell-cell interactions, spatiotemporal distribution 
of ECM proteins and CAMs, and chemotactic signals (Leckband and Prakasam, 2006; 
Theveneau and Mayor, 2012, 2014).  
A notable example of this is when neural crest cells undergo an epithelial-to-
mesenchymal transition (EMT). For neural crest cells to successfully emigrate from the 
neural tube, cells must temporarily lose their intercellular adhesion properties, yet 
maintain contact with a substrate on which to migrate, be free from physical obstacles, 
and acquire migratory potential (Duband and Thiery, 1982; Newgreen and Gibbins, 1982; 
Savagner, 2015; Sternberg and Kimber, 1986; Taneyhill and Padmanabhan, 2014). These 
requirements indicate that the basal lamina portion of the basement membrane must be 
broken down for cells to emigrate, and in NCC this is facilitated by various secreted 
proteases, including ADAM-10, and matrix metalloproteases 2 and 9 (MMP2 and 
MMP9) (Taneyhill and Padmanabhan, 2014). 
Part of the process of NCC emigration requires the dynamic expression of ECM 
components, which continues to change throughout early development as NCCs 
continually interact with their microenvironment (Perris and Perissinotto, 2000). Prior to 
detachment from the neural tube, NCCs express E-cadherin but this is replaced with N-
cadherin as NCCs delaminate and begin to migrate (Erickson and Perris, 1993; Lim and 
Thiery, 2012; Nakagawa and Takeichi, 1995; Taneyhill, 2008). During EMT, to increase 
their migratory potential while simultaneously reducing intercellular adhesion, it has been 
proposed that migrating neural crest cells bind to a fibronectin substratum using integrins, 
while reducing the level of N-cadherin intercellular adhesion during NCC migration 
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(Monier-Gavelle and Duband, 1997). As N-cadherin is downregulated to allow for NCC 
migration (Cheung et al., 2005), Cadherin 6 is upregulated, which has been shown to 
assist in cell motility by assisting in NCC detachment (Clay and Halloran, 2014; 
Nakagawa and Takeichi, 1995; Park and Gumbiner, 2010). This cadherin switching 
results in the down-regulation of cadherins, which normally maintain tight cell-cell 
contacts, thus allowing the cell to become free. Thus, decreased adhesion promotes cell 
motility (Perris and Perissinotto, 2000; Theveneau and Mayor, 2012).  
After NCC have delaminated from the dorsal neural tube and begun to migrate 
through the embryo, further changes in the spatiotemporal expression of ECM proteins 
occurs, influencing the way NCC interact with their microenvironment (Perris and 
Perissinotto, 2000). The regulation of neural crest cell migration can be broadly broken 
down into being controlled by permissive, non-permissive, or inhibitory components. 
Permissive components support NCC movement, non-permissive ones promote weak 
cell-adhesion but do not aid in locomotion, and inhibitory components impede NCC 
migration (Perris and Perissinotto, 2000). Generally, ECM components are considered to 
play a permissive role (Theveneau and Mayor, 2012), but even within the family of ECM 
proteins, certain proteins are more permissive than others. It has been proposed that 
because NCC migration can be regulated by spatiotemporal changes in the ECM 
components, the ratio of permissive to non-permissive ECM components, and the level of 
inhibitory components are key to migratory success (Perris and Perissinotto, 2000). 
Additionally, individual ECM components have varying levels of permissiveness 
depending on the spatiotemporal location, which needs to be carefully considered when 
determining what relative gene expression changes may mean in the context of RDH10 
and RA signaling on the development of the ENS. For example, laminins have been cited 
as NCC migration promoting elements near the neural tube during initial NCC migration 
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(Perris, 1997), while in the enteric nervous system, increased laminin in both mouse and 
humans in late ENS colonization has been associated with the inhibition of NCC 
migration and the pathogenesis of colonic aganglionosis (Alpy et al., 2005; Druckenbrod 
and Epstein, 2009; Parikh et al., 1992).  
ECM-Modulated ENS Colonization 
As indicated previously, spatiotemporal distribution of ECM components has a 
profound effect on NCC migration. And with the longest migratory path of NCCs being 
into the gastrointestinal tract, it is not surprising that ECM abnormalities may be 
responsible in the pathogenesis of HSCR (Alpy et al., 2005; Parikh et al., 1992). 
Numerous ECM components have been implicated in the proper development of ENCC 
and the formation of the ENS, such as laminin, MMP2 and MMP9, β1 integrin, L1Cam 
and N-Cam (Alpy et al., 2005; Anderson, 2010; Anderson et al., 2006c; Breau et al., 
2009; Breau et al., 2006; Druckenbrod and Epstein, 2009; Fu et al., 2006). 
In a study examining human patient bowel specimens of distal aganglionic and 
proximal aganglionic segments, laminin was found to be highly expressed in the 
aganglionic zone of the colon, along with differences in laminin intensities in the inner 
and outer muscular layers (abnormal ECM distribution) and reorganization of the 
subepithelial basement membranes of the aganglionic versus ganglionic colon 
preparations (Alpy et al., 2005; Parikh et al., 1992). Consistent with this human study, 
data from mouse experiments suggest that a change in the gut microenvironment occurs 
at E14.5 when the gut is no longer permissive to migrating ENCCs, and that high laminin 
levels may play a role in this non-permissive environment (Druckenbrod and Epstein, 
2009).   
During ENCC migration, cells must be able to attach and detach to other cells and 
substrates to continue effective migration. Therefore, it is imperative that proteases are 
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functional to allow for adequate cell detachment (Anderson, 2010). MMP2 and MMP9 
inhibition result in disrupted migration of ENCCs in mouse gut explants (Anderson, 
2010). MMP2 is expressed within the developing gut environment and is necessary for 
the complexity of the NCC network (Anderson, 2010; Anderson et al., 2006c).  
Integrins play an important role in normal development by interacting with matrix 
proteins (Tsang et al., 2010). β1 integrin depletion in ENCCs result in their failure to 
colonize the gut completely, leading to descending colon aganglionosis, along with an 
abnormal ganglia network organization (Breau et al., 2006). Interestingly, ENCCs in 
which β1 integrin are depleted, colonized low Fibronectin (FN) and Tenascin (TNC) 
environments. But in areas of high FN and TNC, such as the hindgut and cecum, β1 
integrin mutants showed abnormally aggregated ENCCs and distal colonic aganglionosis. 
This suggests that β1 integrins are necessary to overcome TNC-mediated inhibition and 
enhance FN-dependent migration in the cecum and distal hindgut (Breau et al., 2009). 
These results highlight the delicate relationship of cellular adhesion between ENCC and 
their microenvironment to allow for normal migration through the gut (Barlow, 2014). 
Due to a similar phenotype induced by blocking MMPs, and the fact that integrins can act 
as MMP receptors, it has been postulated that β1 integrins and MMPs may interact in the 
developing gut (Anderson, 2010). 
One cell adhesion molecule expressed by early migrating ENCCs which has a 
significant effect on ENS development is L1CAM by making ENCC movement more 
efficient. Although L1Cam mutant mice have a functional ENS at birth, they do exhibit 
delayed colonization during development, and gut explants cultured in the presence of 
L1Cam-function-blocking antibodies had more NCCs which broke away from the typical 
chain migration population to migrate independently, then subsequently become 
immobile (Anderson et al., 2006c). This adhesion molecule acts as a modifier for HSCR-
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associated genes like Sox10, Ednrb and Edn (Anderson et al., 2006c; Wallace and 
Anderson, 2011; Wallace et al., 2010; Wallace et al., 2011).  
Lastly, it has been shown that the addition of polysialic acid (PSA) to N-CAM 
alters cell-cell interactions. This PSA addition is modulated by bone morphogenic protein 
(BMP), and modulating BMP results in reduced ENCC migration into the distal bowel 
and reduction of enteric neuron ganglion formation by altering cell-cell interactions, 
suggesting that PSA-NCAM may influence HSCR penetrance (Fu et al., 2006). 
Because these ECM components have been implicated in the pathogenesis of 
HSCR, it is important to investigate these components in the context of Rdh10
trex/trex
 
embryos as well as with other known HSCR genes, as they may act as modifiers to 
increase the penetrance or severity of the HSCR phenotype. 
Vitamin A Deficiency and Extracellular Matrix 
Vitamin A and its conversion to retinoic acid play significant roles in embryonic 
development and continued postnatal processes. The actions of vitamin A can be 
modulated through transcriptional and non-transcriptional regulation. RA signaling 
affects the synthesis of many ECM proteins (such as collagen, laminin, fibronectin, 
elastin and proteoglycans and entactin) and cellular membrane receptors (such as 
integrins), and may therefore have an effect on the many organ systems in which ECM 
components play a role (Aguilar et al., 2009; Axel et al., 2001; Barber et al., 2014; Lee 
and Jeong, 2012; Matsui, 1996). Of particular interest in this thesis work is whether 
vitamin A metabolism affects ECM components, which subsequently alters ENCC 
migration, and formation of the ENS, leading to a Hirschsprung Disease phenotype. 
Modifying the structure and composition of ECM in Vitamin A Deficiency 
Diseases (VADD) can lead to pathological changes in affected organ systems (Barber et 
al., 2014). In most VADD organ phenotypes, excessive ECM deposition is a major 
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complication which often leads to fibrosis. A thicker BM may lead to organ dysfunction 
and eventually may lead to organ failure (Barber et al., 2014). 
In VADD, the kidney has increased collagen IV, alongside a decrease in MMP 2 
and 9 (Marin et al., 2005). The decrease in MMPs contributes to a thickened BM, as the 
BM degrading capacity is reduced with less MMP activity (Barber et al., 2014). In the 
lungs of rats subjected to a VAD diet, a thickened alveolar BM was observed alongside a 
similar increase in collagen IV and decrease in MMP 2 and 9 as seen in kidneys, but also 
experience increased collagen I, and lowered elastin and laminin proteins (Esteban-Pretel 
et al., 2013). Not unexpectedly, the liver also exhibits ECM changes when subjected to 
VAD. The liver is responsible for the storage of most of the body’s vitamin A in the form 
of retinyl ester droplets in hepatic stellate cells (HSC). These HSCs are important for 
secreting the correct amount of ECM molecules, and MMPs (Geerts, 2001). When HSCs 
are compromised due to liver injury, the role of ECM secretion is also compromised and 
may lead to liver fibrosis (Geerts, 2001).  
Importantly, other chronic diseases, such as alcoholism and diabetes, can further 
exacerbate VADD phenotypes (Clugston and Blaner, 2012). ECM components collagen 
IV, laminin 1 and fibronectin are increased in VAD (Aguilar et al., 2009). In the skin, RA 
promotes collagen production in the dermis, which is regulated by MMP and 
hyaluronidase (HAse) production. Too much MMP and HAse production leads to 
elevated collagen degradation and ineffectual skin maintenance. Type 1 diabetic mice and 
rats subjected to a VAD diet experienced increased MMP2 and HAse activity, indicating 
a possible relationship between diabetes and VAD deficiency-induced skin abnormalities 
(Takahashi and Takasu, 2011).  
It is logical to conclude that if vitamin A deficiency can cause changes in ECM 
composition, then it may be possible to reverse any negative effects via vitamin A 
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supplementation. However, it is important to note that there are contradictory studies 
regarding the efficacy of retinoid or vitamin A supplementation (Barber et al., 2014; 
Zhou et al., 2012).   
Thus, many studies have described changes in organs systems such as the 
kidneys, lungs, liver and skin due to VAD related ECM changes. Furthermore, it has been 
well established that appropriate levels of ECM components are important for neural 
crest cell migration. Therefore, it is not unreasonable to assume that VAD may cause 
additional ECM changes that affect GI tract development, and specifically affect the 
migration of vagal neural crest cells into the developing gut.  
ECM component changes in Rdh10
trex/trex 
mutants 
It is well known that appropriate spatiotemporally expressed ECM components 
are vital for neural crest cell migration. Combined with RNA Seq data showing 
perturbations in numerous ECM components, this suggests that ECM changes in the gut 
microenvironment may play a significant role in the pathogenesis of total intestinal 
aganglionosis seen in Rdh10
trex/trex 
embryos.  
Numerous ECM components were identified as being altered in Rdh10
trex/trex
 
mutants. In general, we expected to find upregulated “non-permissive” and “inhibitory” 
ECM components and downregulated “permissive” components in Rdh10
trex/trex
 embryos, 
compared to wild-type littermates. Using RNA Seq to broadly examine the ECM 
components known to play a specific role in ENS formation, ENCC development, or that 
are regulated by retinoid signaling (Table IV-2), we found two genes (Collagen 1A1 and 
Collagen 6A3) with greater than two-fold difference with significant p-values (p<0.05), 
and surprisingly, these genes were previously reported as “permissive” components. Two 
more “permissive” components, Fibronectin, and Tenascin-C had greater than 1.5 
expression fold increases with significant p-values (p<0.05), again opposing our 
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hypothesis. One gene that followed our hypothesis in fold change directionality was 
Aggrecan, an “inhibitory” component, with a 1.829 fold increase (p<0.05). In contrast to 
what we expected, none of the proteases (MMP2, MMP9, or ADAM10) were 
significantly altered in Rdh10
trex/trex
 embryos. In an effort to validate RNA Seq data using 
qPCR, we compared Rdh10
trex/trex
 mutants to wild-type littermates, and found that 
LAMC3 had a 53% reduction in relative expression level (p<0.05), and COL1A1, 
COL1A2, TnC and FN1 had a 172%, 136%, 122% and 120% relative increase in 
expression levels, respectively (Figure IV-21), with both COL1A1 and COL1A2 relative 
increases being significant (p<0.05). Surprisingly, of the known retinoid mediated ECM 
components, only relative expression levels of Laminin C3, Collagen 1A1, 1A2 and 6A3 
were significantly changed (p<0.05). The reduction of LAMC3 was an interesting 
finding, as laminins are considered to be overall “permissive” components in NCC 
migration, but were found to be highly expressed in the distal aganglionic bowels of mice 
and humans. However, high laminin causality has not been established. It is not clear if 
the elevated level of laminin is the cause of the HSCR phenotype or a result of the failure 
of ENCCs to enter the distal bowel and remodel the ECM. 
From the numerous studies investigating the ECM in regards to its role in NCC 
migration and in VADD, it is clear that appropriate spatiotemporal distributions of these 
important components have a profound effect normal development. To our surprise, we 
did not see an overt pattern of upregulated “non-permissive” and “inhibitory” ECM 
components or downregulated “permissive” components in Rdh10
trex/trex
 mutants. Most of 
the ECM analysis reveals low fold change differences in individual components, but we 
suspect that the overall changes in the gestalt of the ECM play a larger role in 
comprehensively changing the permissiveness of the microenvironment that ENCCs must 
traverse. In the future it will be necessary to investigate which ECM components may 
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specifically be necessary in the microenvironment directly surrounding the developing 
foregut, which the ENCCs must traverse, and use immunohistochemistry to visualize 
how the ECM components are spatiotemporally modified in Rdh10
trex/trex
 mutants.  
RDH10 HAS NOT BEEN CONFIRMED NOR DENIED AS POTENTIAL HSCR MODIFIER GENE  
Our preliminary investigations of crossing Rdh10
trex/+ 
to lines known to have 
defects in NCC or ENS development did not identify RDH10 as a modifier of HSCR 
through Pax3
+/-
, Gcnf
+/-
 or Tcof1
+/-
. However, this just suggests that the development of 
the ENS in these compound heterozygous crosses suggest that RDH10 likely does not act 
through the same ENCC developmental pathways as these genes (such as p53 dependent 
apoptosis pathway (Pax3 and Tcof1) or by modulating neural stem cell populations 
(Gcnf)), but does not rule out the possibility that RDH10 may act as a modifier of other 
important ENS development or microenvironmental genes. 
General Conclusion 
Results from these studies have established RDH10 and vitamin A deficiency as 
new models for studying HSCR, providing information regarding the spatiotemporal 
requirements for RA during embryonic intestinal development, the pathogenic cellular 
mechanisms of RDH10 deficient animals, as well as the interactions of RA with 
pathways that govern normal ENS NCC colonization and ECM maintenance.  
Future Directions 
Here I outline potential future experiments that would further improve our 
knowledge of how RA might act in relation to the formation of the ENS, normal 
development of the gastrointestinal system, and in the context of maintaining a NCC 
permissive ECM. 
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ANALYZE DIRECT BINDING OF RA TO IMPORTANT ENS DEVELOPMENT GENES 
Using Motif Map (http://motifmap.ics.uci.edu/), we searched for putative retinoid 
X receptor binding motifs 1000bp upstream and downstream of ENS development genes 
and ECM components of interest that were altered in Rdh10
trex/trex
 molecular expression 
assays. We identified a putative retinoid binding site upstream of Gdnf . To test if this 
putative RXR binding site is active in Gdnf, thus making Gdnf responsive to retinoid 
signaling, we would clone the Gdnf promotor including the putative RXR binding site 
then fuse it to a luciferase reporter. After transfecting these plasmids into a retinoid 
responsive cell line, we could test if RA induces increased transcription by measuring 
luciferase activity after the addition of RA to the media. If there is no difference with 
RA-deficient versus RA-supplemented media, we know that this putative binding site is 
not active. However, if we see that RA increases luciferase activity, we would need to 
determine if the putative RXR binding site is responsible for RA responsiveness. To do 
this, we would mutagenize the putative RXR binding site, and test if RA induces 
transcription of the mutagenized Gdnf promotor. If the addition of RA results in the same 
increase in luciferase as seen in the non-mutagenized version of the plasmid, we know 
the assumed RA responsiveness was not due to the putative RXR site. If the addition of 
RA does not result in an increase in luciferase activity, we can conclude that the RXR 
binding site is active and does induce transcription of Gdnf, and thus, Gdnf is directly 
responsive to RA.  
EXAMINE ENS CELL POPULATION FOR PRESENCE OF GLIAL CELLS AND APPROPRIATE 
RATIO OF NEURONAL SUBTYPES 
Enteric glial cells, also derived from neural crest cells, begin differentiating after 
neurons, around E11.5 (Young et al., 2003). These cells have been well characterized for 
their role as support cells of the enteric neurons, necessary for providing nourishment, 
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physical support and protection. However, this cell type is also important for regulating 
synaptic transmission, regulation of gut motility, gut secretion and absorption and 
immunological responses (reviewed briefly in (Boesmans et al., 2015)). Glial cells are 
frequently identified by immunohistochemistry, staining positively with GFAP and 
S100β, along with many overlapping antibodies that stain progenitor cells (such as 
SOX10 and p75) (Coelho-Aguiar et al., 2015). 
Because the function of the ENS relies on both neurons and glia, it is important to 
stain the guts of rescued Rdh10
trex/trex
 as well as the distal colons of RDH10 conditional 
lines, RDH10
flox/flox
; Wnt1Cre and RDH10
flox/flox
; ER
T2
Cre to confirm the presence of this 
important cell type. We plan to use the GFAP and S100β antibodies. We do not expect to 
see a difference in the glial populations, as it has been suggested that although retinoids 
may enhance neuronal differentiation, they have not been found to block glial 
differentiation (Sato and Heuckeroth, 2008).  
In addition to checking for unaltered glial populations, it would be interesting to 
examine if rescued Rdh10
trex/trex
, and RDH10
flox/flox
; Wnt1Cre intestines develop 
appropriate populations of neuronal subtypes, which can be a positive indicator that the 
ENS would function properly (as in (Hotta et al., 2013)). To do this, we would stain 
neurons for the major neuronal populations, choline acetyltransferase (ChAT) and nitric 
oxide synthase (NOS) neurons. 
INVESTIGATE ECM COMPONENTS AND LEVEL OF PERMISSIVENESS SPECIFIC FOR ENCC 
MIGRATION 
To further investigate how mutant NCCs respond to different ECM components 
and densities of the matrix, we can conduct in vitro assays culturing ENCCs harvested 
from the vagal stream of E8.5 Wnt1Cre; R26YFP embryos on various substrates. We 
could compare differences in migratory dynamics on different ECM coated plates, 
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varying the coating of the plate (collagen, fibronectin or laminin), and the collagen gel 
media conditioning treatments, by adding additional ECM components to the gel. ENCCs 
would be plated, and analyzed after growing overnight. We expect that when ENCCs are 
cultured with a denser ECM, the cells will not migrate as efficiently.  Results from these 
experiments would allow us to perturb the migratory environment and determine how 
changes in ECM components affect the ability of these cells to migrate, and will also 
shed light onto which ECM components play the most important role for normal ENCC 
migration. 
IDENTIFY NOVEL CAUSES OF HSCR USING NEXT-GENERATION SEQUENCING 
TECHNIQUES 
As stated before, we only know the genetic cause of about half of the cases of 
HSCR, and it is important to continue to investigate potential causes of this devastating 
disease. We propose the use of next-generation sequencing techniques as a way to 
identify important new pathways.  
Potential experiment: RNA sequencing to analyze difference of rescued and vehicle-
treated Rdh10
trex/trex
 microenvironmental changes  
Another interesting experiment would be to analyze the differences in the 
microenvironment of retinal rescued and vehicle-treated Rdh10
trex/trex
 tissues. In a model 
examining intestinal adaptation using vitamin A deficiency as a model, VAD resulted in 
changes in expression of ECM components, such as collagen IV (Swartz-Basile et al., 
2003). Here, we propose using the same twice per day retinal gavage rescue between 
E8.5-E9.5 and harvest the embryos at late E9.5, and conduct an RNA sequencing 
experiment on the same tissues as RNASeq2 (Figure II-13). Using KEGG pathway 
analysis, it would be interesting to look at what pathways were “rescued” with retinal. 
We predict that the ECM components would not be as drastically different between the 
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Rdh10
trex/trex
 tissues and their wild-type vehicle treated littermates. For adequate controls, 
we would also need to re-run untreated Rdh10
trex/trex
 embryonic tissues as well. 
Potential Experiment: Investigate RDH10 as a modifier gene by crossing Rdh10
trex/+
 
to other ENCC development genes 
Only half of the HSCR cases are attributable to known genetic defects, and it is 
therefore necessary to explore other pathways and potential modifiers of this disease. It 
has been established that numerous genes may act as modifiers to the HSCR phenotype. 
Using mice readily available in the lab, we crossed Rdh10
trex/+ 
to different heterozygous 
mice that have previously shown a NCC phenotype when analyzed in homozygous 
mutants. Although there was no distal colonic aganglionosis phenotype when Rdh10
trex/+ 
was crossed with Pax3
+/-
, Gcnf
+/-
 or Tcof1
+/-
, we will continue to investigate RDH10 and 
vitamin A deficiency as potential modifiers of the HSCR phenotype.  
We speculate that Rdh10
trex/+ 
crossed to L1cam, Gdnf, Ret, Sox10, Ednrb or Edn3 
mutants may cause a distal colonic aganglionosis phenotype, as these genes are known to 
be modified by other genes, or the expression in our Rdh10
trex/trex 
embryos was 
significantly reduced, suggesting that RDH10 may act through downstream pathways and 
could act to potentiate the mild HSCR phenotype. Additionally, after further analyzing 
changes in the ECM using cryosections of Rdh10
trex/trex 
embryos, it would be interesting 
to cross Rdh10
trex/+ 
to animals with heterozygous mutations in those components, then 
analyze through which pathway RDH10 acts to modify the development of ENCCs, 
colonization of the gut, and formation of the ENS. 
Potential Experiment: Whole exome and genome sequencing 
In an effort to help discover genes that play a role in the pathogenesis of HSCR in 
human cases, we suggest whole exome and whole genome sequencing of patient samples 
as an ideal way to identify new causative mutations. This type of approach would be well 
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suited to finding new genes that play a role in HSCR, as well as modifier genes. With the 
decrease in whole exome sequencing costs, it is now faster and cheaper to sequence the 
whole exome rather than just targeting known mutations. 
Currently, our idea is to collaborate with Children’s Mercy Hospital and the 
University of Kansas Medical center, through a joint IRB that is already in place. Our 
point of contact would be Stephen Kingsmore. The first step in starting this sequencing 
project is to find ideal candidates with HSCR. Thus far, we have identified 3 potential 
candidates that have been treated at KUMC, and believe recruiting these families to this 
study would be well received, as knowing the potential inheritance of these mutations 
could help families with planning subsequent children. 
If we are able to identify new mutations that contribute to the etiology of HSCR, 
we can begin making new mouse models of these mutations to begin the process of 
understanding the pathogenesis of those mutations. 
INVESTIGATE VITAMIN A SUPPLEMENTATION AS A POTENTIAL RESCUE FOR 
ENVIRONMENTALLY-INDUCED VAD IN RODENTS AND HUMANS 
Currently, all of the models of total intestinal aganglionosis are genetic, including 
this new Rdh10
trex/trex 
model. However, the ability to modulate the phenotype through 
dietary modification brings up the interesting possibility that perhaps some cases of 
HSCR are modulated through a pathway such as RA, and vitamin A metabolism (i.e. RA 
as a modifier of HSCR). In addition to looking for genes that RDH10 and RA may 
modify, we would also like to investigate how VAD plays a role in HSCR in rodent 
models and eventually in humans.  
Chronic diseases, such as alcoholism, can further exacerbate VADD phenotypes. 
Chronic alcoholism further aggravates VAD mediated liver damage, as chronic alcohol 
consumption is known to deplete retinol stores, by increasing the rate of catabolism of 
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retinol, leading to similar problems as those found in VADD (Clugston and Blaner, 
2012). Numerous studies in rodent models have explored chronic alcohol consumption in 
association with decreased retinoid status (reviewed in (Clugston and Blaner, 2012)). It 
would be an interesting experiment to administer alcohol to an animal model where 
embryos exhibit distal colonic aganglionic, such as Rdh10
flox/flox; 
ERT2Cre animals (given 
tamoxifen at E7.5), to evaluate if the decrease in retinol availability due to maternal 
chronic alcohol use exacerbates the phenotype. Additionally, mothers of retinal rescued 
Rdh10
trex/trex 
embryos (with twice daily retinal gavages from E7.5-9.5) could also be a 
good model to examine if alcohol use inhibits the retinal rescue.  
In the context of a greater (human) public health issue, if we note that HSCR 
incidence is higher in countries with VAD (currently data not available), we may be able 
to investigate the possibility that vitamin A fortification may lead to decreased incidence 
of HSCR, similar to how maternal ingestion of folic acid reduces the incidence of neural 
tube defects (Pitkin, 2007). Because we do not currently have that data, we can look at 
the United States, where VAD alone is an uncommon occurrence, except in the alcoholic 
population and women with low socioeconomic status (SES), as alcohol consumption has 
been associated with decreased liver stores of retinol (Clugston and Blaner, 2012). 
Retrospective chart review may help us determine if there is a link between alcohol 
consumption or low SES and the incidence of HSCR. We suspect that alcohol 
consumption will be associated with HSCR cases with L1Cam mutations, as ethanol has 
been shown to block L1-mediated cell adhesion (Greenberg, 2003).  
According to the 2012 Substance Abuse and Mental Health Services 
Administration (SAMHSA), in 2012 in the United States, 87.6% of people 18 and up 
reported drinking alcohol in their lifetime, and approximated 17 million adults had an 
alcohol use disorder, which included 5.7 million women (SAMHSA, 2012). Apart from 
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the economic, social and family burden, and morbidity and mortality that alcohol use 
disorders present, there is also an alarming problem alcohol can pose on unwilling 
participants, such as fetuses. It is estimated that Fetal Alcohol Syndrome (FAS) occurs 
between 2-7 cases per 1000 (Stratton, 1996), and  FAS spectrum disorders may be as 
high as 20-50 cases per 1000 (May et al., 2009).  
First, it would be important to determine the vitamin A status of women of child-
bearing age with a history of alcohol consumption. In 2002, it was estimated to cost $15 
to measure retinol concentration of blood preserved on filter paper. This test is 
particularly convenient for collecting blood samples, as it only requires a finger prick of 
10-12µL of blood soaked into a filter paper, as compared to a minimum of 200 µL with 
typical venipuncture which requires refrigeration when transported, and can be analyzed 
later, using high performance liquid chromatography system. However, a new technology 
to measure retinol binding protein (RBP) by antibody staining is estimated at $1, and an 
even newer method to semi-quantitatively assess RBP in whole blood is estimated at 25 
cents (de Pee and Dary, 2002). Measuring RBP concentration is easier to analyze than 
serum retinol levels, and correlates well with serum retinol concentrations, and should be 
a good indicator of VAD status. With these retinol and RBP measuring capabilities and 
increasingly low cost, it should be financially feasible to analyze the vitamin A status of 
female alcohol consumers in the United States. 
If differences in vitamin A status of female alcohol consumers versus females 
who abstain from alcohol use are found, women interested in becoming pregnant could 
be provided vitamin A supplementation to improve their retinol levels to a healthy level 
(>0.70 µmol/L). If successful, studies such as this may eventually lead to a reduction in 
the incidence of RA acting as a modifier to genetic disease such as HSCR.  
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VII. APPENDIX 
This section includes qPCR and RNA sequencing data. Additionally, this section 
includes the references and contributions for six papers of which I am an author that have 
been published and/or submitted during my time in the Trainor Laboratory (Aoto et al., 
2015; Billings et al., 2013; Butler Tjaden et al., [in preparation]; Butler Tjaden and 
Trainor, 2013; Lenti et al., [in preparation]; Sandell et al., 2014).  
qPCR Data 
Nine target genes of interest and three endogenous controls were run on three 
plates using the same portion of the embryo used in RNA Seq2, from posterior to the otic 
vesicle to the 7
th
 somite, just anterior to the forelimb bud (Figure II-13 B). Figure VII-1 is 
a histogram of the relative expression of the nine target genes of interest after being 
normalized using the three endogenous controls (Figure VII-2).  Relative expression (of 
all genes) results are graphed with 95% confidence intervals. 
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Three appropriate endogenous controls (Figure VII-2) for each sample set were 
selected from a panel of five primer sets using geNorm in qBase plus. Results are 
graphed with standard error bars. 
 
Figure VII-1: Histogram of nine genes of interest after normalization to three 
endogenous controls. GDNF, RET, GFRα1, LAMC3, COL1A1, 
COL1A2 and GATA3 have significant p-values (p<0.05).  
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All primer sets used were experimentally determined to be within 10% of ideal 
efficiency. Relative quantities (of each gene) are graphed with 95% confidence intervals. 
For these genes, pooled mutants have statistically significant lower expression of GDNF 
(Figure VII-3), GFRα1 (Figure VII-4), RET (Figure VII-5) and LAMC3 (Figure VII-6). 
These same mutants have statistically significant higher expression of COL1A1 (Figure 
VII-7), COL1A2 (Figure VII-8), and GATA3 (Figure VII-9). There is no statistically 
significant difference between wild-type and mutant embryos with regards to TNC 
(Figure VII-10) and FN1 (Figure VII-11).  
 
Figure VII-2: Histogram of endogenous controls. Results are graphed with standard 
error bars. 
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Figure VII-3: Histogram of relative expression levels (+/- 95% Confidence 
Intervals) of GDNF for all control and mutant embryos. 
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Figure VII-4: Histogram of relative expression levels (+/- 95% Confidence 
Intervals) of GFRα1 for all control and mutant embryos. 
 
0.000000
0.200000
0.400000
0.600000
0.800000
1.000000
1.200000
1.400000
1.600000
1.800000
2.000000
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
m
u
t
m
u
t
m
u
t
m
u
t
m
u
t
m
u
t
m
u
t
m
u
t
R
e
la
ti
ve
 Q
u
an
ti
ti
e
s 
(+
/-
 9
5
%
 C
I)
 
GFRα1 
 165 
 
 
Figure VII-5: Histogram of relative expression levels (+/- 95% Confidence 
Intervals) of RET for all control and mutant embryos. 
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Figure VII-6: Histogram of relative expression levels (+/- 95% Confidence 
Intervals) of LAMC3 for all control and mutant embryos. 
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Figure VII-7: Histogram of relative expression levels (+/- 95% Confidence 
Intervals) of COL1A1 for all control and mutant embryos.  
 
0.000000
0.500000
1.000000
1.500000
2.000000
2.500000
3.000000
3.500000
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
m
u
t
m
u
t
m
u
t
m
u
t
m
u
t
m
u
t
m
u
t
m
u
t
R
e
la
ti
ve
 Q
u
an
ti
ti
e
s 
(+
/-
 9
5
%
 C
I)
 
COL1A1 
 
Figure VII-8: Histogram of relative expression levels (+/- 95% Confidence 
Intervals) of COL1A2 for all control and mutant embryos. 
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Figure VII-9: Histogram of relative expression levels (+/- 95% Confidence 
Intervals) of GATA3 for all control and mutant embryos. 
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Figure VII-10: Histogram of relative expression levels (+/- 95% Confidence 
Intervals) of TNC for all control and mutant embryos. 
 
0.000000
0.500000
1.000000
1.500000
2.000000
2.500000
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
co
n
tr
o
l
m
u
t
m
u
t
m
u
t
m
u
t
m
u
t
m
u
t
m
u
t
m
u
t
R
e
la
ti
ve
 Q
u
an
ti
ti
e
s 
(+
/-
 9
5
%
 C
I)
 
TNC 
 168 
 
RNA Sequencing 
Two rounds of RNA Sequencing (RNA Seq) were performed on Rdh10
trex 
embryos at E9.5. In RNA Seq1, we used a portion of the embryo from below the otic 
vesicle to the base of the tail. In the RNA Seq2, we used only the portion of the embryo 
from just below the otic vesicle to just above the forelimb, and excluded the heart (Figure 
II-13). The RNA sequencing analysis was done by Chris Seidel, PhD (CWS) a genomics 
specialist at the Stowers Institute. The figures and DE summary tables in this section 
were created by CWS. 
CWS ANALYSIS FOR RNA SEQ1 AND RNA SEQ2 
RNA Seq1 analysis was performed on tissue taken from the torso region of mouse 
embryos at developmental time E9.5. Total RNA was collected and used to create polyA 
strand-specific libraries. The experiment was performed in triplicate on 3 mutants and 3 
 
Figure VII-11: Histogram of relative expression levels (+/- 95% Confidence 
Intervals) of FN1 for all control and mutant embryos. 
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wild-type littermates. Data was collected by counting read mappings to 39017 genes. 
However after filtering for genes with a sum total of at least 1 count per million (cpm) 
across all six samples, the final analyzed data set contains 19205 genes. 
RNA Seq2 analysis was performed on tissue taken from the area of the first seven 
somites of mouse embryos at developmental time E9.5. Total RNA was collected and 
used to create polyA strand-specific libraries. The experiment was performed in triplicate 
on 4 mutants and 4 wild-type littermates. Data was collected by counting read mappings 
to 39017 genes. However after filtering for genes with a sum total of at least 1 count per 
million (cpm) across all eight samples, the final analyzed data set contains 22674 genes. 
MA Plot 
By plotting the ratio of gene expression (M; log base 2 of trex/wt) against the 
combined signal from both types of sample (A; average log2 of cpm) we can evaluate the 
relationship between ratios and the signal strength in the experiment. Genes with low p-
values and a fold change of two are highlighted in color. In the MA plots for RNA Seq2 
(Figure VII-13), genes considered differentially expressed with a p-value of 0.01 or less 
are highlighted in color. This experiment shows more evidence of differential expression 
than RNA Seq1 (Figure VII-12). However, as Figure VII-13 A illustrates, many of genes 
considered DE based simply on p-value have very low ratios (log2 = 0.2, or 1.15 fold). 
Figure VII-13 B zooms in to get a better view of this, and Figure VII-13 C illustrates only 
the genes from the last two columns of the DE Summary Table, with a p-value  of less 
than 0.01 AND at least 2-fold change. 
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Differentially expressed (DE) Summary table 
The DE summary table for RNA Seq1 (Table VII-1) shows the number of genes 
changed up or down by an adjusted p-value of less than 0.05. It also shows how many 
genes change with an un-adjusted p-value of 0.05 and the minimum expression ratio of 
the resulting up or down gene sets. The last two columns show the number of genes that 
change by at least two-fold with a p-value of less than 0.05. 
 
Figure VII-12: MA plot for RNA Seq1  
 
A
 
B
 
C
 
Figure VII-13: MA plot for RNA Seq2. (A) All the data with DE genes highlighted 
(B) Data plotted on symmetric scale with DE genes highlighted (C) Data 
points with 2-fold change plotted  
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The DE summary table for RNA Seq2 (Table VII-2) shows the number of genes 
changed up or down by an adjusted p-value of less than 0.01. It also shows how many 
genes change with an un-adjusted p-value of 0.01 and the minimum expression ratio of 
the resulting up or down gene sets. The last two columns show the number of genes that 
change by at least two-fold with a p-value of less than 0.01.  
Sample trex_1 had a low correlation when compared to the other samples (see 
Data Characteristics). So the data was processed two ways – once with all samples (trex 
all) and once with trex_1 omitted (trex oo, outlier omitted). The majority of the analysis 
makes use of the data with the outlier omitted, but the DE characteristics for both are 
shown above, and the significantly flagged genes from both analyses are marked in the 
final excel table. 
 
Gene Ontology (GO) Analysis  
To get a sense of the biological themes enriched in the mutant, or in wild-type 
relative to mutant, the up and down gene sets were examined for enrichment of GO terms 
for the biological process ontology. The top 10 terms by p-value are shown in the bar 
Table VII-1: DE summary table for RNA Seq1 
  0.05 0.05 min ratio fc > 2 and p < 0.05 
ratio p.adj p-value up down up Down 
trex/wt 836 2235 0.164 -0.156 220 258 
 
Table VII-2: DE summary table for RNA Seq 2 
 
0.01 0.01 
  
p < 0.01 & FC 2 
data set padj pval min.up min.dn up dn 
trex oo 1417 2700 0.192 -0.188 355 408 
trex all 1311 2788 0.235 -0.235 493 466 
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plots (Figure VII-14 A, B). The jitter plots represent the gene expression values for all 
genes mapped to the given GO term (Figure VII-14 C, D), and allow us to gauge the 
relative enrichment for the term. Because the gene sets for RNA Seq1 (Figure VII-14) are 
relatively small  (220 genes up and 258 genes down), a larger set of genes was defined by 
taking any gene with a p-value of less than 0.01 (regardless of fold change), leading to up 
and down sets of 603 and 618 genes respectively (Figure VII-15). These larger sets were 
examined for GO term enrichment. The number of genes in each set which map to a GO 
term is shown in the plot title.  
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C
 
D
 
 
Figure VII-14: Top 10 GO Terms for gene sets for RNA Seq1 with at least two-fold 
change and p-value less than 0.05. Here there were 220 genes up and 
258 genes down. 
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In RNA Seq2, the top up or down gene sets according to the last two columns of 
the DE table were examined for enrichment of GO terms from the Biological Process 
Ontology. The top 10 terms are shown in the bar plots. 
A  B  
C  D  
 
Figure VII-15: Top 10 GO Terms for gene sets for RNA Seq1 with p-value less than 
0.01, regardless of fold-change. Here there were 603 genes up and 618 
genes down.  
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To examine the overlap between RNA Seq1 (called here “nbu1”) and RNA Seq2 
(called here “nbu2”), genes changed in either experiment up or down by a given p-value 
cutoff were compared (Figure VII-17). For RNA Seq1, the p-value cutoff was 0.05, 
whereas for RNA Seq2 the p-value cutoff was 0.01.These experiments were performed 
A 
 
B 
 
C 
 
D 
 
 
Figure VII-16: Top 10 GO Terms for gene sets for RNA Seq2 with at least two-fold 
change and p-value less than 0.01. Here there were 278 genes up and 359 
genes down. 
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about a year apart. During this time the edgeR packaged used for calculating p-values has 
changed. For the overlap comparison, the data for RNA Seq1 was re-analyzed using the 
latest version of edgeR. 
 
Signaling Pathway Impact Analysis (SPIA) algorithm 
Signaling Pathway Impact Analysis (SPIA) algorithm (Tarca et al., 2009) was 
used to assess Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway 
perturbations. For RNA Seq1, a set of 1357 differentially expressed genes were selected 
with a p-value of less than 0.01. The top 10 pathways for RNA Seq 1 (Table VII-3) and 
RNA Seq 2 (Table VII-4) are shown KEGG pathways are mapped to entrez gene ids, 
whereas the DE genes are based on ensembl identifiers, and thus have to be mapped to 
entrez ids. RNA Seq1 began with a set of 1357 ensembl ids, and 1200 were successfully 
mapped to entrez ids. RNASeq2 began with a set of 2700 ensemble ids, and 2424 were 
successfully mapped to entrez ids. 
  
Figure VII-17: Overlap of differentially expressed genes from RNA Seq1 (nbu1) and 
RNA Seq2 (nbu2) experiments. 
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Data Characteristics 
Total gene counts for RNA Seq 1 (Figure VII-18 A) and RNA Seq 2 (Figure 
VII-18 B). RNA Seq1 MDS plots are shown in Figure VII-19. MDS Plots with all versus 
select data are shown in Figure VII-20. CPM correlation and MDS plots for RNA Seq2 
are reported in Figure VII-21.  
Table VII-3: SPIA Summary Table for RNA Seq1 
Name pSize NDE pNDE pG pGFdr pGFWER Status 
ECM-receptor interaction 86 21 1.71E-08 4.03E-08 4.84E-06 4.84E-06 Inhibited 
Focal adhesion 201 33 7.60E-08 2.71E-07 1.63E-05 3.25E-05 Inhibited 
Basal cell carcinoma 55 14 2.40E-06 7.30E-06 0.000292 0.0008761 Inhibited 
Hedgehog signaling pathway 54 12 5.45E-05 0.0004958 0.0125349 0.0594968 Activated 
Melanogenesis 97 15 0.0005128 0.0005223 0.0125349 0.0626746 Inhibited 
Maturity onset diabetes of the young 26 7 0.000578 0.0009084 0.018168 0.1090078 Activated 
Complement and coagulation cascades 76 11 0.0046533 0.0039642 0.0679573 0.4757012 Inhibited 
Transcriptional misregulation in cancer 163 21 0.0005805 0.0049064 0.0688454 0.5887665 Inhibited 
Neuroactive ligand-receptor interaction 278 28 0.0038209 0.0051634 0.0688454 0.6196086 Inhibited 
Cholinergic synapse 111 10 0.1167815 0.0143377 0.1720526 1 Activated 
 
Table VII-4: SPIA Summary Table for RNA Seq2 
Name pSize NDE pNDE pG pGFdr pGFWER Status 
ECM-receptor interaction 85 30 6.36E-07 7.78E-08 7.30E-06 9.18E-06 Activated 
Focal adhesion 198 56 1.04E-07 1.24E-07 7.30E-06 1.46E-05 Activated 
Axon guidance 128 35 5.24E-05 0.000209 0.00821 0.02463 Activated 
Basal cell carcinoma 55 18 0.000322 0.002462 0.072615 0.290459 Inhibited 
Cholinergic synapse 108 23 0.024222 0.003622 0.085469 0.427343 Inhibited 
TGF-beta signaling pathway 80 20 0.006063 0.010163 0.19987 1 Inhibited 
Bladder cancer 40 13 0.002276 0.012629 0.212882 1 Activated 
Serotonergic synapse 111 24 0.018216 0.017234 0.254197 1 Inhibited 
Retrograde endocannabinoid signaling 96 23 0.005972 0.036247 0.422168 1 Activated 
Amoebiasis 91 22 0.006318 0.036349 0.422168 1 Inhibited 
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Figure VII-18: Total gene counts for both RNA Seq experiments. 
 
A 
 
B 
 
Figure VII-19: RNA Seq1 MDS plots 
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A 
 
B 
 
Figure VII-20: RNA Seq1 MDS Plots with all versus select data 
 A
 
B 
 
Figure VII-21: CPM correlation and MDS plot for RNA Seq 2 
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RNA SEQUENCING DATA TABLES 
The following tables have been modified from all genes analyzed by CWS. For 
the following RNA Seq data tables, m=log2 (trex/wt), flag of 1=p<0.01, and flag of 
2=p<0.01 and a fold change of >2. Positive flag values indicate up-regulation and 
negative flag values indicate down-regulation. In the interest of space, only genes with 
flag of 2 are included in the tables below of upregulated genes (Table VII-5 and Table 
VII-7), and flag of -2 of downregulated genes (Table VII-6 VI-6 and Table VI-8). Also 
included are tables where genes had a flag of 2 (or -2) in both RNA Seq1 and RNA Seq 2 
(Table VII-9 and Table VII-10).  
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Table VII-5: RNA Seq1 Upregulated genes 
gene m p-value description 
Apoc2 3.262737 0.000403 apolipoprotein C-II  
Apoa4 3.054253 0.003068 apolipoprotein A-IV  
Kng1 2.928748 0.003715 kininogen 1  
Egr2 2.849418 4.18E-08 early growth response 2  
Npbwr1 2.758083 7.46E-08 neuropeptides B/W receptor 1  
2610528A11Rik 2.622459 3.81E-19 RIKEN cDNA 2610528A11 gene  
Slco4c1 2.356697 0.001588 solute carrier organic anion transporter family, 
member 4C1  
Apob 2.327529 0.00062 apolipoprotein B  
8030451A03Rik 2.316358 0.00019 RIKEN cDNA 8030451A03 gene  
4933402E13Rik 2.253192 0.003181 RIKEN cDNA 4933402E13 gene  
Ehf 2.141605 6.71E-05 ets homologous factor  
Pdzk1 2.046233 0.001239 PDZ domain containing 1  
Fga 1.927084 0.006879 fibrinogen alpha chain  
Dppa3 1.919458 0.001136 developmental pluripotency-associated 3  
Fxyd2 1.884388 0.007618 FXYD domain-containing ion transport regulator 2  
Cubn 1.87574 0.004079 cubilin (intrinsic factor-cobalamin receptor)  
Slc2a2 1.871248 0.0018 solute carrier family 2 (facilitated glucose 
transporter), member 2  
Kcna1 1.835507 7.76E-09 potassium voltage-gated channel, shaker-related 
subfamily, member 1  
Kcnv2 1.830699 0.005659 potassium channel, subfamily V, member 2  
Mfi2 1.786665 0.009315 antigen p97 (melanoma associated) identified by 
monoclonal antibodies 133.2 and 96.5  
Chdh 1.773377 0.006604 choline dehydrogenase  
Tbx22 1.745098 5.40E-06 T-box 22  
BC025446 1.741658 0.006696 cDNA sequence BC025446  
Tmem40 1.741658 0.000531 transmembrane protein 40  
Apoa1 1.737104 0.008686 apolipoprotein A-I  
AC108833.1 1.73055 0.007654  
Trim14 1.727948 0.001124 tripartite motif-containing 14  
Acan 1.712667 0.000851 aggrecan  
Slc39a5 1.697535 0.009476 solute carrier family 39 (metal ion transporter), 
member 5  
Ascl2 1.692857 0.000572 achaete-scute complex homolog 2 (Drosophila)  
Cfi 1.692501 0.004585 complement component factor i  
Creb3l3 1.69225 0.001874 cAMP responsive element binding protein 3-like 3  
A730049H05Rik 1.68436 1.02E-06 RIKEN cDNA A730049H05 gene  
Luzp2 1.68081 0.001872 leucine zipper protein 2  
Gm4876 1.665338 0.004728 predicted gene 4876  
Cldn2 1.655651 0.00035 claudin 2  
AC093341.1 1.641567 0.001638  
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Apom 1.640644 0.009292 apolipoprotein M  
Fgf3 1.63726 1.94E-08 fibroblast growth factor 3  
Tdo2 1.627928 6.37E-16 tryptophan 2,3-dioxygenase  
Adm2 1.622027 0.001472 adrenomedullin 2  
Nxf7 1.607706 0.004585 nuclear RNA export factor 7  
Otog 1.600939 0.001025 otogelin  
Serpina3m 1.590503 0.009272 serine (or cysteine) peptidase inhibitor, clade A, 
member 3M  
Serpina3e-ps 1.561 0.000109 serine (or cysteine) peptidase inhibitor, clade A, 
member 3E, pseudogene  
WI1-2736D10.2 1.559727 0.007021  
Slc39a4 1.548374 0.00255 solute carrier family 39 (zinc transporter), member 4  
Otx1 1.525308 0.001845 orthodenticle homolog 1 (Drosophila)  
Nr4a3 1.519571 4.48E-08 nuclear receptor subfamily 4, group A, member 3  
Oas1a 1.516998 0.005471 2'-5' oligoadenylate synthetase 1A  
Igfbp1 1.516853 0.008216 insulin-like growth factor binding protein 1  
Gfra3 1.516324 7.40E-12 glial cell line derived neurotrophic factor family 
receptor alpha 3  
Spink3 1.51467 0.000223 serine peptidase inhibitor, Kazal type 3  
Mrc1 1.514218 4.74E-11 mannose receptor, C type 1  
Ttr 1.499947 0.000128 transthyretin  
Xlr4a 1.498707 0.003468 X-linked lymphocyte-regulated 4A  
Hbb-b2 1.480548 0.007766 hemoglobin, beta adult minor chain  
RP23-183E20.1 1.479715 8.54E-05  
Ier3 1.464769 1.31E-06 immediate early response 3  
Slc26a9 1.462893 0.001126 solute carrier family 26, member 9  
Slc44a4 1.460978 0.00559 solute carrier family 44, member 4  
CT030259.2 1.458222 0.000468  
Ddit4 1.457286 1.64E-09 DNA-damage-inducible transcript 4  
Wnt8a 1.456862 5.32E-06 wingless-related MMTV integration site 8A  
Anxa8 1.440242 8.99E-05 annexin A8  
Gmnc 1.440242 0.003958 geminin coiled-coil domain containing  
F2 1.437928 0.001674 coagulation factor II  
Asb10 1.436285 0.000991 ankyrin repeat and SOCS box-containing 10  
Gm20483 1.427544 0.007744 predicted gene 20483  
Hbb-b1 1.424149 0.006227 hemoglobin, beta adult major chain  
Pitx1 1.411706 0.000487 paired-like homeodomain transcription factor 1  
Tac2 1.406616 9.96E-09 tachykinin 2  
Gm17231 1.396203 1.19E-05 predicted gene 17231  
Gpr50 1.39504 3.02E-14 G-protein-coupled receptor 50  
Adrb3 1.392615 0.002324 adrenergic receptor, beta 3  
March1 1.387459 0.003612 membrane-associated ring finger (C3HC4) 1  
Lrrc23 1.386481 0.003778 leucine rich repeat containing 23  
Gadl1 1.366664 5.92E-05 glutamate decarboxylase-like 1  
3830417A13Rik 1.365108 4.28E-05 RIKEN cDNA 3830417A13 gene  
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Vstm5 1.362018 0.000504 V-set and transmembrane domain containing 5  
Cfc1 1.34504 0.004565 cripto, FRL-1, cryptic family 1  
Epyc 1.328295 1.96E-05 epiphycan  
Marc1 1.326412 0.003468 mitochondrial amidoxime reducing component 1  
9030617O03Rik 1.322264 0.007851 RIKEN cDNA 9030617O03 gene  
Folr1 1.308083 0.003349 folate receptor 1 (adult)  
Rab17 1.307699 0.008857 RAB17, member RAS oncogene family  
C1qc 1.306424 0.002874 complement component 1, q subcomponent, C chain  
Slc7a8 1.300695 0.001643 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 8  
AC107641.1 1.279279 0.003573  
Caln1 1.278649 0.002966 calneuron 1  
Rgs11 1.270199 3.68E-05 regulator of G-protein signaling 11  
Eno2 1.265891 4.31E-08 enolase 2, gamma neuronal  
Gp9 1.263624 0.003472 glycoprotein 9 (platelet)  
Hand1 1.262596 2.25E-21 heart and neural crest derivatives expressed 
transcript 1  
Serpina10 1.255682 0.005427 serine (or cysteine) peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), member 10  
Fst 1.244594 2.63E-18 follistatin  
Rarres2 1.242338 1.68E-09 retinoic acid receptor responder (tazarotene induced) 
2  
Scn7a 1.235142 0.000359 sodium channel, voltage-gated, type VII, alpha  
Iigp1 1.234903 0.000111 interferon inducible GTPase 1  
Neat1 1.232566 1.39E-06 nuclear paraspeckle assembly transcript 1 (non-
protein coding)  
Actg2 1.231184 8.00E-05 actin, gamma 2, smooth muscle, enteric  
BC006965 1.231013 0.004431 cDNA sequence BC006965  
Stab2 1.22901 1.54E-07 stabilin 2  
Hsd17b14 1.226426 0.001018 hydroxysteroid (17-beta) dehydrogenase 14  
Gpx6 1.220721 0.000113 glutathione peroxidase 6  
Ccbp2 1.220704 0.006495 chemokine binding protein 2  
Hpcal4 1.215086 0.000494 hippocalcin-like 4  
Ccdc79 1.212762 0.006638 coiled-coil domain containing 79  
Stac 1.209231 0.007195 src homology three (SH3) and cysteine rich domain  
Gm129 1.203724 2.40E-07 predicted gene 129  
Stc2 1.188874 5.31E-11 stanniocalcin 2  
Wdr38 1.180093 3.02E-08 WD repeat domain 38  
BC021785 1.177742 0.006219 cDNA sequence BC021785  
Lcp2 1.174784 2.55E-05 lymphocyte cytosolic protein 2  
Egln3 1.168236 6.50E-11 EGL nine homolog 3 (C. elegans)  
Mas1 1.167297 0.008193 MAS1 oncogene  
Phlda2 1.158091 9.81E-06 pleckstrin homology-like domain, family A, member 2  
Dmrt3 1.154384 0.006563 doublesex and mab-3 related transcription factor 3  
Chl1 1.150635 1.60E-11 cell adhesion molecule with homology to L1CAM  
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Nkx2-3 1.127007 2.09E-07 NK2 transcription factor related, locus 3 (Drosophila)  
Trf 1.122882 0.001754 transferrin  
AL589650.1 1.119805 0.000213  
Cxcl14 1.109104 0.000179 chemokine (C-X-C motif) ligand 14  
Car7 1.107214 4.94E-05 carbonic anhydrase 7  
Ang 1.106502 0.006833 angiogenin, ribonuclease, RNase A family, 5  
Mr1 1.09826 0.001186 major histocompatibility complex, class I-related  
Fmo1 1.096127 5.48E-05 flavin containing monooxygenase 1  
Gm12829 1.089854 0.001341 predicted gene 12829  
Gm12688 1.08962 0.000294 predicted gene 12688  
Bhlhe40 1.084691 1.34E-05 basic helix-loop-helix family, member e40  
Proca1 1.083799 0.002105 protein interacting with cyclin A1  
Rora 1.083525 1.09E-06 RAR-related orphan receptor alpha  
Ndrg1 1.082031 7.48E-11 N-myc downstream regulated gene 1  
Gm16439 1.081224 1.68E-08 predicted pseudogene 16439  
Mcmdc2 1.074651 0.000181 minichromosome maintenance domain containing 2  
AC163637.1 1.070576 0.000132  
Akr1c19 1.070375 0.005073 aldo-keto reductase family 1, member C19  
Prss35 1.064669 2.92E-08 protease, serine, 35  
Nkx2-9 1.059247 7.74E-06 NK2 transcription factor related, locus 9 (Drosophila)  
Cyp26b1 1.048927 3.16E-05 cytochrome P450, family 26, subfamily b, polypeptide 
1  
Bnip3 1.039486 1.39E-15 BCL2/adenovirus E1B interacting protein 3  
Ly96 1.03394 0.00652 lymphocyte antigen 96  
Stc1 1.033301 6.08E-06 stanniocalcin 1  
Slc13a4 1.026625 0.0034 solute carrier family 13 (sodium/sulfate symporters), 
member 4  
Abi3bp 1.022992 0.000404 ABI gene family, member 3 (NESH) binding protein  
Bmp3 1.019009 5.92E-07 bone morphogenetic protein 3  
Afp 1.01761 0.001843 alpha fetoprotein  
5330426P16Rik 1.015939 0.001389 RIKEN cDNA 5330426P16 gene  
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Table VII-6: RNA Seq1 Downregulated genes 
gene m pval description 
Gcg -8.29156 5.66E-56 glucagon  
Hk3 -4.81943 1.45E-51 hexokinase 3  
Ptf1a -4.10094 1.50E-08 pancreas specific transcription factor, 1a  
Hoxa10 -3.65309 2.26E-17 homeobox A10  
Inmt -3.39429 8.07E-07 indolethylamine N-methyltransferase  
Ghrl -3.37494 2.80E-10 ghrelin  
Gsx1 -3.28215 1.05E-07 GS homeobox 1  
Sln -3.24306 1.66E-09 sarcolipin  
Hoxd10 -3.24189 5.95E-34 homeobox D10  
Hoxa11as -3.22849 3.51E-14 HOXA11 antisense RNA (non-protein coding)  
Csn3 -3.17569 1.01E-17 casein kappa  
Hoxd11 -3.12848 2.95E-21 homeobox D11  
Robo3 -3.03242 9.35E-17 roundabout homolog 3 (Drosophila)  
Gabrg2 -3.00554 6.68E-07 gamma-aminobutyric acid (GABA) A receptor, subunit 
gamma 2  
Barx1 -2.9671 3.18E-35 BarH-like homeobox 1  
2310002L09Rik -2.86649 1.68E-06 RIKEN cDNA 2310002L09 gene  
Lhx5 -2.83101 1.80E-12 LIM homeobox protein 5  
Hoxd13 -2.80119 1.69E-09 homeobox D13  
Skor1 -2.79293 1.15E-06 SKI family transcriptional corepressor 1  
Myom3 -2.78351 1.40E-08 myomesin family, member 3  
Unc5a -2.74687 4.06E-59 unc-5 homolog A (C. elegans)  
Rspo4 -2.63469 8.79E-36 R-spondin family, member 4  
Chrna3 -2.61797 2.85E-23 cholinergic receptor, nicotinic, alpha polypeptide 3  
Hoxa11 -2.61392 1.77E-13 homeobox A11  
Tbx15 -2.56279 4.84E-15 T-box 15  
Nxf3 -2.55129 4.50E-11 nuclear RNA export factor 3  
NA -2.54666 5.73E-05 NA 
Myh3 -2.49175 2.29E-26 myosin, heavy polypeptide 3, skeletal muscle, 
embryonic  
C130071C03Rik -2.47039 9.02E-23 RIKEN cDNA C130071C03 gene  
Lhx9 -2.42406 3.54E-46 LIM homeobox protein 9  
Hs3st2 -2.42405 1.31E-06 heparan sulfate (glucosamine) 3-O-sulfotransferase 2  
Vwde -2.40572 6.94E-05 von Willebrand factor D and EGF domains  
Bhlhe23 -2.37168 2.65E-08 basic helix-loop-helix family, member e23  
Nrg3 -2.35551 0.000167 neuregulin 3  
Musk -2.35551 0.000145 muscle, skeletal, receptor tyrosine kinase  
D930028M14Rik -2.34475 1.23E-16 RIKEN cDNA D930028M14 gene  
Chat -2.27539 0.000134 choline acetyltransferase  
Gm13652 -2.26979 1.38E-12 predicted gene 13652  
Crp -2.26167 1.13E-06 C-reactive protein, pentraxin-related  
Tenm1 -2.24951 0.000971 teneurin transmembrane protein 1  
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Stk32a -2.23385 2.42E-24 serine/threonine kinase 32A  
Calb1 -2.22421 6.11E-05 calbindin 1  
Cdx1 -2.21435 4.11E-23 caudal type homeobox 1  
Alx3 -2.19948 5.95E-34 aristaless-like homeobox 3  
En1 -2.19389 2.17E-14 engrailed 1  
Chrnb4 -2.19372 4.83E-19 cholinergic receptor, nicotinic, beta polypeptide 4  
Cntn2 -2.18273 1.73E-23 contactin 2  
Msc -2.17689 7.59E-11 musculin  
Hic1 -2.17209 7.33E-13 hypermethylated in cancer 1  
Ankrd2 -2.15414 6.03E-12 ankyrin repeat domain 2 (stretch responsive muscle)  
Gpx2 -2.14701 0.000121 glutathione peroxidase 2  
Pdx1 -2.11013 1.65E-07 pancreatic and duodenal homeobox 1  
Tnnc2 -2.10478 1.51E-16 troponin C2, fast  
Actl6b -2.10154 0.000275 actin-like 6B  
Tmem132e -2.09686 8.01E-28 transmembrane protein 132E  
Nr0b1 -2.07599 3.36E-07 nuclear receptor subfamily 0, group B, member 1  
Sgcg -2.06909 0.00032 sarcoglycan, gamma (dystrophin-associated 
glycoprotein)  
AC154412.1 -2.06909 0.00016  
Lin7a -2.02641 1.52E-17 lin-7 homolog A (C. elegans)  
Mstn -2.02626 2.29E-09 myostatin  
Scrt1 -1.99641 1.30E-08 scratch homolog 1, zinc finger protein (Drosophila)  
Pyy -1.9872 3.84E-07 peptide YY  
Pou2f2 -1.96167 5.34E-08 POU domain, class 2, transcription factor 2  
1110059M19Rik -1.94114 4.89E-05 RIKEN cDNA 1110059M19 gene  
Ecel1 -1.93551 1.21E-10 endothelin converting enzyme-like 1  
1700128E19Rik -1.92091 1.08E-06 RIKEN cDNA 1700128E19 gene  
Ppp2r2c -1.90115 3.55E-13 protein phosphatase 2 (formerly 2A), regulatory 
subunit B (PR 52), gamma isoform  
Nhlh2 -1.86466 7.27E-21 nescient helix loop helix 2  
Dcx -1.86449 2.42E-19 doublecortin  
Lhx2 -1.85329 5.93E-25 LIM homeobox protein 2  
Sim2 -1.83517 0.000123 single-minded homolog 2 (Drosophila)  
Gsx2 -1.83371 5.76E-08 GS homeobox 2  
Fam19a1 -1.81625 0.000237 family with sequence similarity 19, member A1  
A730090H04Rik -1.81625 0.000241 RIKEN cDNA A730090H04 gene  
C130021I20Rik -1.81319 1.64E-27 Riken cDNA C130021I20  gene  
Nepn -1.79565 2.18E-26 nephrocan  
Slc17a7 -1.79374 3.23E-06 solute carrier family 17 (sodium-dependent inorganic 
phosphate cotransporter), member 7  
Grifin -1.78892 0.001774 galectin-related inter-fiber protein  
Kcnh5 -1.74198 0.001422 potassium voltage-gated channel, subfamily H (eag-
related), member 5  
Nxph1 -1.73546 0.003329 neurexophilin 1  
Gjd4 -1.72906 4.28E-05 gap junction protein, delta 4  
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Crlf1 -1.72313 7.35E-07 cytokine receptor-like factor 1  
Gpr179 -1.71851 0.002578 G protein-coupled receptor 179  
Gm7325 -1.67161 0.000179 predicted gene 7325  
Chrna1 -1.67107 0.000155 cholinergic receptor, nicotinic, alpha polypeptide 1 
(muscle)  
Neb -1.67004 9.19E-07 nebulin  
Ephx1 -1.65365 1.63E-06 epoxide hydrolase 1, microsomal  
Mylk4 -1.6524 1.24E-05 myosin light chain kinase family, member 4  
Syt4 -1.65125 2.69E-06 synaptotagmin IV  
Rhbdl3 -1.64246 1.17E-23 rhomboid, veinlet-like 3 (Drosophila)  
Nyap2 -1.63231 8.15E-05 neuronal tyrosine-phophorylated phosphoinositide 3-
kinase adaptor 2  
3110047P20Rik -1.63231 4.25E-05 RIKEN cDNA 3110047P20 gene  
Gm16140 -1.62697 0.00046 predicted gene 16140  
Svop -1.61227 4.39E-05 SV2 related protein  
Insc -1.59986 7.65E-08 inscuteable homolog (Drosophila)  
9430024E24Rik -1.59704 7.30E-07 RIKEN cDNA 9430024E24 gene  
Myot -1.59525 8.65E-05 myotilin  
Ppfia2 -1.58456 0.000303 protein tyrosine phosphatase, receptor type, f 
polypeptide (PTPRF), interacting protein (liprin), alpha 
2  
Il17b -1.58177 0.000613 interleukin 17B  
Fstl5 -1.58177 0.000652 follistatin-like 5  
Lingo4 -1.5707 0.007381 leucine rich repeat and Ig domain containing 4  
Rfx6 -1.55712 1.46E-05 regulatory factor X, 6  
Nkx2-1 -1.55352 2.73E-05 NK2 homeobox 1  
Sst -1.55351 1.42E-05 somatostatin  
Mybph -1.54288 2.33E-11 myosin binding protein H  
Kirrel2 -1.5411 4.32E-06 kin of IRRE like 2 (Drosophila)  
Myf6 -1.53729 1.29E-06 myogenic factor 6  
Klhl40 -1.53432 0.000265 kelch-like 40  
Amica1 -1.52212 1.91E-11 adhesion molecule, interacts with CXADR antigen 1  
Rarb -1.51686 4.66E-37 retinoic acid receptor, beta  
Dhrs3 -1.51169 2.22E-13 dehydrogenase/reductase (SDR family) member 3  
Chrna5 -1.51163 2.95E-07 cholinergic receptor, nicotinic, alpha polypeptide 5  
Gm14343 -1.5086 0.004264 predicted gene 14343  
RP23-207N5.1 -1.50767 0.000908  
BC030500 -1.49438 0.00048 cDNA sequence BC030500  
Gsc -1.48519 0.006426 goosecoid homeobox  
Scrt2 -1.47379 8.19E-10 scratch homolog 2, zinc finger protein (Drosophila)  
Edar -1.45769 1.80E-06 ectodysplasin-A receptor  
Fbll1 -1.45711 0.00987 fibrillarin-like 1  
Wfdc1 -1.45339 3.03E-05 WAP four-disulfide core domain 1  
Rgs7 -1.44653 0.006035 regulator of G protein signaling 7  
3110035E14Rik -1.43727 8.62E-06 RIKEN cDNA 3110035E14 gene  
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Sncg -1.42944 1.55E-06 synuclein, gamma  
Arg1 -1.42876 1.33E-46 arginase, liver  
Il1rn -1.42668 0.001805 interleukin 1 receptor antagonist  
Foxq1 -1.42424 1.17E-05 forkhead box Q1  
Mmp24 -1.417 0.001074 matrix metallopeptidase 24  
Cxcl13 -1.40946 7.02E-09 chemokine (C-X-C motif) ligand 13  
Grm2 -1.40937 1.55E-05 glutamate receptor, metabotropic 2  
Tmem8c -1.40493 0.000181 transmembrane protein 8C  
Atp2a1 -1.40008 1.68E-10 ATPase, Ca++ transporting, cardiac muscle, fast twitch 
1  
Cps1 -1.39032 0.006936 carbamoyl-phosphate synthetase 1  
Srms -1.38277 0.001792 src-related kinase lacking C-terminal regulatory 
tyrosine and N-terminal myristylation sites  
Barhl2 -1.38277 0.005251 BarH-like 2 (Drosophila)  
Ina -1.37857 1.63E-09 internexin neuronal intermediate filament protein, 
alpha  
Lmx1b -1.36869 4.89E-23 LIM homeobox transcription factor 1 beta  
Islr2 -1.34874 0.000203 immunoglobulin superfamily containing leucine-rich 
repeat 2  
Myog -1.34069 1.64E-11 myogenin  
Gm16010 -1.34007 0.000513 predicted gene 16010  
Bhlhe22 -1.32914 5.23E-07 basic helix-loop-helix family, member e22  
Pcsk2 -1.32201 0.000227 proprotein convertase subtilisin/kexin type 2  
Ntrk1 -1.31822 2.93E-07 neurotrophic tyrosine kinase, receptor, type 1  
March4 -1.31708 0.003705 membrane-associated ring finger (C3HC4) 4  
Fam163a -1.3141 0.00075 family with sequence similarity 163, member A  
Lhx4 -1.31341 1.11E-06 LIM homeobox protein 4  
Mnx1 -1.31188 4.64E-07 motor neuron and pancreas homeobox 1  
Fndc5 -1.30622 2.21E-13 fibronectin type III domain containing 5  
Nppc -1.30066 1.75E-05 natriuretic peptide type C  
Tecta -1.29897 0.00049 tectorin alpha  
Hoxa4 -1.28821 1.52E-14 homeobox A4  
Kcnj10 -1.27811 3.19E-07 potassium inwardly-rectifying channel, subfamily J, 
member 10  
Scml4 -1.2728 2.74E-05 sex comb on midleg-like 4 (Drosophila)  
Slc10a4 -1.26966 4.22E-05 solute carrier family 10 (sodium/bile acid 
cotransporter family), member 4  
Scn9a -1.26865 0.005063 sodium channel, voltage-gated, type IX, alpha  
Glra1 -1.25302 9.61E-07 glycine receptor, alpha 1 subunit  
Ugt8a -1.25182 0.000381 UDP galactosyltransferase 8A  
Foxn4 -1.23014 0.000909 forkhead box N4  
Stmn3 -1.22941 1.93E-07 stathmin-like 3  
Trim67 -1.22609 0.000373 tripartite motif-containing 67  
Ctxn3 -1.22341 0.00062 cortexin 3  
Gm16582 -1.21832 1.84E-06 predicted gene 16582  
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Cdk5r2 -1.21832 1.84E-06 cyclin-dependent kinase 5, regulatory subunit 2 (p39)  
Dlx4 -1.20729 0.009829 distal-less homeobox 4  
C78197 -1.20527 0.004576 expressed sequence C78197  
Scg2 -1.20439 0.004912 secretogranin II  
Srrm3 -1.2001 4.01E-05 serine/arginine repetitive matrix 3  
2700069I18Rik -1.19928 0.001117 RIKEN cDNA 2700069I18 gene  
Rasgef1c -1.19177 8.50E-05 RasGEF domain family, member 1C  
Tshz1 -1.18932 9.65E-37 teashirt zinc finger family member 1  
Slc38a5 -1.18784 1.98E-07 solute carrier family 38, member 5  
Tmem59l -1.18147 1.88E-05 transmembrane protein 59-like  
Pcdh20 -1.17756 0.000977 protocadherin 20  
Gfra1 -1.1759 5.36E-11 glial cell line derived neurotrophic factor family 
receptor alpha 1  
Atcay -1.17337 1.03E-05 ataxia, cerebellar, Cayman type homolog (human)  
Nanos3 -1.17303 0.008216 nanos homolog 3 (Drosophila)  
Dock10 -1.16576 3.47E-07 dedicator of cytokinesis 10  
Pou3f4 -1.16083 5.37E-09 POU domain, class 3, transcription factor 4  
Ano5 -1.1524 0.003455 anoctamin 5  
Fgf4 -1.14891 0.004583 fibroblast growth factor 4  
Elavl3 -1.14779 1.82E-09 ELAV (embryonic lethal, abnormal vision, Drosophila)-
like 3 (Hu antigen C)  
Pax7 -1.14745 6.02E-12 paired box gene 7  
Syndig1 -1.14657 0.000441 synapse differentiation inducing 1  
Rgs9 -1.14627 6.23E-08 regulator of G-protein signaling 9  
Neurog1 -1.14364 1.56E-07 neurogenin 1  
Klhl14 -1.14299 8.04E-06 kelch-like 14  
Plk3 -1.13558 4.34E-12 polo-like kinase 3  
Stmn4 -1.13302 4.18E-07 stathmin-like 4  
Ap3b2 -1.1317 1.15E-08 adaptor-related protein complex 3, beta 2 subunit  
Gnat3 -1.12483 0.00414 guanine nucleotide binding protein, alpha transducing 
3  
Nefm -1.11882 4.29E-06 neurofilament, medium polypeptide  
1700109F18Rik -1.1139 2.68E-06 RIKEN cDNA 1700109F18 gene  
Adcy8 -1.10402 6.84E-07 adenylate cyclase 8  
Ttbk1 -1.1001 2.22E-05 tau tubulin kinase 1  
C1ql3 -1.09221 0.001522 C1q-like 3  
Gm13781 -1.09036 0.000816 predicted gene 13781  
Kcnk10 -1.09029 0.002251 potassium channel, subfamily K, member 10  
Prdm13 -1.09027 8.44E-08 PR domain containing 13  
Asic2 -1.08914 8.39E-06 acid-sensing (proton-gated) ion channel 2  
Zfp536 -1.08571 1.03E-05 zinc finger protein 536  
Arhgap36 -1.07916 7.86E-06 Rho GTPase activating protein 36  
Nkx2-6 -1.06592 0.000319 NK2 transcription factor related, locus 6 (Drosophila)  
Galnt9 -1.05442 0.002538 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 9  
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Gm15055 -1.0534 0.009146 predicted gene 15055  
Rec8 -1.05254 0.001933 REC8 homolog (yeast)  
Gm12892 -1.05188 1.17E-14 predicted gene 12892  
Tubb3 -1.05104 1.25E-08 tubulin, beta 3 class III  
Eva1a -1.05018 0.000964 eva-1 homolog A (C. elegans)  
Mylpf -1.04946 1.64E-06 myosin light chain, phosphorylatable, fast skeletal 
muscle  
Scg3 -1.04879 1.77E-07 secretogranin III  
Rundc3a -1.04651 5.76E-07 RUN domain containing 3A  
Disp2 -1.04641 0.001046 dispatched homolog 2 (Drosophila)  
Nkx1-2 -1.0463 0.000739 NK1 transcription factor related, locus 2 (Drosophila)  
Stmn2 -1.03964 7.39E-06 stathmin-like 2  
Hoxd9 -1.03771 5.49E-10 homeobox D9  
E330013P04Rik -1.037 0.001731 RIKEN cDNA E330013P04 gene  
Gm16551 -1.03607 1.62E-08 predicted gene 16551  
Myt1 -1.0356 1.07E-06 myelin transcription factor 1  
Pnmal1 -1.02742 0.00012 PNMA-like 1  
Onecut3 -1.02579 0.000432 one cut domain, family member 3  
Onecut2 -1.0257 1.36E-08 one cut domain, family member 2  
Arpp21 -1.02504 0.001053 cyclic AMP-regulated phosphoprotein, 21  
Ascl1 -1.02091 2.85E-06 achaete-scute complex homolog 1 (Drosophila)  
Cabp7 -1.01555 0.005897 calcium binding protein 7  
Rab3c -1.01555 0.000244 RAB3C, member RAS oncogene family  
Lamc3 -1.01243 1.99E-06 laminin gamma 3  
Emx2 -1.0091 1.26E-06 empty spiracles homeobox 2  
Krt5 -1.00886 5.01E-07 keratin 5  
Chst8 -1.00395 8.66E-05 carbohydrate (N-acetylgalactosamine 4-0) 
sulfotransferase 8  
Hoxa1 -1.00204 3.36E-11 homeobox A1  
 
  
 191 
Table VII-7: RNA Seq2 Upregulated genes 
gene m pval description 
S100g 6.3116 1.51E-06 S100 calcium binding protein G  
Hoxc8 5.6762 3.78E-69 homeobox C8  
Oc90 5.0688 0.002635 otoconin 90  
Apoa4 4.9514 6.08E-05 apolipoprotein A-IV  
Krt13 4.9056 0.000361 keratin 13  
Trappc3l 4.5625 3.40E-07 trafficking protein particle complex 3 like  
Gpr50 4.4919 2.61E-38 G-protein-coupled receptor 50  
Gm15634 4.2751 0.006069 predicted gene 15634  
NA 4.2688 0.008368 NA 
Tdgf1 4.2153 2.74E-07 teratocarcinoma-derived growth factor 1  
Ms4a2 4.2067 4.93E-06 membrane-spanning 4-domains, subfamily A, member 2  
Nppb 4.1482 0.000117 natriuretic peptide type B  
4933402E13Rik 4.1186 9.85E-07 RIKEN cDNA 4933402E13 gene  
Ccl2 4.0760 0.000298 chemokine (C-C motif) ligand 2  
Cldn14 3.9145 4.12E-05 claudin 14  
Gm15283 3.7415 7.21E-11 predicted gene 15283  
Epyc 3.7284 3.03E-09 epiphycan  
2610528A11Rik 3.6810 5.84E-09 RIKEN cDNA 2610528A11 gene  
Phf11b 3.6338 0.000394 PHD finger protein 11B  
Apob 3.5982 1.81E-07 apolipoprotein B  
Chac1 3.5382 1.63E-06 ChaC, cation transport regulator 1  
NA 3.5301 0.002692 NA 
Clec18a 3.4706 4.22E-06 C-type lectin domain family 18, member A  
Chst13 3.4295 0.001138 carbohydrate (chondroitin 4) sulfotransferase 13  
Gm11734 3.4244 0.000817 predicted gene 11734  
Ier3 3.4155 8.42E-11 immediate early response 3  
Tdo2 3.3696 4.54E-11 tryptophan 2,3-dioxygenase  
Gmnc 3.2955 0.003174 geminin coiled-coil domain containing  
Tac2 3.2249 2.52E-11 tachykinin 2  
Pitx1 3.2222 1.88E-08 paired-like homeodomain transcription factor 1  
5031434C07Rik 3.1690 0.003766 RIKEN cDNA 5031434C07 gene  
Ascl2 3.1602 1.55E-06 achaete-scute complex homolog 2 (Drosophila)  
Spp2 3.1559 0.00023 secreted phosphoprotein 2  
Abcc2 3.0814 1.02E-05 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 2  
Eno2 3.0518 5.77E-09 enolase 2, gamma neuronal  
Scnn1g 2.9885 0.001638 sodium channel, nonvoltage-gated 1 gamma  
Aire 2.9717 6.34E-08 autoimmune regulator (autoimmune 
polyendocrinopathy candidiasis ectodermal dystrophy)  
Hand1 2.9643 1.03E-24 heart and neural crest derivatives expressed transcript 1  
Egr2 2.9135 0.000452 early growth response 2  
Ddit4 2.8577 3.04E-13 DNA-damage-inducible transcript 4  
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Hoxc6 2.8239 6.76E-10 homeobox C6  
Cubn 2.8002 7.40E-06 cubilin (intrinsic factor-cobalamin receptor)  
Hoxa9 2.7910 8.50E-05 homeobox A9  
Gm22661 2.7695 0.000237 predicted gene, 22661  
Gm27505 2.7664 0.000927 predicted gene, 27505  
Postn 2.7624 3.31E-23 periostin, osteoblast specific factor  
Gm12746 2.7229 8.56E-06 predicted gene 12746  
Trap1a 2.7038 0.000209 tumor rejection antigen P1A  
Inhbb 2.6890 0.000169 inhibin beta-B  
Vax1 2.6850 0.004055 ventral anterior homeobox 1  
Muc13 2.6152 1.60E-05 mucin 13, epithelial transmembrane  
Hoxa7 2.5947 0.000394 homeobox A7  
Card14 2.5809 0.00059 caspase recruitment domain family, member 14  
Prss35 2.5807 7.19E-16 protease, serine 35  
Bhlhe40 2.5717 1.70E-07 basic helix-loop-helix family, member e40  
Gm27533 2.5154 0.00452 predicted gene, 27533  
Ppp1r3c 2.4615 2.90E-06 protein phosphatase 1, regulatory (inhibitor) subunit 3C  
Adm2 2.4377 9.67E-06 adrenomedullin 2  
Rarres2 2.4159 6.12E-17 retinoic acid receptor responder (tazarotene induced) 2  
Xlr5c 2.4155 0.002879 X-linked lymphocyte-regulated 5C  
5730403I07Rik 2.4112 0.001647 RIKEN cDNA 5730403I07 gene  
Mab21l2 2.3708 1.44E-17 mab-21-like 2 (C. elegans)  
Hoxb9 2.3384 8.42E-06 homeobox B9  
Oxtr 2.3344 4.88E-06 oxytocin receptor  
Muc2 2.3090 7.92E-07 mucin 2  
Car7 2.2961 3.72E-26 carbonic anhydrase 7  
9330159N05Rik 2.2957 6.47E-05 RIKEN cDNA 9330159N05 gene  
Stc1 2.2617 1.18E-12 stanniocalcin 1  
Gm20467 2.2583 5.38E-10 predicted gene 20467  
Gm14685 2.2466 0.000326 predicted gene 14685  
Ndrg1 2.2381 3.25E-09 N-myc downstream regulated gene 1  
Gfra3 2.2332 5.24E-13 glial cell line derived neurotrophic factor family receptor 
alpha 3  
Otx2 2.2231 5.08E-07 orthodenticle homolog 2  
Ptgs2 2.2133 1.35E-09 prostaglandin-endoperoxide synthase 2  
Egln3 2.2053 9.01E-13 egl-9 family hypoxia-inducible factor 3  
mt-Th 2.2024 0.002926 mitochondrially encoded tRNA histidine  
Ciart 2.1966 5.30E-16 circadian associated repressor of transcription  
Gm12022 2.1949 0.000438 predicted gene 12022  
Cdrt4 2.1518 0.006047 CMT1A duplicated region transcript 4  
Gm11027 2.1456 0.007256 predicted gene 11027  
S1pr5 2.1240 0.000732 sphingosine-1-phosphate receptor 5  
Kcne3 2.1106 4.56E-14 potassium voltage-gated channel, Isk-related subfamily, 
gene 3  
Gm28006 2.1080 0.00509 predicted gene, 28006  
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Gm17202 2.0993 0.00032 predicted gene 17202  
Stc2 2.0729 3.23E-13 stanniocalcin 2  
Wnt8a 2.0659 7.46E-13 wingless-type MMTV integration site family, member 8A  
Gm16439 2.0629 5.18E-11 predicted pseudogene 16439  
Trib3 2.0300 4.02E-05 tribbles homolog 3 (Drosophila)  
Serpina3f 1.9971 0.003113 serine (or cysteine) peptidase inhibitor, clade A, 
member 3F  
Slc22a3 1.9707 2.36E-07 solute carrier family 22 (organic cation transporter), 
member 3  
P4ha2 1.9672 3.35E-14 procollagen-proline, 2-oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase), alpha II polypeptide  
Hmx2 1.9522 0.007064 H6 homeobox 2  
Bhlhe41 1.9245 2.49E-05 basic helix-loop-helix family, member e41  
Neat1 1.9199 1.61E-09 nuclear paraspeckle assembly transcript 1 (non-protein 
coding)  
Ankrd37 1.9152 1.92E-07 ankyrin repeat domain 37  
Adm 1.9099 0.000358 adrenomedullin  
Nkx2-3 1.8991 2.68E-15 NK2 homeobox 3  
Avpr1b 1.8909 2.14E-05 arginine vasopressin receptor 1B  
Tmem211 1.8877 0.002634 transmembrane protein 211  
Rgs11 1.8856 8.75E-07 regulator of G-protein signaling 11  
Dio3os 1.8852 4.19E-05 deiodinase, iodothyronine type III, opposite strand  
Lrrc15 1.8456 0.000149 leucine rich repeat containing 15  
Chl1 1.8436 4.67E-16 cell adhesion molecule with homology to L1CAM  
Bnip3 1.8414 1.01E-13 BCL2/adenovirus E1B interacting protein 3  
Nxf7 1.8316 0.000185 nuclear RNA export factor 7  
Vldlr 1.8170 5.13E-12 very low density lipoprotein receptor  
Pla1a 1.8167 0.005513 phospholipase A1 member A  
Kcnh7 1.8160 2.64E-08 potassium voltage-gated channel, subfamily H (eag-
related), member 7  
5033428I22Rik 1.8159 5.01E-09 RIKEN cDNA 5033428I22 gene  
Tsix 1.8061 0.008786 X (inactive)-specific transcript, opposite strand  
Ndufa4l2 1.8008 0.000129 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 
4-like 2  
1110018N20Rik 1.7993 0.003328 RIKEN cDNA 1110018N20 gene  
Syndig1l 1.7993 0.004407 synapse differentiation inducing 1 like  
Prdm6 1.7960 2.84E-12 PR domain containing 6  
Krt19 1.7883 1.80E-09 keratin 19  
Hoxc9 1.7637 0.00019 homeobox C9  
Vstm5 1.7598 8.22E-06 V-set and transmembrane domain containing 5  
NA 1.7528 0.000395 NA 
Rhox5 1.7197 7.25E-06 reproductive homeobox 5  
Hoxd8 1.7032 0.004158 homeobox D8  
Gm26992 1.7030 0.007749 predicted gene, 26992  
Il19 1.7027 0.001991 interleukin 19  
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Pfkp 1.7024 1.34E-10 phosphofructokinase, platelet  
1700001L05Rik 1.6988 3.17E-07 RIKEN cDNA 1700001L05 gene  
Kcnk3 1.6926 7.28E-07 potassium channel, subfamily K, member 3  
Rxfp1 1.6917 1.29E-08 relaxin/insulin-like family peptide receptor 1  
Pparg 1.6856 0.000889 peroxisome proliferator activated receptor gamma  
Gm14506 1.6832 1.26E-06 predicted gene 14506  
Mgarp 1.6821 1.37E-08 mitochondria localized glutamic acid rich protein  
Fam184b 1.6811 9.50E-08 family with sequence similarity 184, member B  
Upk1b 1.6593 0.000615 uroplakin 1B  
Abi3bp 1.6585 5.07E-11 ABI gene family, member 3 (NESH) binding protein  
Gm11536 1.6534 0.001737 predicted gene 11536  
Cox4i2 1.6471 6.33E-08 cytochrome c oxidase subunit IV isoform 2  
Gm6277 1.6350 8.25E-06 predicted gene 6277  
Pfkfb3 1.6140 3.93E-13 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3  
Gm16754 1.6090 2.12E-10 predicted gene, 16754  
Pla2g5 1.6052 0.000239 phospholipase A2, group V  
Adamts2 1.6021 2.09E-11 a disintegrin-like and metallopeptidase (reprolysin type) 
with thrombospondin type 1 motif, 2  
Mir483 1.5994 0.00293 microRNA 483  
Pof1b 1.5968 7.91E-05 premature ovarian failure 1B  
Kcna1 1.5941 4.65E-05 potassium voltage-gated channel, shaker-related 
subfamily, member 1  
Efna3 1.5928 7.24E-10 ephrin A3  
Gjb5 1.5813 2.36E-09 gap junction protein, beta 5  
Fam65c 1.5721 5.17E-11 family with sequence similarity 65, member C  
Gdf10 1.5500 3.43E-09 growth differentiation factor 10  
Hoxa6 1.5482 2.18E-05 homeobox A6  
Phlda2 1.5360 9.66E-07 pleckstrin homology-like domain, family A, member 2  
Tnfaip3 1.5306 1.07E-06 tumor necrosis factor, alpha-induced protein 3  
Ppp1r3g 1.5266 3.84E-06 protein phosphatase 1, regulatory (inhibitor) subunit 3G  
Bmp3 1.5179 1.00E-08 bone morphogenetic protein 3  
H2-Ab1 1.5146 0.006489 histocompatibility 2, class II antigen A, beta 1  
Gm15850 1.5143 0.002541 predicted gene 15850  
Fas 1.5127 4.17E-07 Fas (TNF receptor superfamily member 6)  
Hoxb5os 1.4983 1.92E-09 homeobox B5 and homeobox B6, opposite strand  
Fam71f2 1.4946 0.000342 family with sequence similarity 71, member F2  
A730049H05Rik 1.4938 1.51E-06 RIKEN cDNA A730049H05 gene  
Slc2a3 1.4910 3.31E-12 solute carrier family 2 (facilitated glucose transporter), 
member 3  
Fat2 1.4787 2.15E-06 FAT tumor suppressor homolog 2 (Drosophila)  
Rora 1.4781 9.40E-08 RAR-related orphan receptor alpha  
Cbln3 1.4743 1.72E-06 cerebellin 3 precursor protein  
Fst 1.4674 1.50E-29 follistatin  
Col1a1 1.4652 8.60E-15 collagen, type I, alpha 1  
Plcxd1 1.4581 2.31E-05 phosphatidylinositol-specific phospholipase C, X domain 
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containing 1  
Adamts18 1.4562 3.55E-11 a disintegrin-like and metallopeptidase (reprolysin type) 
with thrombospondin type 1 motif, 18  
Pi15 1.4481 4.53E-05 peptidase inhibitor 15  
Stac 1.4473 6.03E-05 src homology three (SH3) and cysteine rich domain  
Hrct1 1.4416 0.009552 histidine rich carboxyl terminus 1  
Gm26670 1.4394 0.004075 predicted gene, 26670  
Notumos 1.4375 0.003677 notum pectinacetylesterase homolog (Drosophila), 
opposite strand  
Slc16a3 1.4339 2.70E-19 solute carrier family 16 (monocarboxylic acid 
transporters), member 3  
Dkk2 1.4248 6.04E-09 dickkopf homolog 2 (Xenopus laevis)  
2500002B13Rik 1.4220 7.32E-09 RIKEN cDNA 2500002B13 gene  
5330426P16Rik 1.4199 4.42E-05 RIKEN cDNA 5330426P16 gene  
Ptprv 1.4099 1.50E-07 protein tyrosine phosphatase, receptor type, V  
Lyve1 1.4095 2.07E-05 lymphatic vessel endothelial hyaluronan receptor 1  
NA 1.4077 0.000193 NA 
Tmem45a 1.4055 3.14E-07 transmembrane protein 45a  
Nr4a3 1.3927 3.79E-09 nuclear receptor subfamily 4, group A, member 3  
Apln 1.3880 6.26E-16 apelin  
Gpx6 1.3869 0.005065 glutathione peroxidase 6  
Grhl3 1.3820 8.06E-09 grainyhead-like 3 (Drosophila)  
Fgf3 1.3676 2.50E-08 fibroblast growth factor 3  
Smoc2 1.3654 3.79E-08 SPARC related modular calcium binding 2  
Hk2 1.3586 2.27E-13 hexokinase 2  
Cdk15 1.3445 0.00631 cyclin-dependent kinase 15  
Sp7 1.3443 0.000246 Sp7 transcription factor 7  
Gm26826 1.3429 0.000509 predicted gene, 26826  
Wisp1 1.3363 5.75E-08 WNT1 inducible signaling pathway protein 1  
Hpcal4 1.3350 0.000762 hippocalcin-like 4  
Col14a1 1.3273 1.12E-14 collagen, type XIV, alpha 1  
Klk13 1.3058 0.000591 kallikrein related-peptidase 13  
Aldoc 1.3029 4.18E-06 aldolase C, fructose-bisphosphate  
Zan 1.2993 3.21E-07 zonadhesin  
Gm15179 1.2978 0.001406 predicted gene 15179  
Appbp2os 1.2963 5.53E-05 amyloid beta precursor protein (cytoplasmic tail) 
binding protein 2, opposite strand  
3110057O12Rik 1.2848 2.30E-07 RIKEN cDNA 3110057O12 gene  
3830417A13Rik 1.2792 0.001321 RIKEN cDNA 3830417A13 gene  
Pdk1 1.2668 2.93E-16 pyruvate dehydrogenase kinase, isoenzyme 1  
Ero1l 1.2570 2.47E-10 ERO1-like (S. cerevisiae)  
Cyp26b1 1.2569 8.30E-06 cytochrome P450, family 26, subfamily b, polypeptide 1  
Rgcc 1.2568 4.64E-07 regulator of cell cycle  
Kdm4d 1.2567 0.003917 lysine (K)-specific demethylase 4D  
Ovol1 1.2544 0.004006 OVO homolog-like 1 (Drosophila)  
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Gdap10 1.2510 1.36E-06 ganglioside-induced differentiation-associated-protein 
10  
Tlr12 1.2493 0.001699 toll-like receptor 12  
Slc39a4 1.2493 0.002273 solute carrier family 39 (zinc transporter), member 4  
G430049J08Rik 1.2469 5.84E-05 RIKEN cDNA G430049J08 gene  
Gm12758 1.2459 6.38E-06 predicted gene 12758  
Hoxb7 1.2403 1.31E-09 homeobox B7  
Cabp1 1.2311 4.45E-09 calcium binding protein 1  
9530026P05Rik 1.2310 1.35E-08 RIKEN cDNA 9530026P05 gene  
March10 1.2294 0.000374 membrane-associated ring finger (C3HC4) 10  
Oas3 1.2195 0.000477 2'-5' oligoadenylate synthetase 3  
Cyp2s1 1.2179 0.00131 cytochrome P450, family 2, subfamily s, polypeptide 1  
Stab2 1.2069 5.27E-07 stabilin 2  
Hgfac 1.2064 0.006643 hepatocyte growth factor activator  
Fgf15 1.2062 1.56E-11 fibroblast growth factor 15  
F7 1.2039 0.002034 coagulation factor VII  
Calml4 1.1981 0.000716 calmodulin-like 4  
Arrdc3 1.1973 3.59E-10 arrestin domain containing 3  
Gm11454 1.1911 0.002667 predicted gene 11454  
Serpine1 1.1881 0.001276 serine (or cysteine) peptidase inhibitor, clade E, member 
1  
C1qtnf7 1.1863 1.78E-06 C1q and tumor necrosis factor related protein 7  
0610040F04Rik 1.1775 0.004962 RIKEN cDNA 0610040F04 gene  
Pgm2 1.1772 1.71E-07 phosphoglucomutase 2  
Gm17382 1.1737 0.001136 predicted gene, 17382  
Gm2117 1.1726 9.29E-06 predicted gene 2117  
Arhgef4 1.1718 0.000135 Rho guanine nucleotide exchange factor (GEF) 4  
Bmp2 1.1640 4.03E-05 bone morphogenetic protein 2  
Cfap70 1.1630 0.00134 cilia and flagella associated protein 70  
Gm12688 1.1622 2.42E-08 predicted gene 12688  
Fosl2 1.1609 7.40E-06 fos-like antigen 2  
Pde4b 1.1586 1.47E-06 phosphodiesterase 4B, cAMP specific  
Nfatc2 1.1549 2.94E-06 nuclear factor of activated T cells, cytoplasmic, 
calcineurin dependent 2  
4833403I15Rik 1.1543 0.006369 RIKEN cDNA 4833403I15 gene  
Adamts9 1.1528 6.83E-17 a disintegrin-like and metallopeptidase (reprolysin type) 
with thrombospondin type 1 motif, 9  
Iigp1 1.1511 0.000884 interferon inducible GTPase 1  
Ahnak 1.1475 6.33E-20 AHNAK nucleoprotein (desmoyokin)  
Hes7 1.1473 0.002624 hairy and enhancer of split 7 (Drosophila)  
Mtus2 1.1463 9.00E-07 microtubule associated tumor suppressor candidate 2  
Mt1 1.1454 7.55E-05 metallothionein 1  
Adra2c 1.1454 0.002593 adrenergic receptor, alpha 2c  
Proser2 1.1424 0.000175 proline and serine rich 2  
Gm2061 1.1411 0.003243 predicted gene 2061  
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Prima1 1.1409 0.001729 proline rich membrane anchor 1  
2310002F09Rik 1.1403 3.50E-07 RIKEN cDNA 2310002F09 gene  
Apold1 1.1389 2.54E-05 apolipoprotein L domain containing 1  
Sowahb 1.1376 2.07E-09 sosondowah ankyrin repeat domain family member B  
Gm17501 1.1273 0.003506 predicted gene, 17501  
NA 1.1254 0.001118 NA 
Kbtbd11 1.1231 1.03E-14 kelch repeat and BTB (POZ) domain containing 11  
B230323A14Rik 1.1211 4.93E-06 RIKEN cDNA B230323A14 gene  
Abcc8 1.1189 4.52E-06 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 8  
Col6a3 1.1188 6.58E-08 collagen, type VI, alpha 3  
Lamb3 1.1152 0.004279 laminin, beta 3  
Plekha2 1.1151 1.97E-05 pleckstrin homology domain-containing, family A 
(phosphoinositide binding specific) member 2  
Notum 1.1137 2.66E-08 notum pectinacetylesterase homolog (Drosophila)  
BC006965 1.1135 0.003903 cDNA sequence BC006965  
Cysltr1 1.1107 2.94E-06 cysteinyl leukotriene receptor 1  
1810010H24Rik 1.1103 0.002492 RIKEN cDNA 1810010H24 gene  
Pmaip1 1.1039 3.00E-07 phorbol-12-myristate-13-acetate-induced protein 1  
Gm26600 1.0945 0.000311 predicted gene, 26600  
Il16 1.0930 7.46E-05 interleukin 16  
Gabre 1.0923 5.89E-07 gamma-aminobutyric acid (GABA) A receptor, subunit 
epsilon  
Gm16046 1.0913 0.000598 predicted gene 16046  
Gm26721 1.0890 0.00122 predicted gene, 26721  
Krt8 1.0859 4.64E-08 keratin 8  
Gm16201 1.0845 0.008769 predicted gene 16201  
P4ha1 1.0825 2.68E-14 procollagen-proline, 2-oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase), alpha 1 polypeptide  
Tmprss13 1.0750 0.007021 transmembrane protease, serine 13  
F630040K05Rik 1.0674 0.000453 RIKEN cDNA F630040K05 gene  
Fam162a 1.0668 3.89E-12 family with sequence similarity 162, member A  
Gm19705 1.0636 0.007092 predicted gene, 19705  
Ccdc80 1.0511 8.59E-11 coiled-coil domain containing 80  
Smtnl2 1.0484 0.00026 smoothelin-like 2  
Gm26908 1.0343 0.001184 predicted gene, 26908  
Gm17399 1.0258 4.40E-05 predicted gene, 17399  
Zfp804a 1.0223 0.001958 zinc finger protein 804A  
Prelid2 1.0222 1.05E-07 PRELI domain containing 2  
Plod2 1.0144 1.31E-09 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2  
D930048N14Rik 1.0138 1.08E-05 RIKEN cDNA D930048N14 gene  
Adamts16 1.0092 2.66E-06 a disintegrin-like and metallopeptidase (reprolysin type) 
with thrombospondin type 1 motif, 16  
Ndrg2 1.0008 0.009803 N-myc downstream regulated gene 2  
Ntrk2 0.9997 1.20E-09 neurotrophic tyrosine kinase, receptor, type 2  
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Ikbke 0.9991 1.69E-05 inhibitor of kappaB kinase epsilon  
Ticam2 0.9955 0.00057 toll-like receptor adaptor molecule 2  
Gpr146 0.9946 0.00095 G protein-coupled receptor 146  
Dlx5 0.9903 5.24E-06 distal-less homeobox 5  
Tacstd2 0.9902 0.000278 tumor-associated calcium signal transducer 2  
Gm15834 0.9901 0.001606 predicted gene 15834  
Fam196b 0.9892 7.10E-07 family with sequence similarity 196, member B  
Car12 0.9800 2.95E-07 carbonic anyhydrase 12  
Maff 0.9779 4.60E-05 v-maf musculoaponeurotic fibrosarcoma oncogene 
family, protein F (avian)  
Pygl 0.9761 7.71E-06 liver glycogen phosphorylase  
Tchh 0.9722 0.005754 trichohyalin  
Lrp2 0.9721 3.13E-11 low density lipoprotein receptor-related protein 2  
C920006O11Rik 0.9720 0.008273 RIKEN cDNA C920006O11 gene  
C1ql2 0.9617 0.0045 complement component 1, q subcomponent-like 2  
Slc7a3 0.9598 0.000426 solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 3  
Cav1 0.9593 0.001112 caveolin 1, caveolae protein  
Hmox1 0.9561 2.38E-05 heme oxygenase (decycling) 1  
Lbx1 0.9521 0.000329 ladybird homeobox homolog 1 (Drosophila)  
A530016L24Rik 0.9484 0.002008 RIKEN cDNA A530016L24 gene  
Slc26a10 0.9466 0.000216 solute carrier family 26, member 10  
4632428C04Rik 0.9440 0.001396 RIKEN cDNA 4632428C04 gene  
Cd300a 0.9411 0.002866 CD300A antigen  
Ccser1 0.9410 3.35E-05 coiled-coil serine rich 1  
Hmha1 0.9385 3.17E-12 histocompatibility (minor) HA-1  
Nabp1 0.9345 7.30E-07 nucleic acid binding protein 1  
Fstl3 0.9341 0.000171 follistatin-like 3  
Ccng2 0.9238 5.93E-06 cyclin G2  
Cnnm1 0.9223 1.53E-06 cyclin M1  
Snx31 0.9204 0.00872 sorting nexin 31  
Aldoart1 0.8944 1.88E-05 aldolase 1 A, retrogene 1  
Pik3ip1 0.8907 0.000714 phosphoinositide-3-kinase interacting protein 1  
Gm16091 0.8903 0.006066 predicted gene 16091  
Jpx 0.8867 0.000147 Jpx transcript, Xist activator (non-protein coding)  
Mir6950 0.8817 1.79E-05 microRNA 6950  
Mt2 0.8812 0.000525 metallothionein 2  
Upp1 0.8724 0.001325 uridine phosphorylase 1  
Cftr 0.8720 0.004048 cystic fibrosis transmembrane conductance regulator  
Ppargc1b 0.8681 0.000362 peroxisome proliferative activated receptor, gamma, 
coactivator 1 beta  
Egln1 0.8674 1.74E-06 egl-9 family hypoxia-inducible factor 1  
Gm14321 0.8630 1.40E-05 predicted gene 14321  
Gng8 0.8621 0.000139 guanine nucleotide binding protein (G protein), gamma 
8  
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Mpp2 0.8590 6.33E-05 membrane protein, palmitoylated 2 (MAGUK p55 
subfamily member 2)  
Gm16008 0.8567 3.67E-05 predicted gene 16008  
Lingo3 0.8548 0.002815 leucine rich repeat and Ig domain containing 3  
A930033H14Rik 0.8492 0.005468 RIKEN cDNA A930033H14 gene  
Proca1 0.8427 0.005133 protein interacting with cyclin A1  
Klf15 0.8309 1.39E-05 Kruppel-like factor 15  
Aldoa 0.8308 3.01E-14 aldolase A, fructose-bisphosphate  
Sdc4 0.8292 0.001106 syndecan 4  
NA 0.8259 0.002611 NA 
Clcn3 0.8221 3.10E-08 chloride channel 3  
Gys1 0.8188 1.41E-08 glycogen synthase 1, muscle  
Stab1 0.8173 3.11E-18 stabilin 1  
Ccdc68 0.8173 0.000106 coiled-coil domain containing 68  
NA 0.8160 0.002043 NA 
Neil2 0.8085 0.000869 nei like 2 (E. coli)  
NA 0.8041 0.004386 NA 
Lama5 0.7993 6.77E-13 laminin, alpha 5  
Vegfa 0.7974 2.25E-07 vascular endothelial growth factor A  
Jade2 0.7962 0.002028 jade family PHD finger 2  
Gm12905 0.7888 0.00039 predicted gene 12905  
Idua 0.7680 0.001104 iduronidase, alpha-L-  
Leprel1 0.7622 2.94E-08 leprecan-like 1  
Sez6l 0.7570 0.000952 seizure related 6 homolog like  
Pgk1 0.7519 6.17E-12 phosphoglycerate kinase 1  
Galnt14 0.7490 0.005704 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 14  
Ppil6 0.7463 0.009482 peptidylprolyl isomerase (cyclophilin)-like 6  
Gm16759 0.7413 0.009797 predicted gene, 16759  
Loxl2 0.7385 4.86E-09 lysyl oxidase-like 2  
Irx4 0.7335 0.00056 Iroquois related homeobox 4 (Drosophila)  
Gm27247 0.7331 0.008319 predicted gene 27247  
Gm21451 0.7308 1.61E-08 predicted gene, 21451  
Adamts17 0.7294 0.001537 a disintegrin-like and metallopeptidase (reprolysin type) 
with thrombospondin type 1 motif, 17  
9130020K20Rik 0.7288 0.007371 RIKEN cDNA 9130020K20 gene  
Nrxn3 0.7240 0.003173 neurexin III  
Gm5537 0.7237 1.12E-09 predicted gene 5537  
Slc38a3 0.7166 0.009121 solute carrier family 38, member 3  
Grem1 0.7114 3.72E-06 gremlin 1  
Pgk1-rs7 0.7013 1.20E-09 phosphoglycerate kinase-1, related sequence-7  
Gm11457 0.6901 0.005323 predicted gene 11457  
4930581F22Rik 0.6836 0.000914 RIKEN cDNA 4930581F22 gene  
Pappa 0.6659 3.17E-07 pregnancy-associated plasma protein A  
Crebrf 0.6648 0.000849 CREB3 regulatory factor  
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Dbp 0.6410 0.000435 D site albumin promoter binding protein  
Sesn2 0.6400 0.002055 sestrin 2  
Renbp 0.5822 0.004922 renin binding protein  
Zfr2 0.5820 0.004232 zinc finger RNA binding protein 2  
Pls1 0.5628 0.008874 plastin 1 (I-isoform)  
Pck2 0.5394 0.001264 phosphoenolpyruvate carboxykinase 2 (mitochondrial)  
Lmx1a 0.5220 0.00727 LIM homeobox transcription factor 1 alpha  
Snora19 4.2910 0.010113 small nucleolar RNA, H/ACA box 19  
Gm20519 3.8206 0.031506 predicted gene 20519  
Slc28a1 3.5223 0.07143 solute carrier family 28 (sodium-coupled nucleoside 
transporter), member 1  
Mir126a 2.8644 0.01557 microRNA 126a  
Gm14488 2.8627 0.014594 predicted gene 14488  
Fut1 2.8595 0.016065 fucosyltransferase 1  
1700001C19Rik 2.6795 0.031216 RIKEN cDNA 1700001C19 gene  
Gm6214 2.4686 0.061049 predicted gene 6214  
Serpina3e-ps 2.4556 0.012386 serine (or cysteine) peptidase inhibitor, clade A, 
member 3E, pseudogene  
Gm22858 2.4340 0.013852 predicted gene, 22858  
Wnt8b 2.2977 0.037083 wingless-type MMTV integration site family, member 8B  
Gpr132 2.2230 0.118686 G protein-coupled receptor 132  
Gm18199 2.2015 0.011976 predicted gene, 18199  
Gm6471 2.2005 0.010632 predicted gene 6471  
Gm13594 2.1256 0.048411 predicted gene 13594  
AI747448 2.0847 0.024155 expressed sequence AI747448  
Gm11549 2.0824 0.023002 predicted gene 11549  
Mir3100 2.0738 0.021297 microRNA 3100  
Spink13 1.9461 0.033918 serine peptidase inhibitor, Kazal type 13  
4833427G06Rik 1.9454 0.035172 RIKEN cDNA 4833427G06 gene  
Arhgef38 1.9434 0.096119 Rho guanine nucleotide exchange factor (GEF) 38  
Gm9869 1.9421 0.02172 predicted gene 9869  
Mir335 1.7607 0.018899 microRNA 335  
AU018091 1.5919 0.010629 expressed sequence AU018091  
Gm13735 1.5883 0.027831 predicted gene 13735  
Gm16126 1.5862 0.023326 predicted gene 16126  
D6Ertd527e 1.5437 0.048866 DNA segment, Chr 6, ERATO Doi 527, expressed  
Slc26a9 1.4921 0.019569 solute carrier family 26, member 9  
Gm26984 1.4642 0.011527 predicted gene, 26984  
Gm12981 1.4604 0.011418 predicted gene 12981  
Nkpd1 1.4126 0.037624 NTPase, KAP family P-loop domain containing 1  
Nrn1 1.3397 0.042069 neuritin 1  
Gm53 1.3340 0.017683 predicted gene 53  
Slc22a30 1.3313 0.036909 solute carrier family 22, member 30  
Amdhd1 1.3272 0.033479 amidohydrolase domain containing 1  
Il17f 1.3145 0.078024 interleukin 17F  
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Prss33 1.2922 0.12203 protease, serine 33  
Cct6b 1.2922 0.025637 chaperonin containing Tcp1, subunit 6b (zeta)  
mt-Tg 1.2682 0.013559 mitochondrially encoded tRNA glycine  
NA 1.2649 0.015202 NA 
Gm26665 1.2595 0.032755 predicted gene, 26665  
Gipr 1.2396 0.022775 gastric inhibitory polypeptide receptor  
9630001P10Rik 1.2132 0.014674 RIKEN cDNA 9630001P10 gene  
4930509E16Rik 1.1698 0.020072 RIKEN cDNA 4930509E16 gene  
Gm15482 1.1547 0.049394 predicted gene 15482  
Them7 1.1289 0.021342 thioesterase superfamily member 7  
Gm15327 1.1285 0.095969 predicted gene 15327  
Lgals3 1.1172 0.015271 lectin, galactose binding, soluble 3  
Hmx3 1.0847 0.324376 H6 homeobox 3  
Zfp296 1.0795 0.044361 zinc finger protein 296  
Gm10037 1.0716 0.0544 predicted gene 10037  
Gm960 1.0615 0.010942 predicted gene 960  
4930547M16Rik 1.0583 0.019667 RIKEN cDNA 4930547M16 gene  
4933405D12Rik 1.0255 0.022324 RIKEN cDNA 4933405D12 gene  
Wfdc3 1.0167 0.028827 WAP four-disulfide core domain 3  
Dmrt3 1.0017 0.017948 doublesex and mab-3 related transcription factor 3  
Tmem221 0.9856 0.019006 transmembrane protein 221  
Tppp 0.9646 0.011359 tubulin polymerization promoting protein  
4933433G15Rik 0.9625 0.058176 RIKEN cDNA 4933433G15 gene  
Gm17509 0.9434 0.012218 predicted gene, 17509  
Runx3 0.9285 0.029809 runt related transcription factor 3  
Car9 0.9013 0.031226 carbonic anhydrase 9  
Gabrg1 0.8880 0.011267 gamma-aminobutyric acid (GABA) A receptor, subunit 
gamma 1  
Unc5cl 0.8760 0.040075 unc-5 homolog C (C. elegans)-like  
Gm17249 0.8759 0.045134 predicted gene, 17249  
Acan 0.8712 0.032858 aggrecan  
Mir363 0.8685 0.03347 microRNA 363  
Ackr2 0.8675 0.016523 atypical chemokine receptor 2  
Gm13710 0.8621 0.056722 predicted gene 13710  
Otog 0.8550 0.102197 otogelin  
Lrfn2 0.8528 0.071106 leucine rich repeat and fibronectin type III domain 
containing 2  
Rasgrp1 0.8489 0.02024 RAS guanyl releasing protein 1  
Gm16251 0.8487 0.057285 predicted gene 16251  
Insl3 0.8343 0.072218 insulin-like 3  
Apol7d 0.8281 0.01423 apolipoprotein L 7d  
Adgb 0.8258 0.02522 androglobin  
Creg2 0.8183 0.014344 cellular repressor of E1A-stimulated genes 2  
Npas2 0.8019 0.053954 neuronal PAS domain protein 2  
5730405O15Rik 0.7919 0.035313 RIKEN cDNA 5730405O15 gene  
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Gm21905 0.7894 0.093381 predicted gene, 21905  
Catsperd 0.7785 0.011706 catsper channel auxiliary subunit delta  
C230037L18Rik 0.7769 0.010725 RIKEN cDNA C230037L18 gene  
A730020E08Rik 0.7681 0.030041 RIKEN cDNA A730020E08 gene  
Cyb5r2 0.7642 0.02078 cytochrome b5 reductase 2  
Gm13830 0.7636 0.010082 predicted gene 13830  
Gm12762 0.7563 0.044293 predicted gene 12762  
Fgf11 0.7496 0.013861 fibroblast growth factor 11  
Tmem74b 0.7473 0.017437 transmembrane protein 74B  
Gm9929 0.7416 0.033198 predicted gene 9929  
Vstm2l 0.7291 0.066502 V-set and transmembrane domain containing 2-like  
Hk1os 0.7289 0.043254 hexokinase 1, opposite strand  
Cfap44 0.7191 0.056252 cilia and flagella associated protein 44  
Cblc 0.7094 0.058288 Casitas B-lineage lymphoma c  
Gm6297 0.7044 0.032469 predicted gene 6297  
Extl1 0.7025 0.032671 exostoses (multiple)-like 1  
4933406C10Rik 0.7011 0.038591 RIKEN cDNA 4933406C10 gene  
Tnfsf13os 0.6887 0.048634 tumor necrosis factor (ligand) superfamily, member 13, 
opposite strand  
Grip1os3 0.6865 0.019209 glutamate receptor interacting protein 1, opposite 
strand 3  
BB218582 0.6751 0.010453 expressed sequence BB218582  
Ttll10 0.6650 0.021826 tubulin tyrosine ligase-like family, member 10  
Zfp133-ps 0.6543 0.013436 zinc finger protein 133, pseudogene  
Gm12454 0.6479 0.061544 predicted gene 12454  
A2m 0.6430 0.019693 alpha-2-macroglobulin  
Catsperg2 0.6385 0.122745 catsper channel auxiliary subunit gamma 2  
Zc3h6 0.6019 0.020286 zinc finger CCCH type containing 6  
1700029J07Rik 0.5914 0.013494 RIKEN cDNA 1700029J07 gene  
Chrna6 0.5839 0.159565 cholinergic receptor, nicotinic, alpha polypeptide 6  
Ace 0.5744 0.057498 angiotensin I converting enzyme (peptidyl-dipeptidase 
A) 1  
Catsperg1 0.5616 0.023239 catsper channel auxiliary subunit gamma 1  
Sncb 0.5593 0.102107 synuclein, beta  
Trim66 0.5560 0.264916 tripartite motif-containing 66  
Mef2b 0.5011 0.21463 myocyte enhancer factor 2B  
Fhad1 0.4944 0.210794 forkhead-associated (FHA) phosphopeptide binding 
domain 1  
Gad1os 0.4938 0.09448 glutamate decarboxylase 1, opposite strand  
BC107364 0.4936 0.209646 cDNA sequence BC107364  
Stag3 0.4831 0.015149 stromal antigen 3  
Aldh1l2 0.0175 0.956757 aldehyde dehydrogenase 1 family, member L2  
Gm853 0.0000 1 predicted gene 853  
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gene m pval description 
Eif2s3y -10.919 9.33E-10 eukaryotic translation initiation factor 2, subunit 3, 
structural gene Y-linked  
Kdm5d -10.596 2.23E-09 lysine (K)-specific demethylase 5D  
Gcg -8.426 9.44E-08 glucagon  
Ddx3y -7.820 1.93E-07 DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked  
Insm2 -5.375 8.77E-05 insulinoma-associated 2  
Rgs13 -5.307 0.001073 regulator of G-protein signaling 13  
Vsx2 -5.061 0.000711 visual system homeobox 2  
Otp -4.926 5.52E-10 orthopedia homolog (Drosophila)  
Gabrg2 -4.860 9.39E-13 gamma-aminobutyric acid (GABA) A receptor, subunit 
gamma 2  
Uty -4.629 0.000212 ubiquitously transcribed tetratricopeptide repeat 
gene, Y chromosome  
Cox8b -4.542 0.007044 cytochrome c oxidase subunit VIIIb  
Gm5590 -4.541 0.004983 predicted gene 5590  
Hk3 -4.288 4.44E-47 hexokinase 3  
Dhrs7c -4.183 4.14E-06 dehydrogenase/reductase (SDR family) member 7C  
Ptf1a -4.130 2.13E-11 pancreas specific transcription factor, 1a  
Gm27199 -3.999 0.000358 predicted gene 27199  
Msc -3.934 1.94E-26 musculin  
Gsx1 -3.794 1.02E-06 GS homeobox 1  
Tlx3 -3.767 3.00E-07 T cell leukemia, homeobox 3  
Robo3 -3.736 1.70E-11 roundabout homolog 3 (Drosophila)  
Fmo2 -3.714 0.000117 flavin containing monooxygenase 2  
Scg2 -3.529 3.53E-09 secretogranin II  
2310002L09Rik -3.511 4.75E-12 RIKEN cDNA 2310002L09 gene  
Cxcl11 -3.399 2.32E-05 chemokine (C-X-C motif) ligand 11  
Crp -3.379 6.06E-07 C-reactive protein, pentraxin-related  
Chrna3 -3.321 1.39E-42 cholinergic receptor, nicotinic, alpha polypeptide 3  
C130071C03Rik -3.248 5.09E-22 RIKEN cDNA C130071C03 gene  
AI854517 -3.211 5.40E-11 expressed sequence AI854517  
Il1rn -3.207 5.43E-10 interleukin 1 receptor antagonist  
Hes2 -3.166 5.51E-07 hairy and enhancer of split 2 (Drosophila)  
Folr4 -3.152 0.000305 folate receptor 4 (delta)  
Prr32 -3.115 5.06E-09 proline rich 32  
Skor1 -3.107 6.01E-09 SKI family transcriptional corepressor 1  
NA -3.060 4.09E-11 NA 
Lrrc75aos2 -3.046 0.000657 leucine rich repeat containing 75A, opposite strand 2  
Slc6a5 -3.038 9.16E-05 solute carrier family 6 (neurotransmitter transporter, 
glycine), member 5  
Olfr315 -2.985 0.00054 olfactory receptor 315  
1700128E19Rik -2.959 2.03E-15 RIKEN cDNA 1700128E19 gene  
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Csn3 -2.946 5.03E-22 casein kappa  
Chrna9 -2.928 0.00144 cholinergic receptor, nicotinic, alpha polypeptide 9  
Hoxa10 -2.870 0.008068 homeobox A10  
Unc5a -2.862 1.40E-87 unc-5 homolog A (C. elegans)  
Slc6a20a -2.846 0.000616 solute carrier family 6 (neurotransmitter transporter), 
member 20A  
Gm12082 -2.834 8.23E-05 predicted gene 12082  
Lhx5 -2.800 5.71E-11 LIM homeobox protein 5  
Gm12224 -2.800 0.001533 predicted gene 12224  
Ttc9b -2.798 2.19E-06 tetratricopeptide repeat domain 9B  
Nkx2-1 -2.793 6.87E-17 NK2 homeobox 1  
Ppp1r3a -2.772 3.52E-08 protein phosphatase 1, regulatory (inhibitor) subunit 
3A  
Barx1 -2.760 1.33E-07 BarH-like homeobox 1  
Myh3 -2.758 1.32E-61 myosin, heavy polypeptide 3, skeletal muscle, 
embryonic  
1810010K12Rik -2.739 5.08E-08 RIKEN cDNA 1810010K12 gene  
Fbll1 -2.704 0.000429 fibrillarin-like 1  
A730046J19Rik -2.686 0.00016 RIKEN cDNA A730046J19 gene  
Bhlhe23 -2.685 5.34E-08 basic helix-loop-helix family, member e23  
Tlx2 -2.679 7.97E-08 T cell leukemia, homeobox 2  
Lamp5 -2.609 0.000793 lysosomal-associated membrane protein family, 
member 5  
Kirrel2 -2.602 8.53E-14 kin of IRRE like 2 (Drosophila)  
Adcyap1 -2.591 2.45E-09 adenylate cyclase activating polypeptide 1  
Gm24105 -2.585 0.004302 predicted gene, 24105  
Klhl14 -2.562 6.87E-18 kelch-like 14  
Nppc -2.557 8.48E-13 natriuretic peptide type C  
Grifin -2.552 7.96E-06 galectin-related inter-fiber protein  
Tnnc2 -2.522 7.07E-26 troponin C2, fast  
NA -2.518 4.27E-05 NA 
Musk -2.513 1.40E-07 muscle, skeletal, receptor tyrosine kinase  
Chrnb4 -2.507 2.04E-25 cholinergic receptor, nicotinic, beta polypeptide 4  
Myot -2.505 9.70E-08 myotilin  
Pitx3 -2.504 0.008777 paired-like homeodomain transcription factor 3  
Mstn -2.504 2.68E-24 myostatin  
Nhlh2 -2.503 5.26E-19 nescient helix loop helix 2  
Klhl35 -2.494 6.52E-06 kelch-like 35  
Grm2 -2.489 6.24E-10 glutamate receptor, metabotropic 2  
Bhlhe22 -2.466 1.66E-19 basic helix-loop-helix family, member e22  
Klhl40 -2.449 1.22E-07 kelch-like 40  
Barhl1 -2.449 6.35E-05 BarH-like 1 (Drosophila)  
Cntn2 -2.444 7.40E-23 contactin 2  
Sln -2.428 4.35E-07 sarcolipin  
Gnat3 -2.420 2.21E-09 guanine nucleotide binding protein, alpha transducing 
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3  
Mylk4 -2.413 1.29E-08 myosin light chain kinase family, member 4  
Scml4 -2.389 2.04E-12 sex comb on midleg-like 4 (Drosophila)  
Hist2h4 -2.376 0.002318 histone cluster 2, H4  
Nwd2 -2.372 2.49E-07 NACHT and WD repeat domain containing 2  
Scrt1 -2.345 5.08E-08 scratch homolog 1, zinc finger protein (Drosophila)  
Kctd8 -2.308 0.000795 potassium channel tetramerisation domain containing 
8  
Tmem132e -2.301 8.19E-22 transmembrane protein 132E  
Gm12408 -2.297 0.005693 predicted gene 12408  
Gm16140 -2.289 8.15E-07 predicted gene 16140  
3110039M20Rik -2.279 3.87E-14 RIKEN cDNA 3110039M20 gene  
St8sia3os -2.278 8.85E-07 ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 3, opposite strand  
Sgcg -2.278 1.36E-05 sarcoglycan, gamma (dystrophin-associated 
glycoprotein)  
Cabp7 -2.261 4.46E-08 calcium binding protein 7  
Nefm -2.260 1.21E-23 neurofilament, medium polypeptide  
Tmem182 -2.249 1.89E-07 transmembrane protein 182  
Stk32a -2.247 1.68E-25 serine/threonine kinase 32A  
Dcx -2.242 1.66E-22 doublecortin  
Nacad -2.234 3.60E-11 NAC alpha domain containing  
B3galt2 -2.224 0.003333 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, 
polypeptide 2  
Oit1 -2.223 0.00388 oncoprotein induced transcript 1  
Foxg1 -2.222 7.73E-14 forkhead box G1  
D930028M14Rik -2.173 8.32E-16 RIKEN cDNA D930028M14 gene  
Il7 -2.165 0.003468 interleukin 7  
Ecel1 -2.162 2.13E-09 endothelin converting enzyme-like 1  
Phox2a -2.155 7.09E-17 paired-like homeobox 2a  
Alx3 -2.154 4.76E-18 aristaless-like homeobox 3  
Gm14133 -2.154 0.009814 predicted gene 14133  
Mypn -2.136 0.000108 myopalladin  
Mylpf -2.133 3.74E-28 myosin light chain, phosphorylatable, fast skeletal 
muscle  
Inmt -2.118 0.000328 indolethylamine N-methyltransferase  
Gsx2 -2.116 6.72E-14 GS homeobox 2  
Ankrd2 -2.104 2.98E-11 ankyrin repeat domain 2 (stretch responsive muscle)  
Cdhr1 -2.103 4.02E-08 cadherin-related family member 1  
Neb -2.090 2.07E-15 nebulin  
C1ql3 -2.087 6.50E-09 C1q-like 3  
Gjd4 -2.069 3.16E-06 gap junction protein, delta 4  
Stmn2 -2.063 1.09E-17 stathmin-like 2  
Dbh -2.060 0.000712 dopamine beta hydroxylase  
Resp18 -2.058 0.004709 regulated endocrine-specific protein 18  
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Myh13 -2.057 0.000177 myosin, heavy polypeptide 13, skeletal muscle  
Oasl2 -2.051 0.000133 2'-5' oligoadenylate synthetase-like 2  
Htr2a -2.049 0.008644 5-hydroxytryptamine (serotonin) receptor 2A  
Ina -2.032 1.43E-15 internexin neuronal intermediate filament protein, 
alpha  
Cps1 -2.019 0.000189 carbamoyl-phosphate synthetase 1  
3110035E14Rik -2.013 4.84E-09 RIKEN cDNA 3110035E14 gene  
Myh2 -2.009 0.000586 myosin, heavy polypeptide 2, skeletal muscle, adult  
Myoz2 -2.005 0.002367 myozenin 2  
4930469K13Rik -1.998 3.08E-06 RIKEN cDNA 4930469K13 gene  
Ctxn3 -1.997 1.47E-10 cortexin 3  
Sstr3 -1.987 0.009493 somatostatin receptor 3  
Hs3st2 -1.987 2.40E-05 heparan sulfate (glucosamine) 3-O-sulfotransferase 2  
Kcnh5 -1.976 0.007434 potassium voltage-gated channel, subfamily H (eag-
related), member 5  
Phox2b -1.955 9.87E-26 paired-like homeobox 2b  
Gm16582 -1.954 1.38E-10 predicted gene 16582  
Stmn3 -1.949 2.19E-14 stathmin-like 3  
1700011H14Rik -1.949 2.36E-07 RIKEN cDNA 1700011H14 gene  
Sst -1.946 2.29E-09 somatostatin  
Stmn4 -1.945 3.52E-12 stathmin-like 4  
Neurod1 -1.942 2.28E-10 neurogenic differentiation 1  
Chat -1.939 9.76E-13 choline acetyltransferase  
Aldh1a7 -1.937 5.08E-13 aldehyde dehydrogenase family 1, subfamily A7  
Myom3 -1.923 7.00E-07 myomesin family, member 3  
Cdk5r2 -1.917 6.41E-10 cyclin-dependent kinase 5, regulatory subunit 2 (p39)  
Chrng -1.914 1.49E-08 cholinergic receptor, nicotinic, gamma polypeptide  
Fgf6 -1.909 0.000204 fibroblast growth factor 6  
Ppp1r17 -1.905 4.53E-12 protein phosphatase 1, regulatory subunit 17  
BC048679 -1.900 0.000504 cDNA sequence BC048679  
B3gat2 -1.891 0.000413 beta-1,3-glucuronyltransferase 2 
(glucuronosyltransferase S)  
Insc -1.888 9.17E-09 inscuteable homolog (Drosophila)  
Pou2f2 -1.886 1.77E-07 POU domain, class 2, transcription factor 2  
Syt4 -1.868 3.62E-08 synaptotagmin IV  
Cerkl -1.841 9.68E-10 ceramide kinase-like  
Prdm13 -1.839 6.09E-17 PR domain containing 13  
Lin7a -1.831 3.68E-11 lin-7 homolog A (C. elegans)  
Casq2 -1.825 3.59E-09 calsequestrin 2  
Rhbdl3 -1.813 4.63E-20 rhomboid, veinlet-like 3 (Drosophila)  
Hic1 -1.812 2.94E-12 hypermethylated in cancer 1  
Mybph -1.810 1.62E-14 myosin binding protein H  
Scn9a -1.810 1.19E-06 sodium channel, voltage-gated, type IX, alpha  
Gabrq -1.807 0.001399 gamma-aminobutyric acid (GABA) A receptor, subunit 
theta  
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Chrna5 -1.803 5.45E-10 cholinergic receptor, nicotinic, alpha polypeptide 5  
Gm2990 -1.802 1.73E-05 predicted gene 2990  
Myf6 -1.802 5.89E-09 myogenic factor 6  
4930426D05Rik -1.792 2.84E-13 RIKEN cDNA 4930426D05 gene  
Ttbk1 -1.790 2.53E-12 tau tubulin kinase 1  
Atcay -1.778 4.02E-11 ataxia, cerebellar, Cayman type homolog (human)  
6030408B16Rik -1.765 0.000313 RIKEN cDNA 6030408B16 gene  
Tubb3 -1.761 2.15E-27 tubulin, beta 3 class III  
Thsd7b -1.760 1.10E-06 thrombospondin, type I, domain containing 7B  
NA -1.759 2.21E-06 NA 
Cck -1.745 8.67E-08 cholecystokinin  
Wfdc1 -1.745 1.28E-09 WAP four-disulfide core domain 1  
Xkr7 -1.740 3.52E-09 X Kell blood group precursor related family member 7 
homolog  
Ablim3 -1.735 2.15E-10 actin binding LIM protein family, member 3  
Ano5 -1.727 4.13E-07 anoctamin 5  
Dhrs3 -1.725 1.53E-11 dehydrogenase/reductase (SDR family) member 3  
Insm1 -1.722 1.09E-17 insulinoma-associated 1  
Kcnj8 -1.718 0.005016 potassium inwardly-rectifying channel, subfamily J, 
member 8  
Nefl -1.717 2.17E-17 neurofilament, light polypeptide  
Unc79 -1.714 3.09E-06 unc-79 homolog (C. elegans)  
Ppfia2 -1.711 0.000137 protein tyrosine phosphatase, receptor type, f 
polypeptide (PTPRF), interacting protein (liprin), alpha 
2  
Filip1 -1.709 8.97E-17 filamin A interacting protein 1  
En1 -1.690 3.61E-09 engrailed 1  
Il17b -1.679 0.001633 interleukin 17B  
Pah -1.678 7.49E-06 phenylalanine hydroxylase  
Fam163a -1.671 6.50E-06 family with sequence similarity 163, member A  
Sncg -1.671 1.40E-09 synuclein, gamma  
Elavl3 -1.665 3.77E-15 ELAV (embryonic lethal, abnormal vision, Drosophila)-
like 3 (Hu antigen C)  
Scrt2 -1.660 1.86E-09 scratch homolog 2, zinc finger protein (Drosophila)  
Hs3st5 -1.654 0.000693 heparan sulfate (glucosamine) 3-O-sulfotransferase 5  
Ap3b2 -1.648 1.53E-09 adaptor-related protein complex 3, beta 2 subunit  
Pou3f4 -1.646 1.88E-08 POU domain, class 3, transcription factor 4  
Gm14343 -1.646 0.000172 predicted gene 14343  
Nrg3 -1.645 1.09E-06 neuregulin 3  
Gm12239 -1.644 0.000147 predicted gene 12239  
Ntrk1 -1.643 2.54E-12 neurotrophic tyrosine kinase, receptor, type 1  
Tmem8c -1.639 4.70E-06 transmembrane protein 8C  
Gfra1 -1.625 2.72E-18 glial cell line derived neurotrophic factor family 
receptor alpha 1  
Vsx1 -1.613 4.41E-05 visual system homeobox 1 homolog (zebrafish)  
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Htr3a -1.608 0.001446 5-hydroxytryptamine (serotonin) receptor 3A  
Neurog1 -1.607 5.82E-12 neurogenin 1  
Galnt9 -1.601 1.33E-07 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 9  
Rundc3a -1.598 9.44E-10 RUN domain containing 3A  
Lhx1 -1.593 5.19E-06 LIM homeobox protein 1  
Iqsec3 -1.591 0.00014 IQ motif and Sec7 domain 3  
Mmp24 -1.591 5.88E-07 matrix metallopeptidase 24  
Halr1 -1.590 4.62E-09 Hoxa adjacent long noncoding RNA 1  
Slc17a7 -1.584 7.04E-07 solute carrier family 17 (sodium-dependent inorganic 
phosphate cotransporter), member 7  
Fstl5 -1.583 0.000294 follistatin-like 5  
Gm26871 -1.582 0.001957 predicted gene, 26871  
Gabra1 -1.578 0.006439 gamma-aminobutyric acid (GABA) A receptor, subunit 
alpha 1  
Cacna1s -1.575 0.000303 calcium channel, voltage-dependent, L type, alpha 1S 
subunit  
Pnmal1 -1.565 2.68E-09 PNMA-like 1  
Abcb4 -1.547 0.00387 ATP-binding cassette, sub-family B (MDR/TAP), 
member 4  
Svop -1.547 2.00E-05 SV2 related protein  
Arpp21 -1.547 6.30E-10 cyclic AMP-regulated phosphoprotein, 21  
Gcnt4 -1.545 3.68E-14 glucosaminyl (N-acetyl) transferase 4, core 2 (beta-
1,6-N-acetylglucosaminyltransferase)  
Otor -1.542 0.000404 otoraplin  
Gm12892 -1.540 1.86E-18 predicted gene 12892  
Syt2 -1.526 2.78E-06 synaptotagmin II  
Fndc5 -1.525 8.93E-15 fibronectin type III domain containing 5  
Kcnj10 -1.522 1.59E-06 potassium inwardly-rectifying channel, subfamily J, 
member 10  
Ckb -1.517 9.34E-33 creatine kinase, brain  
Nr0b1 -1.515 0.000179 nuclear receptor subfamily 0, group B, member 1  
Chrna1 -1.513 6.52E-06 cholinergic receptor, nicotinic, alpha polypeptide 1 
(muscle)  
Lrrtm3 -1.513 3.44E-10 leucine rich repeat transmembrane neuronal 3  
Glra1 -1.510 1.01E-05 glycine receptor, alpha 1 subunit  
Foxn4 -1.505 1.86E-05 forkhead box N4  
Myt1 -1.501 5.10E-11 myelin transcription factor 1  
Onecut3 -1.486 5.75E-05 one cut domain, family member 3  
Trim67 -1.481 9.95E-06 tripartite motif-containing 67  
2310015B20Rik -1.480 5.24E-05 RIKEN cDNA 2310015B20 gene  
Ptpn5 -1.476 6.79E-10 protein tyrosine phosphatase, non-receptor type 5  
Gabrb2 -1.461 1.34E-07 gamma-aminobutyric acid (GABA) A receptor, subunit 
beta 2  
Hmx1 -1.461 0.003807 H6 homeobox 1  
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Hpca -1.460 1.71E-07 hippocalcin  
Lamc3 -1.459 1.90E-11 laminin gamma 3  
St18 -1.459 5.67E-08 suppression of tumorigenicity 18  
Tecta -1.457 4.50E-06 tectorin alpha  
Cacng2 -1.453 0.002181 calcium channel, voltage-dependent, gamma subunit 
2  
Myog -1.453 4.69E-11 myogenin  
Prrxl1 -1.440 0.002036 paired related homeobox protein-like 1  
Cxcl13 -1.440 5.24E-11 chemokine (C-X-C motif) ligand 13  
Mast1 -1.435 0.000183 microtubule associated serine/threonine kinase 1  
Scg3 -1.429 2.01E-10 secretogranin III  
1700106J16Rik -1.424 1.50E-05 RIKEN cDNA 1700106J16 gene  
Pax7 -1.421 6.09E-18 paired box 7  
Gm7325 -1.414 5.81E-05 predicted gene 7325  
Gm20501 -1.413 0.005398 predicted gene 20501  
Rab9b -1.411 0.00293 RAB9B, member RAS oncogene family  
Nyap2 -1.408 4.14E-05 neuronal tyrosine-phophorylated phosphoinositide 3-
kinase adaptor 2  
Wnt2b -1.396 1.32E-08 wingless-type MMTV integration site family, member 
2B  
mt-Tt -1.393 1.71E-10 mitochondrially encoded tRNA threonine  
Art1 -1.381 3.14E-05 ADP-ribosyltransferase 1  
Aldh1a1 -1.381 0.004949 aldehyde dehydrogenase family 1, subfamily A1  
Ascl1 -1.380 6.14E-11 achaete-scute complex homolog 1 (Drosophila)  
Apc2 -1.380 3.81E-11 adenomatosis polyposis coli 2  
Rgs18 -1.378 0.002921 regulator of G-protein signaling 18  
Dmrtb1 -1.376 4.91E-06 DMRT-like family B with proline-rich C-terminal, 1  
Cacng6 -1.374 0.000806 calcium channel, voltage-dependent, gamma subunit 
6  
Srrm3 -1.372 4.91E-06 serine/arginine repetitive matrix 3  
Fabp7 -1.371 2.09E-10 fatty acid binding protein 7, brain  
Sez6 -1.365 0.000183 seizure related gene 6  
Clvs1 -1.363 2.51E-11 clavesin 1  
Cdh9 -1.351 0.008476 cadherin 9  
Gm16551 -1.346 2.13E-11 predicted gene 16551  
Dusp15 -1.345 0.000914 dual specificity phosphatase-like 15  
Atp1a3 -1.344 5.22E-06 ATPase, Na+/K+ transporting, alpha 3 polypeptide  
Msx3 -1.336 4.88E-24 msh homeobox 3  
Chgb -1.332 1.11E-06 chromogranin B  
Snord50b -1.330 0.004671 small nucleolar RNA, C/D box 50B  
Adcy8 -1.326 3.87E-09 adenylate cyclase 8  
Ripply3 -1.320 1.83E-17 ripply3 homolog (zebrafish)  
Nccrp1 -1.319 0.000779 non-specific cytotoxic cell receptor protein 1 homolog 
(zebrafish)  
Apba2 -1.310 2.77E-32 amyloid beta (A4) precursor protein-binding, family A, 
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member 2  
Rarb -1.308 1.83E-28 retinoic acid receptor, beta  
Syt1 -1.306 4.24E-06 synaptotagmin I  
C2cd4a -1.299 0.006393 C2 calcium-dependent domain containing 4A  
Gm15680 -1.295 0.002992 predicted gene 15680  
Ugt8a -1.294 5.78E-05 UDP galactosyltransferase 8A  
Sox3 -1.294 8.77E-19 SRY (sex determining region Y)-box 3  
Slitrk6 -1.292 2.00E-09 SLIT and NTRK-like family, member 6  
mt-Tl1 -1.282 0.004199 mitochondrially encoded tRNA leucine 1  
Chrnb2 -1.282 7.31E-07 cholinergic receptor, nicotinic, beta polypeptide 2 
(neuronal)  
Dbx1 -1.282 3.83E-16 developing brain homeobox 1  
Chga -1.281 1.39E-08 chromogranin A  
Arg1 -1.278 5.65E-37 arginase, liver  
Celf3 -1.277 5.75E-07 CUGBP, Elav-like family member 3  
Onecut2 -1.276 1.29E-17 one cut domain, family member 2  
Itgb8 -1.274 2.51E-18 integrin beta 8  
BC030500 -1.270 0.00037 cDNA sequence BC030500  
Cdx1 -1.258 2.30E-05 caudal type homeobox 1  
Gng3 -1.255 3.28E-05 guanine nucleotide binding protein (G protein), 
gamma 3  
Tmem178b -1.250 1.55E-05 transmembrane protein 178B  
Ncan -1.248 6.14E-08 neurocan  
Rgs9 -1.237 3.85E-15 regulator of G-protein signaling 9  
Dner -1.234 7.09E-06 delta/notch-like EGF-related receptor  
Plk3 -1.224 3.23E-12 polo-like kinase 3  
Cd83 -1.223 4.31E-08 CD83 antigen  
Gm16010 -1.222 7.83E-05 predicted gene 16010  
Dtx4 -1.219 1.65E-26 deltex 4 homolog (Drosophila)  
Klhl41 -1.219 6.34E-09 kelch-like 41  
C130060K24Rik -1.217 6.69E-05 RIKEN cDNA C130060K24 gene  
Kcnn1 -1.216 8.59E-07 potassium intermediate/small conductance calcium-
activated channel, subfamily N, member 1  
Atp2b2 -1.213 0.002805 ATPase, Ca++ transporting, plasma membrane 2  
Slc10a4 -1.212 0.000346 solute carrier family 10 (sodium/bile acid 
cotransporter family), member 4  
Nhlh1 -1.212 1.61E-08 nescient helix loop helix 1  
Doc2b -1.208 9.66E-06 double C2, beta  
Arhgap36 -1.208 8.92E-07 Rho GTPase activating protein 36  
1810041L15Rik -1.203 5.14E-10 RIKEN cDNA 1810041L15 gene  
Abhd15 -1.201 1.94E-05 abhydrolase domain containing 15  
Ass1 -1.190 9.00E-09 argininosuccinate synthetase 1  
Drd2 -1.188 0.000413 dopamine receptor D2  
Has3 -1.185 0.001334 hyaluronan synthase 3  
Akap6 -1.180 5.30E-08 A kinase (PRKA) anchor protein 6  
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Disp2 -1.179 0.00059 dispatched homolog 2 (Drosophila)  
Clec1b -1.166 9.28E-10 C-type lectin domain family 1, member b  
Slc6a7 -1.163 0.000361 solute carrier family 6 (neurotransmitter transporter, 
L-proline), member 7  
Dusp14 -1.161 1.75E-08 dual specificity phosphatase 14  
Tshz1 -1.159 5.37E-36 teashirt zinc finger family member 1  
Srpk3 -1.157 0.003842 serine/arginine-rich protein specific kinase 3  
mt-Tk -1.155 6.07E-06 mitochondrially encoded tRNA lysine  
Arhgap20 -1.152 3.49E-08 Rho GTPase activating protein 20  
Grm3 -1.148 0.001033 glutamate receptor, metabotropic 3  
Hfe2 -1.147 1.56E-05 hemochromatosis type 2 (juvenile) (human homolog)  
Clec1a -1.143 7.07E-05 C-type lectin domain family 1, member a  
Lzts1 -1.143 1.68E-05 leucine zipper, putative tumor suppressor 1  
Lrtm1 -1.143 0.000757 leucine-rich repeats and transmembrane domains 1  
Nlrp5-ps -1.141 0.004423 NLR family, pyrin domain containing 5, pseudogene  
Foxq1 -1.139 0.00151 forkhead box Q1  
Stk33 -1.138 2.73E-05 serine/threonine kinase 33  
Syt11 -1.138 3.90E-21 synaptotagmin XI  
Atp2a1 -1.129 2.87E-08 ATPase, Ca++ transporting, cardiac muscle, fast twitch 
1  
Gm807 -1.125 0.007918 predicted gene 807  
Ksr2 -1.125 2.63E-05 kinase suppressor of ras 2  
Sez6l2 -1.125 0.000484 seizure related 6 homolog like 2  
Gdap1 -1.122 1.11E-06 ganglioside-induced differentiation-associated-protein 
1  
Ttyh1 -1.109 3.06E-06 tweety homolog 1 (Drosophila)  
Slc45a1 -1.108 0.006267 solute carrier family 45, member 1  
Gm20649 -1.106 9.25E-16 predicted gene 20649  
Tmem35 -1.105 5.79E-06 transmembrane protein 35  
Moxd1 -1.104 1.59E-08 monooxygenase, DBH-like 1  
Trh -1.103 0.001386 thyrotropin releasing hormone  
Prdm12 -1.098 1.55E-07 PR domain containing 12  
Lrrc4 -1.094 5.57E-09 leucine rich repeat containing 4  
Gpr179 -1.088 0.003242 G protein-coupled receptor 179  
Lhfpl4 -1.083 1.34E-09 lipoma HMGIC fusion partner-like protein 4  
Mapk8ip2 -1.079 3.26E-08 mitogen-activated protein kinase 8 interacting protein 
2  
Islr2 -1.073 0.006343 immunoglobulin superfamily containing leucine-rich 
repeat 2  
Fam57b -1.070 8.97E-05 family with sequence similarity 57, member B  
Rgs8 -1.065 3.76E-10 regulator of G-protein signaling 8  
Syp -1.063 1.35E-08 synaptophysin  
Rem2 -1.062 3.77E-07 rad and gem related GTP binding protein 2  
Pou3f3 -1.059 2.26E-11 POU domain, class 3, transcription factor 3  
Myom2 -1.059 0.004424 myomesin 2  
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Tppp3 -1.056 4.89E-14 tubulin polymerization-promoting protein family 
member 3  
Metrn -1.054 3.11E-37 meteorin, glial cell differentiation regulator  
Chst8 -1.044 6.99E-08 carbohydrate (N-acetylgalactosamine 4-0) 
sulfotransferase 8  
Celsr3 -1.042 4.60E-06 cadherin, EGF LAG seven-pass G-type receptor 3 
(flamingo homolog, Drosophila)  
Trim9 -1.040 7.73E-07 tripartite motif-containing 9  
Slco4a1 -1.039 0.000112 solute carrier organic anion transporter family, 
member 4a1  
Rfx6 -1.035 0.001282 regulatory factor X, 6  
Zic4 -1.034 5.46E-08 zinc finger protein of the cerebellum 4  
Slc16a12 -1.033 0.005662 solute carrier family 16 (monocarboxylic acid 
transporters), member 12  
Tox -1.032 3.20E-09 thymocyte selection-associated high mobility group 
box  
Fcgrt -1.031 2.58E-06 Fc receptor, IgG, alpha chain transporter  
Hecw1 -1.031 0.000617 HECT, C2 and WW domain containing E3 ubiquitin 
protein ligase 1  
Gm715 -1.029 6.35E-05 predicted gene 715  
Syndig1 -1.022 0.001017 synapse differentiation inducing 1  
Syn1 -1.022 0.000103 synapsin I  
Gm20646 -1.020 5.33E-11 predicted gene 20646  
Lhx4 -1.015 1.43E-05 LIM homeobox protein 4  
Gm15385 -1.012 0.00536 predicted gene 15385  
Tspan17 -1.012 0.000226 tetraspanin 17  
Gprin1 -1.009 6.55E-13 G protein-regulated inducer of neurite outgrowth 1  
Gucy2f -1.007 0.006457 guanylate cyclase 2f  
Pdzrn4 -1.005 0.000132 PDZ domain containing RING finger 4  
Ptpro -1.005 7.09E-05 protein tyrosine phosphatase, receptor type, O  
Hpdl -1.002 4.02E-05 4-hydroxyphenylpyruvate dioxygenase-like  
Gdap1l1 -1.002 4.11E-06 ganglioside-induced differentiation-associated protein 
1-like 1  
Smpd3 -0.995 5.96E-08 sphingomyelin phosphodiesterase 3, neutral  
Slc1a2 -0.986 2.78E-07 solute carrier family 1 (glial high affinity glutamate 
transporter), member 2  
Ccdc177 -0.965 8.16E-05 coiled-coil domain containing 177  
Rgs4 -0.965 0.000647 regulator of G-protein signaling 4  
Gm26786 -0.963 2.18E-07 predicted gene, 26786  
Rab3c -0.963 0.000908 RAB3C, member RAS oncogene family  
Elavl4 -0.952 1.47E-10 ELAV (embryonic lethal, abnormal vision, Drosophila)-
like 4 (Hu antigen D)  
Klf2 -0.947 3.98E-06 Kruppel-like factor 2 (lung)  
Tnnt1 -0.944 6.14E-05 troponin T1, skeletal, slow  
Add2 -0.941 6.50E-07 adducin 2 (beta)  
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Gm20594 -0.940 0.001526 predicted gene, 20594  
Dll3 -0.939 2.20E-06 delta-like 3 (Drosophila)  
Ntn4 -0.934 1.57E-05 netrin 4  
Jakmip2 -0.933 1.13E-08 janus kinase and microtubule interacting protein 2  
Pmepa1 -0.925 0.000145 prostate transmembrane protein, androgen induced 1  
C1qtnf3 -0.920 5.31E-05 C1q and tumor necrosis factor related protein 3  
Tagln3 -0.918 4.99E-08 transgelin 3  
Neurod4 -0.918 3.68E-07 neurogenic differentiation 4  
Hoxa4 -0.917 9.18E-09 homeobox A4  
BC064078 -0.899 0.000378 cDNA sequence BC064078  
mt-Tw -0.897 0.000545 mitochondrially encoded tRNA tryptophan  
Wnt16 -0.895 1.83E-06 wingless-type MMTV integration site family, member 
16  
Sarm1 -0.895 0.000145 sterile alpha and HEAT/Armadillo motif containing 1  
Tmem74 -0.893 0.003084 transmembrane protein 74  
Maneal -0.891 1.70E-06 mannosidase, endo-alpha-like  
Dpysl4 -0.891 2.94E-13 dihydropyrimidinase-like 4  
Mab21l1 -0.888 0.009815 mab-21-like 1 (C. elegans)  
1500004A13Rik -0.887 0.001374 RIKEN cDNA 1500004A13 gene  
Eva1a -0.887 0.003189 eva-1 homolog A (C. elegans)  
Dpysl3 -0.885 1.50E-19 dihydropyrimidinase-like 3  
Hist1h4j -0.885 0.005509 histone cluster 1, H4j  
Pantr1 -0.872 9.23E-07 POU domain, class 3, transcription factor 3 adjacent 
noncoding transcript 1  
Slc25a48 -0.866 0.001275 solute carrier family 25, member 48  
Pcdh10 -0.834 0.000144 protocadherin 10  
Mgat5b -0.832 2.97E-05 mannoside acetylglucosaminyltransferase 5, 
isoenzyme B  
Miat -0.830 0.000766 myocardial infarction associated transcript (non-
protein coding)  
Srrm4 -0.825 2.55E-05 serine/arginine repetitive matrix 4  
Onecut1 -0.814 6.84E-06 one cut domain, family member 1  
Nfasc -0.792 0.000101 neurofascin  
Dio2 -0.787 0.002909 deiodinase, iodothyronine, type II  
Cplx1 -0.784 0.00714 complexin 1  
C5ar1 -4.265 0.014909 complement component 5a receptor 1  
1700024G13Rik -2.917 0.015107 RIKEN cDNA 1700024G13 gene  
Duox2 -2.804 0.022449 dual oxidase 2  
Nkx1-1 -2.499 0.012863 NK1 transcription factor related, locus 1 (Drosophila)  
Gm2449 -2.419 0.012221 predicted gene 2449  
Gm14302 -2.231 0.026194 predicted gene 14302  
Crct1 -2.229 0.026248 cysteine-rich C-terminal 1  
A930017M01Rik -2.128 0.03656 RIKEN cDNA A930017M01 gene  
NA -2.079 0.019347 NA 
Ear1 -1.999 0.026975 eosinophil-associated, ribonuclease A family, member 
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1  
Gm14273 -1.990 0.011877 predicted gene 14273  
Actl6b -1.722 0.02109 actin-like 6B  
6330409D20Rik -1.672 0.013378 RIKEN cDNA 6330409D20 gene  
Siah3 -1.583 0.025657 seven in absentia homolog 3 (Drosophila)  
Btn1a1 -1.554 0.04385 butyrophilin, subfamily 1, member A1  
Gm26191 -1.510 0.01362 predicted gene, 26191  
Gm16796 -1.496 0.044201 predicted gene, 16796  
Birc7 -1.487 0.010907 baculoviral IAP repeat-containing 7 (livin)  
Impg1 -1.442 0.045222 interphotoreceptor matrix proteoglycan 1  
Lingo4 -1.401 0.011204 leucine rich repeat and Ig domain containing 4  
Ptprq -1.351 0.019085 protein tyrosine phosphatase, receptor type, Q  
Cpne6 -1.321 0.016862 copine VI  
Olfm3 -1.306 0.018957 olfactomedin 3  
Slc22a6 -1.299 0.012658 solute carrier family 22 (organic anion transporter), 
member 6  
A530084C06Rik -1.294 0.022763 RIKEN cDNA A530084C06 gene  
Spn -1.141 0.014094 sialophorin  
Gm15218 -1.106 0.012899 predicted gene 15218  
Pyy -1.104 0.011684 peptide YY  
Aspdh -1.074 0.021587 aspartate dehydrogenase domain containing  
Hcrtr2 -1.073 0.01019 hypocretin (orexin) receptor 2  
Gm9951 -1.058 0.033985 predicted gene 9951  
Tbx15 -1.052 0.017731 T-box 15  
Col28a1 -1.044 0.052163 collagen, type XXVIII, alpha 1  
Tmem196 -1.037 0.011855 transmembrane protein 196  
Slco1c1 -1.036 0.019351 solute carrier organic anion transporter family, 
member 1c1  
Myt1l -1.006 0.020269 myelin transcription factor 1-like  
Hrh3 -0.974 0.026719 histamine receptor H3  
Padi4 -0.950 0.023123 peptidyl arginine deiminase, type IV  
Galntl6 -0.948 0.012321 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 6  
Pantr2 -0.908 0.019866 POU domain, class 3, transcription factor 3 adjacent 
noncoding transcript 2  
Nckap1l -0.892 0.019571 NCK associated protein 1 like  
Rims4 -0.845 0.018411 regulating synaptic membrane exocytosis 4  
Olfm4 -0.839 0.018012 olfactomedin 4  
Cckar -0.815 0.030533 cholecystokinin A receptor  
Kcnh4 -0.795 0.030118 potassium voltage-gated channel, subfamily H (eag-
related), member 4  
Aldh1b1 -0.766 0.019483 aldehyde dehydrogenase 1 family, member B1  
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Table VII-9: Flag 2 for both RNA Seq1 and RNA Seq2: Upregulated genes 
gene m pval description 
S100g 6.312 1.51E-06 S100 calcium binding protein G  
Hoxc8 5.676 3.78E-69 homeobox C8  
Oc90 5.069 0.002635 otoconin 90  
Apoa4 4.951 6.08E-05 apolipoprotein A-IV  
Krt13 4.906 0.000361 keratin 13  
Trappc3l 4.562 3.40E-07 trafficking protein particle complex 3 like  
Gpr50 4.492 2.61E-38 G-protein-coupled receptor 50  
Gm15634 4.275 0.006069 predicted gene 15634  
NA 4.269 0.008368 NA 
Tdgf1 4.215 2.74E-07 teratocarcinoma-derived growth factor 1  
Ms4a2 4.207 4.93E-06 membrane-spanning 4-domains, subfamily A, 
member 2  
Nppb 4.148 0.000117 natriuretic peptide type B  
4933402E13Rik 4.119 9.85E-07 RIKEN cDNA 4933402E13 gene  
Ccl2 4.076 0.000298 chemokine (C-C motif) ligand 2  
Cldn14 3.915 4.12E-05 claudin 14  
Gm15283 3.741 7.21E-11 predicted gene 15283  
Epyc 3.728 3.03E-09 epiphycan  
2610528A11Rik 3.681 5.84E-09 RIKEN cDNA 2610528A11 gene  
Phf11b 3.634 0.000394 PHD finger protein 11B  
Apob 3.598 1.81E-07 apolipoprotein B  
Chac1 3.538 1.63E-06 ChaC, cation transport regulator 1  
NA 3.530 0.002692 NA 
Clec18a 3.471 4.22E-06 C-type lectin domain family 18, member A  
Chst13 3.430 0.001138 carbohydrate (chondroitin 4) sulfotransferase 13  
Gm11734 3.424 0.000817 predicted gene 11734  
Ier3 3.416 8.42E-11 immediate early response 3  
Tdo2 3.370 4.54E-11 tryptophan 2,3-dioxygenase  
Gmnc 3.295 0.003174 geminin coiled-coil domain containing  
Tac2 3.225 2.52E-11 tachykinin 2  
Pitx1 3.222 1.88E-08 paired-like homeodomain transcription factor 1  
5031434C07Rik 3.169 0.003766 RIKEN cDNA 5031434C07 gene  
Ascl2 3.160 1.55E-06 achaete-scute complex homolog 2 (Drosophila)  
Spp2 3.156 0.00023 secreted phosphoprotein 2  
Abcc2 3.081 1.02E-05 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 2  
Eno2 3.052 5.77E-09 enolase 2, gamma neuronal  
Scnn1g 2.989 0.001638 sodium channel, nonvoltage-gated 1 gamma  
Aire 2.972 6.34E-08 autoimmune regulator (autoimmune 
polyendocrinopathy candidiasis ectodermal 
dystrophy)  
Hand1 2.964 1.03E-24 heart and neural crest derivatives expressed 
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transcript 1  
Egr2 2.913 0.000452 early growth response 2  
Ddit4 2.858 3.04E-13 DNA-damage-inducible transcript 4  
Hoxc6 2.824 6.76E-10 homeobox C6  
Cubn 2.800 7.40E-06 cubilin (intrinsic factor-cobalamin receptor)  
Hoxa9 2.791 8.50E-05 homeobox A9  
Gm22661 2.770 0.000237 predicted gene, 22661  
Gm27505 2.766 0.000927 predicted gene, 27505  
Postn 2.762 3.31E-23 periostin, osteoblast specific factor  
Gm12746 2.723 8.56E-06 predicted gene 12746  
Trap1a 2.704 0.000209 tumor rejection antigen P1A  
Inhbb 2.689 0.000169 inhibin beta-B  
Vax1 2.685 0.004055 ventral anterior homeobox 1  
Muc13 2.615 1.60E-05 mucin 13, epithelial transmembrane  
Hoxa7 2.595 0.000394 homeobox A7  
Card14 2.581 0.00059 caspase recruitment domain family, member 14  
Prss35 2.581 7.19E-16 protease, serine 35  
Bhlhe40 2.572 1.70E-07 basic helix-loop-helix family, member e40  
Gm27533 2.515 0.00452 predicted gene, 27533  
Ppp1r3c 2.462 2.90E-06 protein phosphatase 1, regulatory (inhibitor) subunit 
3C  
Adm2 2.438 9.67E-06 adrenomedullin 2  
Rarres2 2.416 6.12E-17 retinoic acid receptor responder (tazarotene induced) 
2  
Xlr5c 2.415 0.002879 X-linked lymphocyte-regulated 5C  
5730403I07Rik 2.411 0.001647 RIKEN cDNA 5730403I07 gene  
Mab21l2 2.371 1.44E-17 mab-21-like 2 (C. elegans)  
Hoxb9 2.338 8.42E-06 homeobox B9  
Oxtr 2.334 4.88E-06 oxytocin receptor  
Muc2 2.309 7.92E-07 mucin 2  
Car7 2.296 3.72E-26 carbonic anhydrase 7  
9330159N05Ri
k 
2.296 6.47E-05 RIKEN cDNA 9330159N05 gene  
Stc1 2.262 1.18E-12 stanniocalcin 1  
Gm20467 2.258 5.38E-10 predicted gene 20467  
Gm14685 2.247 0.000326 predicted gene 14685  
Ndrg1 2.238 3.25E-09 N-myc downstream regulated gene 1  
Gfra3 2.233 5.24E-13 glial cell line derived neurotrophic factor family 
receptor alpha 3  
Otx2 2.223 5.08E-07 orthodenticle homolog 2  
Ptgs2 2.213 1.35E-09 prostaglandin-endoperoxide synthase 2  
Egln3 2.205 9.01E-13 egl-9 family hypoxia-inducible factor 3  
mt-Th 2.202 0.002926 mitochondrially encoded tRNA histidine  
Ciart 2.197 5.30E-16 circadian associated repressor of transcription  
Gm12022 2.195 0.000438 predicted gene 12022  
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Cdrt4 2.152 0.006047 CMT1A duplicated region transcript 4  
Gm11027 2.146 0.007256 predicted gene 11027  
S1pr5 2.124 0.000732 sphingosine-1-phosphate receptor 5  
Kcne3 2.111 4.56E-14 potassium voltage-gated channel, Isk-related 
subfamily, gene 3  
Gm28006 2.108 0.00509 predicted gene, 28006  
Gm17202 2.099 0.00032 predicted gene 17202  
Stc2 2.073 3.23E-13 stanniocalcin 2  
Wnt8a 2.066 7.46E-13 wingless-type MMTV integration site family, member 
8A  
Gm16439 2.063 5.18E-11 predicted pseudogene 16439  
Trib3 2.030 4.02E-05 tribbles homolog 3 (Drosophila)  
Serpina3f 1.997 0.003113 serine (or cysteine) peptidase inhibitor, clade A, 
member 3F  
Slc22a3 1.971 2.36E-07 solute carrier family 22 (organic cation transporter), 
member 3  
P4ha2 1.967 3.35E-14 procollagen-proline, 2-oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase), alpha II polypeptide  
Hmx2 1.952 0.007064 H6 homeobox 2  
Bhlhe41 1.925 2.49E-05 basic helix-loop-helix family, member e41  
Neat1 1.920 1.61E-09 nuclear paraspeckle assembly transcript 1 (non-
protein coding)  
Ankrd37 1.915 1.92E-07 ankyrin repeat domain 37  
Adm 1.910 0.000358 adrenomedullin  
Nkx2-3 1.899 2.68E-15 NK2 homeobox 3  
Avpr1b 1.891 2.14E-05 arginine vasopressin receptor 1B  
Tmem211 1.888 0.002634 transmembrane protein 211  
Rgs11 1.886 8.75E-07 regulator of G-protein signaling 11  
Dio3os 1.885 4.19E-05 deiodinase, iodothyronine type III, opposite strand  
Lrrc15 1.846 0.000149 leucine rich repeat containing 15  
Chl1 1.844 4.67E-16 cell adhesion molecule with homology to L1CAM  
Bnip3 1.841 1.01E-13 BCL2/adenovirus E1B interacting protein 3  
Nxf7 1.832 0.000185 nuclear RNA export factor 7  
Vldlr 1.817 5.13E-12 very low density lipoprotein receptor  
Pla1a 1.817 0.005513 phospholipase A1 member A  
Kcnh7 1.816 2.64E-08 potassium voltage-gated channel, subfamily H (eag-
related), member 7  
5033428I22Rik 1.816 5.01E-09 RIKEN cDNA 5033428I22 gene  
Tsix 1.806 0.008786 X (inactive)-specific transcript, opposite strand  
Ndufa4l2 1.801 0.000129 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 4-like 2  
1110018N20Ri
k 
1.799 0.003328 RIKEN cDNA 1110018N20 gene  
Syndig1l 1.799 0.004407 synapse differentiation inducing 1 like  
Prdm6 1.796 2.84E-12 PR domain containing 6  
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Krt19 1.788 1.80E-09 keratin 19  
Hoxc9 1.764 0.00019 homeobox C9  
Vstm5 1.760 8.22E-06 V-set and transmembrane domain containing 5  
NA 1.753 0.000395 NA 
Rhox5 1.720 7.25E-06 reproductive homeobox 5  
Hoxd8 1.703 0.004158 homeobox D8  
Gm26992 1.703 0.007749 predicted gene, 26992  
Il19 1.703 0.001991 interleukin 19  
Pfkp 1.702 1.34E-10 phosphofructokinase, platelet  
1700001L05Rik 1.699 3.17E-07 RIKEN cDNA 1700001L05 gene  
Kcnk3 1.693 7.28E-07 potassium channel, subfamily K, member 3  
Rxfp1 1.692 1.29E-08 relaxin/insulin-like family peptide receptor 1  
Pparg 1.686 0.000889 peroxisome proliferator activated receptor gamma  
Gm14506 1.683 1.26E-06 predicted gene 14506  
Mgarp 1.682 1.37E-08 mitochondria localized glutamic acid rich protein  
Fam184b 1.681 9.50E-08 family with sequence similarity 184, member B  
Upk1b 1.659 0.000615 uroplakin 1B  
Abi3bp 1.659 5.07E-11 ABI gene family, member 3 (NESH) binding protein  
Gm11536 1.653 0.001737 predicted gene 11536  
Cox4i2 1.647 6.33E-08 cytochrome c oxidase subunit IV isoform 2  
Gm6277 1.635 8.25E-06 predicted gene 6277  
Pfkfb3 1.614 3.93E-13 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3  
Gm16754 1.609 2.12E-10 predicted gene, 16754  
Pla2g5 1.605 0.000239 phospholipase A2, group V  
Adamts2 1.602 2.09E-11 a disintegrin-like and metallopeptidase (reprolysin 
type) with thrombospondin type 1 motif, 2  
Mir483 1.599 0.00293 microRNA 483  
Pof1b 1.597 7.91E-05 premature ovarian failure 1B  
Kcna1 1.594 4.65E-05 potassium voltage-gated channel, shaker-related 
subfamily, member 1  
Efna3 1.593 7.24E-10 ephrin A3  
Gjb5 1.581 2.36E-09 gap junction protein, beta 5  
Fam65c 1.572 5.17E-11 family with sequence similarity 65, member C  
Gdf10 1.550 3.43E-09 growth differentiation factor 10  
Hoxa6 1.548 2.18E-05 homeobox A6  
Phlda2 1.536 9.66E-07 pleckstrin homology-like domain, family A, member 2  
Tnfaip3 1.531 1.07E-06 tumor necrosis factor, alpha-induced protein 3  
Ppp1r3g 1.527 3.84E-06 protein phosphatase 1, regulatory (inhibitor) subunit 
3G  
Bmp3 1.518 1.00E-08 bone morphogenetic protein 3  
H2-Ab1 1.515 0.006489 histocompatibility 2, class II antigen A, beta 1  
Gm15850 1.514 0.002541 predicted gene 15850  
Fas 1.513 4.17E-07 Fas (TNF receptor superfamily member 6)  
Hoxb5os 1.498 1.92E-09 homeobox B5 and homeobox B6, opposite strand  
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Fam71f2 1.495 0.000342 family with sequence similarity 71, member F2  
A730049H05Ri
k 
1.494 1.51E-06 RIKEN cDNA A730049H05 gene  
Slc2a3 1.491 3.31E-12 solute carrier family 2 (facilitated glucose 
transporter), member 3  
Fat2 1.479 2.15E-06 FAT tumor suppressor homolog 2 (Drosophila)  
Rora 1.478 9.40E-08 RAR-related orphan receptor alpha  
Cbln3 1.474 1.72E-06 cerebellin 3 precursor protein  
Fst 1.467 1.50E-29 follistatin  
Col1a1 1.465 8.60E-15 collagen, type I, alpha 1  
Plcxd1 1.458 2.31E-05 phosphatidylinositol-specific phospholipase C, X 
domain containing 1  
Adamts18 1.456 3.55E-11 a disintegrin-like and metallopeptidase (reprolysin 
type) with thrombospondin type 1 motif, 18  
Pi15 1.448 4.53E-05 peptidase inhibitor 15  
Stac 1.447 6.03E-05 src homology three (SH3) and cysteine rich domain  
Hrct1 1.442 0.009552 histidine rich carboxyl terminus 1  
Gm26670 1.439 0.004075 predicted gene, 26670  
Notumos 1.438 0.003677 notum pectinacetylesterase homolog (Drosophila), 
opposite strand  
Slc16a3 1.434 2.70E-19 solute carrier family 16 (monocarboxylic acid 
transporters), member 3  
Dkk2 1.425 6.04E-09 dickkopf homolog 2 (Xenopus laevis)  
2500002B13Rik 1.422 7.32E-09 RIKEN cDNA 2500002B13 gene  
5330426P16Rik 1.420 4.42E-05 RIKEN cDNA 5330426P16 gene  
Ptprv 1.410 1.50E-07 protein tyrosine phosphatase, receptor type, V  
Lyve1 1.410 2.07E-05 lymphatic vessel endothelial hyaluronan receptor 1  
NA 1.408 0.000193 NA 
Tmem45a 1.405 3.14E-07 transmembrane protein 45a  
Nr4a3 1.393 3.79E-09 nuclear receptor subfamily 4, group A, member 3  
Apln 1.388 6.26E-16 apelin  
Gpx6 1.387 0.005065 glutathione peroxidase 6  
Grhl3 1.382 8.06E-09 grainyhead-like 3 (Drosophila)  
Fgf3 1.368 2.50E-08 fibroblast growth factor 3  
Smoc2 1.365 3.79E-08 SPARC related modular calcium binding 2  
Hk2 1.359 2.27E-13 hexokinase 2  
Cdk15 1.344 0.00631 cyclin-dependent kinase 15  
Sp7 1.344 0.000246 Sp7 transcription factor 7  
Gm26826 1.343 0.000509 predicted gene, 26826  
Wisp1 1.336 5.75E-08 WNT1 inducible signaling pathway protein 1  
Hpcal4 1.335 0.000762 hippocalcin-like 4  
Col14a1 1.327 1.12E-14 collagen, type XIV, alpha 1  
Klk13 1.306 0.000591 kallikrein related-peptidase 13  
Aldoc 1.303 4.18E-06 aldolase C, fructose-bisphosphate  
Zan 1.299 3.21E-07 zonadhesin  
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Gm15179 1.298 0.001406 predicted gene 15179  
Appbp2os 1.296 5.53E-05 amyloid beta precursor protein (cytoplasmic tail) 
binding protein 2, opposite strand  
3110057O12Ri
k 
1.285 2.30E-07 RIKEN cDNA 3110057O12 gene  
3830417A13Rik 1.279 0.001321 RIKEN cDNA 3830417A13 gene  
Pdk1 1.267 2.93E-16 pyruvate dehydrogenase kinase, isoenzyme 1  
Ero1l 1.257 2.47E-10 ERO1-like (S. cerevisiae)  
Cyp26b1 1.257 8.30E-06 cytochrome P450, family 26, subfamily b, polypeptide 
1  
Rgcc 1.257 4.64E-07 regulator of cell cycle  
Kdm4d 1.257 0.003917 lysine (K)-specific demethylase 4D  
Ovol1 1.254 0.004006 OVO homolog-like 1 (Drosophila)  
Gdap10 1.251 1.36E-06 ganglioside-induced differentiation-associated-
protein 10  
Tlr12 1.249 0.001699 toll-like receptor 12  
Slc39a4 1.249 0.002273 solute carrier family 39 (zinc transporter), member 4  
G430049J08Rik 1.247 5.84E-05 RIKEN cDNA G430049J08 gene  
Gm12758 1.246 6.38E-06 predicted gene 12758  
Hoxb7 1.240 1.31E-09 homeobox B7  
Cabp1 1.231 4.45E-09 calcium binding protein 1  
9530026P05Rik 1.231 1.35E-08 RIKEN cDNA 9530026P05 gene  
March10 1.229 0.000374 membrane-associated ring finger (C3HC4) 10  
Oas3 1.220 0.000477 2'-5' oligoadenylate synthetase 3  
Cyp2s1 1.218 0.00131 cytochrome P450, family 2, subfamily s, polypeptide 1  
Stab2 1.207 5.27E-07 stabilin 2  
Hgfac 1.206 0.006643 hepatocyte growth factor activator  
Fgf15 1.206 1.56E-11 fibroblast growth factor 15  
F7 1.204 0.002034 coagulation factor VII  
Calml4 1.198 0.000716 calmodulin-like 4  
Arrdc3 1.197 3.59E-10 arrestin domain containing 3  
Gm11454 1.191 0.002667 predicted gene 11454  
Serpine1 1.188 0.001276 serine (or cysteine) peptidase inhibitor, clade E, 
member 1  
C1qtnf7 1.186 1.78E-06 C1q and tumor necrosis factor related protein 7  
0610040F04Rik 1.177 0.004962 RIKEN cDNA 0610040F04 gene  
Pgm2 1.177 1.71E-07 phosphoglucomutase 2  
Gm17382 1.174 0.001136 predicted gene, 17382  
Gm2117 1.173 9.29E-06 predicted gene 2117  
Arhgef4 1.172 0.000135 Rho guanine nucleotide exchange factor (GEF) 4  
Bmp2 1.164 4.03E-05 bone morphogenetic protein 2  
Cfap70 1.163 0.00134 cilia and flagella associated protein 70  
Gm12688 1.162 2.42E-08 predicted gene 12688  
Fosl2 1.161 7.40E-06 fos-like antigen 2  
Pde4b 1.159 1.47E-06 phosphodiesterase 4B, cAMP specific  
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Nfatc2 1.155 2.94E-06 nuclear factor of activated T cells, cytoplasmic, 
calcineurin dependent 2  
4833403I15Rik 1.154 0.006369 RIKEN cDNA 4833403I15 gene  
Adamts9 1.153 6.83E-17 a disintegrin-like and metallopeptidase (reprolysin 
type) with thrombospondin type 1 motif, 9  
Iigp1 1.151 0.000884 interferon inducible GTPase 1  
Ahnak 1.147 6.33E-20 AHNAK nucleoprotein (desmoyokin)  
Hes7 1.147 0.002624 hairy and enhancer of split 7 (Drosophila)  
Mtus2 1.146 9.00E-07 microtubule associated tumor suppressor candidate 2  
Mt1 1.145 7.55E-05 metallothionein 1  
Adra2c 1.145 0.002593 adrenergic receptor, alpha 2c  
Proser2 1.142 0.000175 proline and serine rich 2  
Gm2061 1.141 0.003243 predicted gene 2061  
Prima1 1.141 0.001729 proline rich membrane anchor 1  
2310002F09Rik 1.140 3.50E-07 RIKEN cDNA 2310002F09 gene  
Apold1 1.139 2.54E-05 apolipoprotein L domain containing 1  
Sowahb 1.138 2.07E-09 sosondowah ankyrin repeat domain family member B  
Gm17501 1.127 0.003506 predicted gene, 17501  
NA 1.125 0.001118 NA 
Kbtbd11 1.123 1.03E-14 kelch repeat and BTB (POZ) domain containing 11  
B230323A14Ri
k 
1.121 4.93E-06 RIKEN cDNA B230323A14 gene  
Abcc8 1.119 4.52E-06 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 8  
Col6a3 1.119 6.58E-08 collagen, type VI, alpha 3  
Lamb3 1.115 0.004279 laminin, beta 3  
Plekha2 1.115 1.97E-05 pleckstrin homology domain-containing, family A 
(phosphoinositide binding specific) member 2  
Notum 1.114 2.66E-08 notum pectinacetylesterase homolog (Drosophila)  
BC006965 1.113 0.003903 cDNA sequence BC006965  
Cysltr1 1.111 2.94E-06 cysteinyl leukotriene receptor 1  
1810010H24Ri
k 
1.110 0.002492 RIKEN cDNA 1810010H24 gene  
Pmaip1 1.104 3.00E-07 phorbol-12-myristate-13-acetate-induced protein 1  
Gm26600 1.095 0.000311 predicted gene, 26600  
Il16 1.093 7.46E-05 interleukin 16  
Gabre 1.092 5.89E-07 gamma-aminobutyric acid (GABA) A receptor, subunit 
epsilon  
Gm16046 1.091 0.000598 predicted gene 16046  
Gm26721 1.089 0.00122 predicted gene, 26721  
Krt8 1.086 4.64E-08 keratin 8  
Gm16201 1.085 0.008769 predicted gene 16201  
P4ha1 1.083 2.68E-14 procollagen-proline, 2-oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase), alpha 1 polypeptide  
Tmprss13 1.075 0.007021 transmembrane protease, serine 13  
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F630040K05Rik 1.067 0.000453 RIKEN cDNA F630040K05 gene  
Fam162a 1.067 3.89E-12 family with sequence similarity 162, member A  
Gm19705 1.064 0.007092 predicted gene, 19705  
Ccdc80 1.051 8.59E-11 coiled-coil domain containing 80  
Smtnl2 1.048 0.00026 smoothelin-like 2  
Gm26908 1.034 0.001184 predicted gene, 26908  
Gm17399 1.026 4.40E-05 predicted gene, 17399  
Zfp804a 1.022 0.001958 zinc finger protein 804A  
Prelid2 1.022 1.05E-07 PRELI domain containing 2  
Plod2 1.014 1.31E-09 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2  
D930048N14Ri
k 
1.014 1.08E-05 RIKEN cDNA D930048N14 gene  
Adamts16 1.009 2.66E-06 a disintegrin-like and metallopeptidase (reprolysin 
type) with thrombospondin type 1 motif, 16  
Ndrg2 1.001 0.009803 N-myc downstream regulated gene 2  
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Table VII-10: Flag -2 for both RNA Seq1 and RNA Seq2: Downregulated Genes 
gene m pval description 
Eif2s3y -10.919 9.33E-10 eukaryotic translation initiation factor 2, subunit 3, 
structural gene Y-linked  
Kdm5d -10.596 2.23E-09 lysine (K)-specific demethylase 5D  
Gcg -8.426 9.44E-08 glucagon  
Ddx3y -7.820 1.93E-07 DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked  
Insm2 -5.375 8.77E-05 insulinoma-associated 2  
Rgs13 -5.307 0.001073 regulator of G-protein signaling 13  
Vsx2 -5.061 0.000711 visual system homeobox 2  
Otp -4.926 5.52E-10 orthopedia homolog (Drosophila)  
Gabrg2 -4.860 9.39E-13 gamma-aminobutyric acid (GABA) A receptor, subunit 
gamma 2  
Uty -4.629 0.000212 ubiquitously transcribed tetratricopeptide repeat gene, 
Y chromosome  
Cox8b -4.542 0.007044 cytochrome c oxidase subunit VIIIb  
Gm5590 -4.541 0.004983 predicted gene 5590  
Hk3 -4.288 4.44E-47 hexokinase 3  
Dhrs7c -4.183 4.14E-06 dehydrogenase/reductase (SDR family) member 7C  
Ptf1a -4.130 2.13E-11 pancreas specific transcription factor, 1a  
Gm27199 -3.999 0.000358 predicted gene 27199  
Msc -3.934 1.94E-26 musculin  
Gsx1 -3.794 1.02E-06 GS homeobox 1  
Tlx3 -3.767 3.00E-07 T cell leukemia, homeobox 3  
Robo3 -3.736 1.70E-11 roundabout homolog 3 (Drosophila)  
Fmo2 -3.714 0.000117 flavin containing monooxygenase 2  
Scg2 -3.529 3.53E-09 secretogranin II  
2310002L09Rik -3.511 4.75E-12 RIKEN cDNA 2310002L09 gene  
Cxcl11 -3.399 2.32E-05 chemokine (C-X-C motif) ligand 11  
Crp -3.379 6.06E-07 C-reactive protein, pentraxin-related  
Chrna3 -3.321 1.39E-42 cholinergic receptor, nicotinic, alpha polypeptide 3  
C130071C03Rik -3.248 5.09E-22 RIKEN cDNA C130071C03 gene  
AI854517 -3.211 5.40E-11 expressed sequence AI854517  
Il1rn -3.207 5.43E-10 interleukin 1 receptor antagonist  
Hes2 -3.166 5.51E-07 hairy and enhancer of split 2 (Drosophila)  
Folr4 -3.152 0.000305 folate receptor 4 (delta)  
Prr32 -3.115 5.06E-09 proline rich 32  
Skor1 -3.107 6.01E-09 SKI family transcriptional corepressor 1  
NA -3.060 4.09E-11 NA 
Lrrc75aos2 -3.046 0.000657 leucine rich repeat containing 75A, opposite strand 2  
Slc6a5 -3.038 9.16E-05 solute carrier family 6 (neurotransmitter transporter, 
glycine), member 5  
Olfr315 -2.985 0.00054 olfactory receptor 315  
1700128E19Rik -2.959 2.03E-15 RIKEN cDNA 1700128E19 gene  
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Csn3 -2.946 5.03E-22 casein kappa  
Chrna9 -2.928 0.00144 cholinergic receptor, nicotinic, alpha polypeptide 9  
Hoxa10 -2.870 0.008068 homeobox A10  
Unc5a -2.862 1.40E-87 unc-5 homolog A (C. elegans)  
Slc6a20a -2.846 0.000616 solute carrier family 6 (neurotransmitter transporter), 
member 20A  
Gm12082 -2.834 8.23E-05 predicted gene 12082  
Lhx5 -2.800 5.71E-11 LIM homeobox protein 5  
Gm12224 -2.800 0.001533 predicted gene 12224  
Ttc9b -2.798 2.19E-06 tetratricopeptide repeat domain 9B  
Nkx2-1 -2.793 6.87E-17 NK2 homeobox 1  
Ppp1r3a -2.772 3.52E-08 protein phosphatase 1, regulatory (inhibitor) subunit 
3A  
Barx1 -2.760 1.33E-07 BarH-like homeobox 1  
Myh3 -2.758 1.32E-61 myosin, heavy polypeptide 3, skeletal muscle, 
embryonic  
1810010K12Rik -2.739 5.08E-08 RIKEN cDNA 1810010K12 gene  
Fbll1 -2.704 0.000429 fibrillarin-like 1  
A730046J19Rik -2.686 0.00016 RIKEN cDNA A730046J19 gene  
Bhlhe23 -2.685 5.34E-08 basic helix-loop-helix family, member e23  
Tlx2 -2.679 7.97E-08 T cell leukemia, homeobox 2  
Lamp5 -2.609 0.000793 lysosomal-associated membrane protein family, 
member 5  
Kirrel2 -2.602 8.53E-14 kin of IRRE like 2 (Drosophila)  
Adcyap1 -2.591 2.45E-09 adenylate cyclase activating polypeptide 1  
Gm24105 -2.585 0.004302 predicted gene, 24105  
Klhl14 -2.562 6.87E-18 kelch-like 14  
Nppc -2.557 8.48E-13 natriuretic peptide type C  
Grifin -2.552 7.96E-06 galectin-related inter-fiber protein  
Tnnc2 -2.522 7.07E-26 troponin C2, fast  
NA -2.518 4.27E-05 NA 
Musk -2.513 1.40E-07 muscle, skeletal, receptor tyrosine kinase  
Chrnb4 -2.507 2.04E-25 cholinergic receptor, nicotinic, beta polypeptide 4  
Myot -2.505 9.70E-08 myotilin  
Pitx3 -2.504 0.008777 paired-like homeodomain transcription factor 3  
Mstn -2.504 2.68E-24 myostatin  
Nhlh2 -2.503 5.26E-19 nescient helix loop helix 2  
Klhl35 -2.494 6.52E-06 kelch-like 35  
Grm2 -2.489 6.24E-10 glutamate receptor, metabotropic 2  
Bhlhe22 -2.466 1.66E-19 basic helix-loop-helix family, member e22  
Klhl40 -2.449 1.22E-07 kelch-like 40  
Barhl1 -2.449 6.35E-05 BarH-like 1 (Drosophila)  
Cntn2 -2.444 7.40E-23 contactin 2  
Sln -2.428 4.35E-07 sarcolipin  
Gnat3 -2.420 2.21E-09 guanine nucleotide binding protein, alpha transducing 
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3  
Mylk4 -2.413 1.29E-08 myosin light chain kinase family, member 4  
Scml4 -2.389 2.04E-12 sex comb on midleg-like 4 (Drosophila)  
Hist2h4 -2.376 0.002318 histone cluster 2, H4  
Nwd2 -2.372 2.49E-07 NACHT and WD repeat domain containing 2  
Scrt1 -2.345 5.08E-08 scratch homolog 1, zinc finger protein (Drosophila)  
Kctd8 -2.308 0.000795 potassium channel tetramerisation domain containing 
8  
Tmem132e -2.301 8.19E-22 transmembrane protein 132E  
Gm12408 -2.297 0.005693 predicted gene 12408  
Gm16140 -2.289 8.15E-07 predicted gene 16140  
3110039M20Rik -2.279 3.87E-14 RIKEN cDNA 3110039M20 gene  
St8sia3os -2.278 8.85E-07 ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 3, opposite strand  
Sgcg -2.278 1.36E-05 sarcoglycan, gamma (dystrophin-associated 
glycoprotein)  
Cabp7 -2.261 4.46E-08 calcium binding protein 7  
Nefm -2.260 1.21E-23 neurofilament, medium polypeptide  
Tmem182 -2.249 1.89E-07 transmembrane protein 182  
Stk32a -2.247 1.68E-25 serine/threonine kinase 32A  
Dcx -2.242 1.66E-22 doublecortin  
Nacad -2.234 3.60E-11 NAC alpha domain containing  
B3galt2 -2.224 0.003333 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, 
polypeptide 2  
Oit1 -2.223 0.00388 oncoprotein induced transcript 1  
Foxg1 -2.222 7.73E-14 forkhead box G1  
D930028M14Rik -2.173 8.32E-16 RIKEN cDNA D930028M14 gene  
Il7 -2.165 0.003468 interleukin 7  
Ecel1 -2.162 2.13E-09 endothelin converting enzyme-like 1  
Phox2a -2.155 7.09E-17 paired-like homeobox 2a  
Alx3 -2.154 4.76E-18 aristaless-like homeobox 3  
Gm14133 -2.154 0.009814 predicted gene 14133  
Mypn -2.136 0.000108 myopalladin  
Mylpf -2.133 3.74E-28 myosin light chain, phosphorylatable, fast skeletal 
muscle  
Inmt -2.118 0.000328 indolethylamine N-methyltransferase  
Gsx2 -2.116 6.72E-14 GS homeobox 2  
Ankrd2 -2.104 2.98E-11 ankyrin repeat domain 2 (stretch responsive muscle)  
Cdhr1 -2.103 4.02E-08 cadherin-related family member 1  
Neb -2.090 2.07E-15 nebulin  
C1ql3 -2.087 6.50E-09 C1q-like 3  
Gjd4 -2.069 3.16E-06 gap junction protein, delta 4  
Stmn2 -2.063 1.09E-17 stathmin-like 2  
Dbh -2.060 0.000712 dopamine beta hydroxylase  
Resp18 -2.058 0.004709 regulated endocrine-specific protein 18  
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Myh13 -2.057 0.000177 myosin, heavy polypeptide 13, skeletal muscle  
Oasl2 -2.051 0.000133 2'-5' oligoadenylate synthetase-like 2  
Htr2a -2.049 0.008644 5-hydroxytryptamine (serotonin) receptor 2A  
Ina -2.032 1.43E-15 internexin neuronal intermediate filament protein, 
alpha  
Cps1 -2.019 0.000189 carbamoyl-phosphate synthetase 1  
3110035E14Rik -2.013 4.84E-09 RIKEN cDNA 3110035E14 gene  
Myh2 -2.009 0.000586 myosin, heavy polypeptide 2, skeletal muscle, adult  
Myoz2 -2.005 0.002367 myozenin 2  
4930469K13Rik -1.998 3.08E-06 RIKEN cDNA 4930469K13 gene  
Ctxn3 -1.997 1.47E-10 cortexin 3  
Sstr3 -1.987 0.009493 somatostatin receptor 3  
Hs3st2 -1.987 2.40E-05 heparan sulfate (glucosamine) 3-O-sulfotransferase 2  
Kcnh5 -1.976 0.007434 potassium voltage-gated channel, subfamily H (eag-
related), member 5  
Phox2b -1.955 9.87E-26 paired-like homeobox 2b  
Gm16582 -1.954 1.38E-10 predicted gene 16582  
Stmn3 -1.949 2.19E-14 stathmin-like 3  
1700011H14Rik -1.949 2.36E-07 RIKEN cDNA 1700011H14 gene  
Sst -1.946 2.29E-09 somatostatin  
Stmn4 -1.945 3.52E-12 stathmin-like 4  
Neurod1 -1.942 2.28E-10 neurogenic differentiation 1  
Chat -1.939 9.76E-13 choline acetyltransferase  
Aldh1a7 -1.937 5.08E-13 aldehyde dehydrogenase family 1, subfamily A7  
Myom3 -1.923 7.00E-07 myomesin family, member 3  
Cdk5r2 -1.917 6.41E-10 cyclin-dependent kinase 5, regulatory subunit 2 (p39)  
Chrng -1.914 1.49E-08 cholinergic receptor, nicotinic, gamma polypeptide  
Fgf6 -1.909 0.000204 fibroblast growth factor 6  
Ppp1r17 -1.905 4.53E-12 protein phosphatase 1, regulatory subunit 17  
BC048679 -1.900 0.000504 cDNA sequence BC048679  
B3gat2 -1.891 0.000413 beta-1,3-glucuronyltransferase 2 
(glucuronosyltransferase S)  
Insc -1.888 9.17E-09 inscuteable homolog (Drosophila)  
Pou2f2 -1.886 1.77E-07 POU domain, class 2, transcription factor 2  
Syt4 -1.868 3.62E-08 synaptotagmin IV  
Cerkl -1.841 9.68E-10 ceramide kinase-like  
Prdm13 -1.839 6.09E-17 PR domain containing 13  
Lin7a -1.831 3.68E-11 lin-7 homolog A (C. elegans)  
Casq2 -1.825 3.59E-09 calsequestrin 2  
Rhbdl3 -1.813 4.63E-20 rhomboid, veinlet-like 3 (Drosophila)  
Hic1 -1.812 2.94E-12 hypermethylated in cancer 1  
Mybph -1.810 1.62E-14 myosin binding protein H  
Scn9a -1.810 1.19E-06 sodium channel, voltage-gated, type IX, alpha  
Gabrq -1.807 0.001399 gamma-aminobutyric acid (GABA) A receptor, subunit 
theta  
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Chrna5 -1.803 5.45E-10 cholinergic receptor, nicotinic, alpha polypeptide 5  
Gm2990 -1.802 1.73E-05 predicted gene 2990  
Myf6 -1.802 5.89E-09 myogenic factor 6  
4930426D05Rik -1.792 2.84E-13 RIKEN cDNA 4930426D05 gene  
Ttbk1 -1.790 2.53E-12 tau tubulin kinase 1  
Atcay -1.778 4.02E-11 ataxia, cerebellar, Cayman type homolog (human)  
6030408B16Rik -1.765 0.000313 RIKEN cDNA 6030408B16 gene  
Tubb3 -1.761 2.15E-27 tubulin, beta 3 class III  
Thsd7b -1.760 1.10E-06 thrombospondin, type I, domain containing 7B  
NA -1.759 2.21E-06 NA 
Cck -1.745 8.67E-08 cholecystokinin  
Wfdc1 -1.745 1.28E-09 WAP four-disulfide core domain 1  
Xkr7 -1.740 3.52E-09 X Kell blood group precursor related family member 7 
homolog  
Ablim3 -1.735 2.15E-10 actin binding LIM protein family, member 3  
Ano5 -1.727 4.13E-07 anoctamin 5  
Dhrs3 -1.725 1.53E-11 dehydrogenase/reductase (SDR family) member 3  
Insm1 -1.722 1.09E-17 insulinoma-associated 1  
Kcnj8 -1.718 0.005016 potassium inwardly-rectifying channel, subfamily J, 
member 8  
Nefl -1.717 2.17E-17 neurofilament, light polypeptide  
Unc79 -1.714 3.09E-06 unc-79 homolog (C. elegans)  
Ppfia2 -1.711 0.000137 protein tyrosine phosphatase, receptor type, f 
polypeptide (PTPRF), interacting protein (liprin), alpha 
2  
Filip1 -1.709 8.97E-17 filamin A interacting protein 1  
En1 -1.690 3.61E-09 engrailed 1  
Il17b -1.679 0.001633 interleukin 17B  
Pah -1.678 7.49E-06 phenylalanine hydroxylase  
Fam163a -1.671 6.50E-06 family with sequence similarity 163, member A  
Sncg -1.671 1.40E-09 synuclein, gamma  
Elavl3 -1.665 3.77E-15 ELAV (embryonic lethal, abnormal vision, Drosophila)-
like 3 (Hu antigen C)  
Scrt2 -1.660 1.86E-09 scratch homolog 2, zinc finger protein (Drosophila)  
Hs3st5 -1.654 0.000693 heparan sulfate (glucosamine) 3-O-sulfotransferase 5  
Ap3b2 -1.648 1.53E-09 adaptor-related protein complex 3, beta 2 subunit  
Pou3f4 -1.646 1.88E-08 POU domain, class 3, transcription factor 4  
Gm14343 -1.646 0.000172 predicted gene 14343  
Nrg3 -1.645 1.09E-06 neuregulin 3  
Gm12239 -1.644 0.000147 predicted gene 12239  
Ntrk1 -1.643 2.54E-12 neurotrophic tyrosine kinase, receptor, type 1  
Tmem8c -1.639 4.70E-06 transmembrane protein 8C  
Gfra1 -1.625 2.72E-18 glial cell line derived neurotrophic factor family 
receptor alpha 1  
Vsx1 -1.613 4.41E-05 visual system homeobox 1 homolog (zebrafish)  
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Htr3a -1.608 0.001446 5-hydroxytryptamine (serotonin) receptor 3A  
Neurog1 -1.607 5.82E-12 neurogenin 1  
Galnt9 -1.601 1.33E-07 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 9  
Rundc3a -1.598 9.44E-10 RUN domain containing 3A  
Lhx1 -1.593 5.19E-06 LIM homeobox protein 1  
Iqsec3 -1.591 0.00014 IQ motif and Sec7 domain 3  
Mmp24 -1.591 5.88E-07 matrix metallopeptidase 24  
Halr1 -1.590 4.62E-09 Hoxa adjacent long noncoding RNA 1  
Slc17a7 -1.584 7.04E-07 solute carrier family 17 (sodium-dependent inorganic 
phosphate cotransporter), member 7  
Fstl5 -1.583 0.000294 follistatin-like 5  
Gm26871 -1.582 0.001957 predicted gene, 26871  
Gabra1 -1.578 0.006439 gamma-aminobutyric acid (GABA) A receptor, subunit 
alpha 1  
Cacna1s -1.575 0.000303 calcium channel, voltage-dependent, L type, alpha 1S 
subunit  
Pnmal1 -1.565 2.68E-09 PNMA-like 1  
Abcb4 -1.547 0.00387 ATP-binding cassette, sub-family B (MDR/TAP), 
member 4  
Svop -1.547 2.00E-05 SV2 related protein  
Arpp21 -1.547 6.30E-10 cyclic AMP-regulated phosphoprotein, 21  
Gcnt4 -1.545 3.68E-14 glucosaminyl (N-acetyl) transferase 4, core 2 (beta-1,6-
N-acetylglucosaminyltransferase)  
Otor -1.542 0.000404 otoraplin  
Gm12892 -1.540 1.86E-18 predicted gene 12892  
Syt2 -1.526 2.78E-06 synaptotagmin II  
Fndc5 -1.525 8.93E-15 fibronectin type III domain containing 5  
Kcnj10 -1.522 1.59E-06 potassium inwardly-rectifying channel, subfamily J, 
member 10  
Ckb -1.517 9.34E-33 creatine kinase, brain  
Nr0b1 -1.515 0.000179 nuclear receptor subfamily 0, group B, member 1  
Chrna1 -1.513 6.52E-06 cholinergic receptor, nicotinic, alpha polypeptide 1 
(muscle)  
Lrrtm3 -1.513 3.44E-10 leucine rich repeat transmembrane neuronal 3  
Glra1 -1.510 1.01E-05 glycine receptor, alpha 1 subunit  
Foxn4 -1.505 1.86E-05 forkhead box N4  
Myt1 -1.501 5.10E-11 myelin transcription factor 1  
Onecut3 -1.486 5.75E-05 one cut domain, family member 3  
Trim67 -1.481 9.95E-06 tripartite motif-containing 67  
2310015B20Rik -1.480 5.24E-05 RIKEN cDNA 2310015B20 gene  
Ptpn5 -1.476 6.79E-10 protein tyrosine phosphatase, non-receptor type 5  
Gabrb2 -1.461 1.34E-07 gamma-aminobutyric acid (GABA) A receptor, subunit 
beta 2  
Hmx1 -1.461 0.003807 H6 homeobox 1  
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Hpca -1.460 1.71E-07 hippocalcin  
Lamc3 -1.459 1.90E-11 laminin gamma 3  
St18 -1.459 5.67E-08 suppression of tumorigenicity 18  
Tecta -1.457 4.50E-06 tectorin alpha  
Cacng2 -1.453 0.002181 calcium channel, voltage-dependent, gamma subunit 2  
Myog -1.453 4.69E-11 myogenin  
Prrxl1 -1.440 0.002036 paired related homeobox protein-like 1  
Cxcl13 -1.440 5.24E-11 chemokine (C-X-C motif) ligand 13  
Mast1 -1.435 0.000183 microtubule associated serine/threonine kinase 1  
Scg3 -1.429 2.01E-10 secretogranin III  
1700106J16Rik -1.424 1.50E-05 RIKEN cDNA 1700106J16 gene  
Pax7 -1.421 6.09E-18 paired box 7  
Gm7325 -1.414 5.81E-05 predicted gene 7325  
Gm20501 -1.413 0.005398 predicted gene 20501  
Rab9b -1.411 0.00293 RAB9B, member RAS oncogene family  
Nyap2 -1.408 4.14E-05 neuronal tyrosine-phophorylated phosphoinositide 3-
kinase adaptor 2  
Wnt2b -1.396 1.32E-08 wingless-type MMTV integration site family, member 
2B  
mt-Tt -1.393 1.71E-10 mitochondrially encoded tRNA threonine  
Art1 -1.381 3.14E-05 ADP-ribosyltransferase 1  
Aldh1a1 -1.381 0.004949 aldehyde dehydrogenase family 1, subfamily A1  
Ascl1 -1.380 6.14E-11 achaete-scute complex homolog 1 (Drosophila)  
Apc2 -1.380 3.81E-11 adenomatosis polyposis coli 2  
Rgs18 -1.378 0.002921 regulator of G-protein signaling 18  
Dmrtb1 -1.376 4.91E-06 DMRT-like family B with proline-rich C-terminal, 1  
Cacng6 -1.374 0.000806 calcium channel, voltage-dependent, gamma subunit 6  
Srrm3 -1.372 4.91E-06 serine/arginine repetitive matrix 3  
Fabp7 -1.371 2.09E-10 fatty acid binding protein 7, brain  
Sez6 -1.365 0.000183 seizure related gene 6  
Clvs1 -1.363 2.51E-11 clavesin 1  
Cdh9 -1.351 0.008476 cadherin 9  
Gm16551 -1.346 2.13E-11 predicted gene 16551  
Dusp15 -1.345 0.000914 dual specificity phosphatase-like 15  
Atp1a3 -1.344 5.22E-06 ATPase, Na+/K+ transporting, alpha 3 polypeptide  
Msx3 -1.336 4.88E-24 msh homeobox 3  
Chgb -1.332 1.11E-06 chromogranin B  
Snord50b -1.330 0.004671 small nucleolar RNA, C/D box 50B  
Adcy8 -1.326 3.87E-09 adenylate cyclase 8  
Ripply3 -1.320 1.83E-17 ripply3 homolog (zebrafish)  
Nccrp1 -1.319 0.000779 non-specific cytotoxic cell receptor protein 1 homolog 
(zebrafish)  
Apba2 -1.310 2.77E-32 amyloid beta (A4) precursor protein-binding, family A, 
member 2  
Rarb -1.308 1.83E-28 retinoic acid receptor, beta  
 230 
Syt1 -1.306 4.24E-06 synaptotagmin I  
C2cd4a -1.299 0.006393 C2 calcium-dependent domain containing 4A  
Gm15680 -1.295 0.002992 predicted gene 15680  
Ugt8a -1.294 5.78E-05 UDP galactosyltransferase 8A  
Sox3 -1.294 8.77E-19 SRY (sex determining region Y)-box 3  
Slitrk6 -1.292 2.00E-09 SLIT and NTRK-like family, member 6  
mt-Tl1 -1.282 0.004199 mitochondrially encoded tRNA leucine 1  
Chrnb2 -1.282 7.31E-07 cholinergic receptor, nicotinic, beta polypeptide 2 
(neuronal)  
Dbx1 -1.282 3.83E-16 developing brain homeobox 1  
Chga -1.281 1.39E-08 chromogranin A  
Arg1 -1.278 5.65E-37 arginase, liver  
Celf3 -1.277 5.75E-07 CUGBP, Elav-like family member 3  
Onecut2 -1.276 1.29E-17 one cut domain, family member 2  
Itgb8 -1.274 2.51E-18 integrin beta 8  
BC030500 -1.270 0.00037 cDNA sequence BC030500  
Cdx1 -1.258 2.30E-05 caudal type homeobox 1  
Gng3 -1.255 3.28E-05 guanine nucleotide binding protein (G protein), gamma 
3  
Tmem178b -1.250 1.55E-05 transmembrane protein 178B  
Ncan -1.248 6.14E-08 neurocan  
Rgs9 -1.237 3.85E-15 regulator of G-protein signaling 9  
Dner -1.234 7.09E-06 delta/notch-like EGF-related receptor  
Plk3 -1.224 3.23E-12 polo-like kinase 3  
Cd83 -1.223 4.31E-08 CD83 antigen  
Gm16010 -1.222 7.83E-05 predicted gene 16010  
Dtx4 -1.219 1.65E-26 deltex 4 homolog (Drosophila)  
Klhl41 -1.219 6.34E-09 kelch-like 41  
C130060K24Rik -1.217 6.69E-05 RIKEN cDNA C130060K24 gene  
Kcnn1 -1.216 8.59E-07 potassium intermediate/small conductance calcium-
activated channel, subfamily N, member 1  
Atp2b2 -1.213 0.002805 ATPase, Ca++ transporting, plasma membrane 2  
Slc10a4 -1.212 0.000346 solute carrier family 10 (sodium/bile acid cotransporter 
family), member 4  
Nhlh1 -1.212 1.61E-08 nescient helix loop helix 1  
Doc2b -1.208 9.66E-06 double C2, beta  
Arhgap36 -1.208 8.92E-07 Rho GTPase activating protein 36  
1810041L15Rik -1.203 5.14E-10 RIKEN cDNA 1810041L15 gene  
Abhd15 -1.201 1.94E-05 abhydrolase domain containing 15  
Ass1 -1.190 9.00E-09 argininosuccinate synthetase 1  
Drd2 -1.188 0.000413 dopamine receptor D2  
Has3 -1.185 0.001334 hyaluronan synthase 3  
Akap6 -1.180 5.30E-08 A kinase (PRKA) anchor protein 6  
Disp2 -1.179 0.00059 dispatched homolog 2 (Drosophila)  
Clec1b -1.166 9.28E-10 C-type lectin domain family 1, member b  
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Slc6a7 -1.163 0.000361 solute carrier family 6 (neurotransmitter transporter, L-
proline), member 7  
Dusp14 -1.161 1.75E-08 dual specificity phosphatase 14  
Tshz1 -1.159 5.37E-36 teashirt zinc finger family member 1  
Srpk3 -1.157 0.003842 serine/arginine-rich protein specific kinase 3  
mt-Tk -1.155 6.07E-06 mitochondrially encoded tRNA lysine  
Arhgap20 -1.152 3.49E-08 Rho GTPase activating protein 20  
Grm3 -1.148 0.001033 glutamate receptor, metabotropic 3  
Hfe2 -1.147 1.56E-05 hemochromatosis type 2 (juvenile) (human homolog)  
Clec1a -1.143 7.07E-05 C-type lectin domain family 1, member a  
Lzts1 -1.143 1.68E-05 leucine zipper, putative tumor suppressor 1  
Lrtm1 -1.143 0.000757 leucine-rich repeats and transmembrane domains 1  
Nlrp5-ps -1.141 0.004423 NLR family, pyrin domain containing 5, pseudogene  
Foxq1 -1.139 0.00151 forkhead box Q1  
Stk33 -1.138 2.73E-05 serine/threonine kinase 33  
Syt11 -1.138 3.90E-21 synaptotagmin XI  
Atp2a1 -1.129 2.87E-08 ATPase, Ca++ transporting, cardiac muscle, fast twitch 
1  
Gm807 -1.125 0.007918 predicted gene 807  
Ksr2 -1.125 2.63E-05 kinase suppressor of ras 2  
Sez6l2 -1.125 0.000484 seizure related 6 homolog like 2  
Gdap1 -1.122 1.11E-06 ganglioside-induced differentiation-associated-protein 
1  
Ttyh1 -1.109 3.06E-06 tweety homolog 1 (Drosophila)  
Slc45a1 -1.108 0.006267 solute carrier family 45, member 1  
Gm20649 -1.106 9.25E-16 predicted gene 20649  
Tmem35 -1.105 5.79E-06 transmembrane protein 35  
Moxd1 -1.104 1.59E-08 monooxygenase, DBH-like 1  
Trh -1.103 0.001386 thyrotropin releasing hormone  
Prdm12 -1.098 1.55E-07 PR domain containing 12  
Lrrc4 -1.094 5.57E-09 leucine rich repeat containing 4  
Gpr179 -1.088 0.003242 G protein-coupled receptor 179  
Lhfpl4 -1.083 1.34E-09 lipoma HMGIC fusion partner-like protein 4  
Mapk8ip2 -1.079 3.26E-08 mitogen-activated protein kinase 8 interacting protein 
2  
Islr2 -1.073 0.006343 immunoglobulin superfamily containing leucine-rich 
repeat 2  
Fam57b -1.070 8.97E-05 family with sequence similarity 57, member B  
Rgs8 -1.065 3.76E-10 regulator of G-protein signaling 8  
Syp -1.063 1.35E-08 synaptophysin  
Rem2 -1.062 3.77E-07 rad and gem related GTP binding protein 2  
Pou3f3 -1.059 2.26E-11 POU domain, class 3, transcription factor 3  
Myom2 -1.059 0.004424 myomesin 2  
Tppp3 -1.056 4.89E-14 tubulin polymerization-promoting protein family 
member 3  
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Metrn -1.054 3.11E-37 meteorin, glial cell differentiation regulator  
Chst8 -1.044 6.99E-08 carbohydrate (N-acetylgalactosamine 4-0) 
sulfotransferase 8  
Celsr3 -1.042 4.60E-06 cadherin, EGF LAG seven-pass G-type receptor 3 
(flamingo homolog, Drosophila)  
Trim9 -1.040 7.73E-07 tripartite motif-containing 9  
Slco4a1 -1.039 0.000112 solute carrier organic anion transporter family, 
member 4a1  
Rfx6 -1.035 0.001282 regulatory factor X, 6  
Zic4 -1.034 5.46E-08 zinc finger protein of the cerebellum 4  
Slc16a12 -1.033 0.005662 solute carrier family 16 (monocarboxylic acid 
transporters), member 12  
Tox -1.032 3.20E-09 thymocyte selection-associated high mobility group 
box  
Fcgrt -1.031 2.58E-06 Fc receptor, IgG, alpha chain transporter  
Hecw1 -1.031 0.000617 HECT, C2 and WW domain containing E3 ubiquitin 
protein ligase 1  
Gm715 -1.029 6.35E-05 predicted gene 715  
Syndig1 -1.022 0.001017 synapse differentiation inducing 1  
Syn1 -1.022 0.000103 synapsin I  
Gm20646 -1.020 5.33E-11 predicted gene 20646  
Lhx4 -1.015 1.43E-05 LIM homeobox protein 4  
Gm15385 -1.012 0.00536 predicted gene 15385  
Tspan17 -1.012 0.000226 tetraspanin 17  
Gprin1 -1.009 6.55E-13 G protein-regulated inducer of neurite outgrowth 1  
Gucy2f -1.007 0.006457 guanylate cyclase 2f  
Pdzrn4 -1.005 0.000132 PDZ domain containing RING finger 4  
Ptpro -1.005 7.09E-05 protein tyrosine phosphatase, receptor type, O  
Hpdl -1.002 4.02E-05 4-hydroxyphenylpyruvate dioxygenase-like  
Gdap1l1 -1.002 4.11E-06 ganglioside-induced differentiation-associated protein 
1-like 1  
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Paper 1: The retinaldehyde reductase DHRS3 is essential for preventing 
the formation of excess retinoic acid during embryonic development  
This paper was a collaborative effort with the Alex Moise laboratory at the 
University of Kansas in Lawrence, Kansas. We performed and analyzed skeletal 
preparations of the embryos (Figure 7 and Supplemental Figure S2).  
 
 
Reference: Billings, S.E., Pierzchalski, K., Butler Tjaden, N.E., Pang, X.-Y., Trainor, 
P.A., Kane, M.A., Moise, A.R., 2013. The retinaldehyde reductase DHRS3 is essential 
for preventing the formation of excess retinoic acid during embryonic development. The 
FASEB Journal. 
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Paper 2: The developmental etiology and pathogenesis of Hirschsprung 
disease 
This paper was an invited review from Translational Research to be included in 
the “Featured New Investigator” series of the journal. My work was selected due to my 
attendance of the 2012 Combined Annual Meeting of the Central Society for Clinical 
Research and Midwestern Section American Federation for Medical Research.  
 
 
Reference: Butler Tjaden, N.E., Trainor, P.A., 2013. The developmental etiology and 
pathogenesis of Hirschsprung disease. Transl Res 162, 1-15. 
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Paper 3: Cochleovestibular nerve development is integrated with 
migratory neural crest 
For this project, I contributed to the methodology development and dissection of 
numerous ears to be used for skeletal preparations and lacZ staining. Specifically, I 
contributed to Figure 1 C and D and Figure 5F.  
 
 
Reference: Sandell, L.L., Butler Tjaden, N.E., Barlow, A.J., Trainor, P.A., 2014. 
Cochleovestibular nerve development is integrated with migratory neural crest cells. Dev 
Biol 385, 200-210. 
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Paper 4: The Mef2c-F10N enhancer is active in migrating neural crest 
cells facilitating analyses of gene function and lineage  
For this paper, I completed the initial miniprep and maxiprep of the Mef2c-F10N 
plasmid from Brian Black (De Val et al., 2008), as well as the mouse colony maintenance 
and initial descriptions and embryo time course of the Mef2c-F10N line. Specifically, I 
contributed to Figure 1: M,N,O; Figure 2 A-D; and provided embryos for sectioning in 
Figure 2 E-H; and Supplemental Figure 1. 
 
 
Reference: Aoto, K., Sandell, L.L., Butler Tjaden, N.E., Yuen, K.C., Watt, K.E., Black, 
B.L., Durnin, M., Trainor, P.A., 2015. Mef2c-F10N enhancer driven beta-galactosidase 
(LacZ) and Cre recombinase mice facilitate analyses of gene function and lineage fate in 
neural crest cells. Dev Biol 402, 3-16. 
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Paper 5: The Oncogenic Transcription Factor Tlx1 Regulates Cyp26b1 
Expression and Retinoic Acid Signaling to Ensure Spleen Development 
For this paper, I harvested spleens of Rdh10
flox/flox
;ER
T2
Cre animals after 
tamoxifen administration at E7.5 and E10.5. The results from these embryos are used in 
figure 2B and 2C. 
 
 
Reference: Lenti, E., Farinello, D., Yokoyama, K.K., Penkov, D., Castagnaro, L., 
Lavorgna, G., Wuputra, K., Sandell, L.L., Butler Tjaden, N.E., Bernassola, F., Pasini, D., 
Wagner, M., Niederreither, K., Hamada, H., Blasi, F., Tonon, G., Trainor, P.A., 
Brendolan, A., [in preparation]. The Oncogenic Transcription Factor Tlx1 Regulates 
Cyp26b1 Expression and Retinoic Acid Signaling to Ensure Spleen Development. 
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Paper 6: RDH10 is necessary for initial vagal neural crest cell 
contribution to embryonic gastrointestinal tract development  
This paper is the bulk of my PhD Thesis work, and is currently in preparation. It 
will be submitted to Human Molecular Genetics.  
 
 
Reference: Butler Tjaden, N.E., Sandell, L.L., Aoto, K., Trainor, P.A., [in preparation]. 
RDH10 is necessary for initial vagal neural crest cell contribution to embryonic 
gastrointestinal tract development. 
 
 
